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CHAPTER 1: Literature Review: The Contribution of Innate Immune 
Cells to Testis Function in the Healthy Testis and Testicular 
Neoplasia  
INTRODUCTION 
 
Dendritic cells (DCs) and macrophages are cells of the innate immune system that 
are the first responders in cases of inflammation caused by pathogens and other in-
sults such as neoplasia. These are called antigen-presenting cells (APC), serving as 
sentinels that capture, recognise and phagocytise pathogens, with the capacity to 
process and present antigens on their surface via human leukocyte antigen (HLA) 
molecules (Palucka and Banchereau, 1999; Janeway, 2001; Steinman and Hemmi, 
2006). The processed antigens can be presented to T-cells, leading to strong im-
mune reactions by the activation of pathogen-specific lymphocytes that are part of 
the adaptive immune system (Janeway, 2001).  
There are distinct subtypes of APCs; macrophages can be classified into classically 
activated M1 and alternatively activated M2 subpopulations, and their differentiation 
into one or the other depends on the local environment (Sica and Mantovani, 2012; 
Martinez and Gordon, 2014; Zhang et al., 2016). M1 macrophages typically produce 
high amounts of pro-inflammatory cytokines and are considered tumour-destructive 
(Sica et al., 2006; Sica et al., 2008 a)/b); Allavena et al., 2008; Biswas and Manto-
vani, 2010). In contrast, M2 macrophages can produce anti-inflammatory cytokines, 
promote angiogenesis and facilitate matrix remodelling that support tumour progres-
sion and metastasis (Sica et al., 2006; Sica et al., 2008 a)/b); Allavena et al., 2008; 
Biswas and Mantovani, 2010). M2 macrophages present in neoplastic tissue may be 
classified as tumour-associated macrophages (TAMs), which express CD163 and 
CD206 and modulate immune-suppressive properties by producing anti-inflammatory 
cytokines such as TGF-β and IL-10 (Grivennikov et al., 2010; Zhang et al., 2011; 
Mantovani et al., 2004; Martinez et al., 2008; Sica et al., 2006; Yang and Zhang, 
2017). Importantly, in different cancer types in which these TAMs are detectable, 
their presence is primarily associated with poor patient outcomes (Yang and Zhang, 
2017; Zhang et al., 2011; Ryder et al., 2008; Lee et al., 2008; Shieh et al., 2009). In 
human testicular germ cell cancers, TAMs have yet to be characterised, and Chapter 
2 of this thesis presents a characterisation of these cells. 
 
  CHAPTER 1 
  3 
Immune privileged organs are defined as organs in which foreign tissue grafts are 
tolerated without evoking detrimental immune responses resulting in rejection 
(Streilein, 1995; Fijak & Meinhardt, 2006). Following this definition, the mammalian 
testis is an immune privileged site, where immune attack of meiotic and postmeiotic 
germ cells that first arise in puberty after self-tolerance has developed and is sup-
pressed to support normal spermatogenesis (Fijak et al., 2018). In the human testis, 
resident M2 macrophages are important contributors to maintenance of the immune-
suppressive local milieu through the secretion of anti-inflammatory cytokines, such as 
IL-10 and TGF-β (Zhao et al., 2014; Chapter 2). Remarkably, the functional polariza-
tion of M2 macrophages has been observed in associated with infections and tu-
mours whereas in the human testis, M2 macrophages seem to be a resident immune 
cell type (Martinez et al., 2009; Cassetta et al., 2011; Zhao et al., 2014, Chapter 2).  
In addition to the presence of macrophages, infiltrating DCs are commonly observed 
in cancers; the outcome for patients, either good or poor, depends on which DC sub-
set is present (Tran Janco et al., 2015). Myeloid and plasmacytoid dendritic cells 
(pDC, mDC; described further in Sectons 1.3.3 and 1.3.4) are dendritic cell subsets 
that arise from myeloid progenitors that form common DC progenitors (CDPs), then 
give rise to pDCs and pre-DCs that are progenitors of these two myeloid subsets 
(Tran Janco et al., 2015). DC subsets, pDCs and mDCs, can induce different immune 
responses during an inflammation depending on environmental factors (Kadowaki, 
2009). Different DC subsets have been reported to possess synergistic immune-
stimulatory as well as immune-suppressive properties, due to the expression of regu-
latory molecules, receptors and their capability for cross-presentation, all of which are 
critical for an effective immune response (Haniffa et al., 2013; Mildner and Jung, 
2014; Da Silva and Barton, 2016; Tran Janco et al., 2015).  
 
This Chapter addresses the function of the testis as an immune-privileged organ, and 
describes the immune cells that are present and contribute to this unique environ-
ment. Furthermore, the features of different macrophage and DCs subsets and their 
functional polarization associated with testicular neoplasia, specifically GCNIS and 
seminoma, are discussed. Additionally, markers used to delineate DC and macro-
phage subsets are presented.  
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1.1 Introduction to cells of the innate and adaptive immune system 
 
The immune system comprises a complex interaction of cells and molecules that 
serves as a protective mechanism against foreign substances, cells and pathogens, 
including bacteria, viruses and parasites (Murphy and Weaver, 2017). The immune 
system is divided into innate and adaptive response mechanisms (Fig. 1). Cells of the 
innate immune system are mast cells, macrophages, dendritic cells, natural killer 
cells (NK cells) and granulocytes (basophils, eosinophils and neutrophils), whereas 
cells of the adaptive immune system are B cells and T cells, NK cells and γδ T cells 
are defined as cells of both the innate and adaptive immune system (Fig. 1) (Dranoff 
et al., 2004). Innate immune system cells are predominantly derived from the myeloid 
lineage during hematopoiesis, whereas T cells and B cells are derived from the 
lymphoid lineage.  
The adaptive immune system is characterized by immunological memories, a 
hallmark feature that leads to strong and antigen-specific immune reactions. The 
orchestrated reaction of all components is defined as an immune reaction. Immune 
reactions are orchestrated through antigen-antibody complexes, initiated by 
phagocytic cells that belong to the innate immune system which present antigens to 
T cells. The innate immune system can nonspecifically and rapidly develop immune 
responses against pathogens. It contains the complement system of soluble proteins, 
as well as phagocytic, antigen-presenting cells (APCs) (Fig. 1). For instance, 
macrophages as APCs differentiate in tissue from circulating monocytes. They can 
phagocytize, engulf and kill microorganisms by secreting digesting enzymes. 
Macrophages can release cytokines to recruit cells of both the adaptive and innate 
immune system and, thus, induce and maintain pathological processes such as 
inflammation (Winnall et al., 2011; Bhushan & Meinhardt, 2017). As part of immune 
responses against pathogens, macrophages act via their phagocytic capacity and 
production of pro-inflammatory molecules including cytokines. Similarly, DCs 
'professionally' process and present antigens derived from engulfed pathogens on 
their surface via HLA molecules that can be recognized by naïve T cells (Janeway, 
2001). Subsequently, adaptive immune reactions are induced that link responses of 
the innate and adaptive immune systems (Heuzé et al., 2013). Moreover, both 
macrophages and dendritic cells are involved in maintaining physiological tissue 
homeostasis (Davies et al., 2013; Wynn et al., 2013; Bhushan & Meinhardt, 2017).  
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In the light of the plasticity of their functions, the focus of this thesis is set on the role 
of macrophages and DCs in the human testis under physiological and pathological 
conditions, i.e. testis cancer development. 
 
Fig. 1: Components of the innate and adaptive immune system. The mature immune 
system is divided into innate and adaptive immune responses. The innate immune system is 
comprised of mast cells, macrophages, dendritic cells, natural killer cells (NK cells) and 
granulocytes (basophils, eosinophils and neutrophils), whereas cells of the adaptive immune 
system are B cells and T cells; NK cells and γδT cells are defined as cells of both the innate 
and adaptive immune systems. Immune cells that are research subject in this thesis are 
highlighted by a red circle. Modified from Dranoff, 2004. 
 
1.2 The testis under physiological conditions 
1.2.1 The immune privilege of the testis  
 
The mammalian testis has been identified as an immune privileged organ enabling 
normal germ cell development (Meinhardt and Hedger, 2011). Immune privilege is 
defined as a special immune environment with the capacity to suppress the rejection 
of foreign tissue grafts (Fijak et al., 2010; Meinhardt & Hedger, 2011; Fijak et al., 
2017). Taking the key function of the immune system to recognize and respond to 
xeno-, allo- and autoantigens as well as the expression of autoantigens by meiotic 
and post-meiotic 96+germ cells into consideration, the testicular immunosuppressive 
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environment is essential to ensure normal germ cell development (Meinhardt and 
Hedger, 2011; Fijak et al., 2017).  
Local immunoregulation in the testis is established through two key features, illustrat-
ed in Figure 2 and Figure 3. First, the meiotic and post-meiotic germ cells that first 
emerge with the onset of puberty are sequestered from direct contact with immune 
cells (Fig. 2). The testis is comprised of two distinct cellular compartments: the inter-
stitial space, where steroidogenic Leydig cells, vasculature, lymphatics and immune 
cells are located, and the seminiferous tubules, where spermatogenesis occurs as 
spermatogonia develop into spermatozoa embedded in the epithelium formed by Ser-
toli cells (Fig. 2) (Zhao et al., 2014). Second, the secretion and expression of immu-
noregulatory molecules including cytokines, hormones and other signaling ligands 
collectively determines the local immune milieu. Somatic cells such as Leydig cells 
and Sertoli cells contribute to forming an immunosuppressive environment by ex-
pression of molecules including activin A, testosterone, programmed death ligand-1 
(PDL-1), growth arrest-specific 6 (Gas6), protein S (ProS) and transforming growth 
factor β (TGF-β) (Fig. 3) (Zhao et al., 2014). In addition, immune cells, particularly 
macrophages, are central to preservation of the testicular immunosuppressive milieu. 
These typically display an immunosuppressive, M2 phenotype and produce anti-
inflammatory cytokines, such as IL-10 and TGF-β (Zhao et al., 2014; Bhushan and 
Meinhardt, 2017; see Chapter 2& 3). Spermatogenic cells can also contribute to the 
immune suppressive environment by the expression of FasL which can bind the Fas-
receptor on T-lymphocytes to induce apoptosis in these cells and thus prevent a 
strong immune reaction against germ cells (Zhao et al., 2014). Thus, germ cell de-
velopment is supported by the actions of immune cells in a healthy testis due to these 
immunosuppressive mechanisms. 
In contrast, breakdown of the (local) tolerance towards germ cells results in vigorous 
autoimmune reactions (autoimmune orchitis) mediated by cells of the adaptive im-
mune system (Fijak et al., 2018). Clinical conditions such as infectious orchitis 
demonstrate that the testicular immune privilege does not preclude innate and specif-
ic immune responses causing inflammation and subsequent infertility (Fijak et al., 
2018). Moreover, testicular cancer is associated with impairment of the physiological 
immune environment as reflected by influx of non-resident immune cells and altered 
local cytokine and chemokine expression (Klein et al., 2016; Loveland et al., 2017). 
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Fig. 2: Schematic of the testis. The testis is compartmentalised into the seminiferous 
tubules with the germinal epithelium (ST) and the interstitial compartment. This 
compartmental division is required to allow germ cell development and avoid autoimmune 
attack against germ cell-specific autoantigens that are first expressed at the onset of puberty. 
In the seminiferous epithelium, germ cell development takes place, with spermatogonia, 
spermatocytes, round and elongated spermatids enclosed by Sertoli cells which are the key 
structural element of the adult seminiferous tubule. Adjacent Sertoli cells are connected by 
tight junctions which form the blood-testis barrier (BTB) that functionally divides the 
seminiferous epithelium into the basal and adluminal compartments. The BTB sequesters 
autoantigens of maturing germ cells from immune cells. In addition to the immune 
suppressive cytokine milieu, the immune privileged state is preserved by this complementary 
mechanism. BL, basal lamina; BTB, blood testis barrier; ES, elongated spermatid; MPC, 
myoid peritubular cell; PSC, primary spermatocyte; RS, round spermatid; SPG, 
spermatogonia; SSC, secondary spermatocyte; ST, seminiferous tubule. From Zhao et al., 
2014. 
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Fig. 3: Regulation of immune responses in the testis is mediated by a combination of 
structural and cellular-derived factors. Production of cytokines and other immuno-
regulatory molecules by interacting cell types (mast cells, dendritic cells (DC), T cells, 
macrophages (Mφ), and Leydig cells) in the testicular interstitial space creates a complex 
immuno-regulatory environment, as outlined in the text. From Loveland et al., 2017. 
 
 
1.2.2 Contribution of testicular macrophages and other immune cells to 
the immune privilege of the testis 
 
The human testis contains a wide variety of immune cells that bear cell-specific 
markers, namely mast cells (tryptase), macrophages (CD68, CD163, CD206), T-
lymphocytes (CD3, CD4, CD8, Foxp3), and dendritic cells (CD11c) (Frungieri et al, 
2002, Hvarness, 2013, Klein et al., 2016; additional data presented in Chapter 2). 
Within the myeloid lineage, DCs and macrophages can be distinguished by the ex-
pression of specific surface markers. In the human testis, phenotypically different 
macrophage populations with distinct marker subsets have been identified: macro-
phages which express CD68 (lysosomal glycoprotein) or CD163 (cell surface glyco-
protein member of the scavenger receptor cysteine-rich superfamily) and CD206 
(mannose receptor, c-type lectin) (Frungieri et al, 2002; Klein et al., 2016; Zheng et 
al., 2016; see Chapter 2).  
Macrophages can be classified into either M1, as classically-activated macrophages 
(pro-inflammatory properties) or M2, as alternatively activated macrophages (anti-
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inflammatory properties). The differentiation into one or the other phenotype depends 
entirely on various signals (Sica and Mantovani, 2012; Martinez and Gordon, 2014).  
In contrast to knowledge of macrophage biology in rodents, the mechanisms that un-
derpin functional polarization into M1 and M2 macrophages in the human testis have 
yet to be elucidated. Unfortunately, the identification of macrophage subsets is chal-
lenging, since the presence of various macrophage markers (CD45, CD11c, CD68, 
CD163, CD206), cytokines (TNF-a, IL-12, IL-10, TGF-β) and chemokine receptors 
(e.g. CCR2) can overlap with their expression in other immune cell types. As a result, 
more than one marker should be used for an assured identification of macrophage 
and DCs subsets.  
DeFalco et al. analysed macrophage populations in adult mice and revealed two dif-
ferent macrophage populations, interstitial-localized (CSF1R+, MHCII-) and peritubu-
lar-localized (CSF1R-, MHCII+) macrophages which are distinguished by the pres-
ence or absence of MHCII and the level of the receptor for cytokine stimulating factor, 
CSF, using both immunofluorescence and flow cytometry (DeFalco et al., 2015). 
Since acute depletion of CX3CR1+ macrophages in the adult testis led to reduction in 
the proliferation and differentiation of spermatogonia, DeFalco hypothesized that the 
peritubular macrophages serve a specific role in maintenance of spermatogonial 
stem cells due to their localisation in close proximity and their synthesis of CSF. Sub-
sequent work using a CX3CR1 transgenic mouse model that expresses a green fluo-
rescence protein reporter construct confirmed these observations, providing addition-
al evidence to classify the interstitial MCSFR+/MHCII− macrophages as immune 
suppressive cells that express immunosuppressive genes, respectively, and peritubu-
lar M-CSFRlo/MHCII+ expressing alternative M2-type activation genes (Mossadegh-
Keller et al., 2017). These outcomes indicate that peritubular macrophages are able 
to present antigens, in contrast to the interstitial macrophages which do not express 
MHCII molecules required for antigen presentation. Therefore, interstitial macro-
phages might be immunosuppressive and lack the capacity to activate other immune 
cells, such as T-cells which belong to the adaptive immune system. Such dual roles 
for testicular macrophages remain to be elucidated in the human.  
In addition to macrophages, CD11c+ DCs are present in the human testis (Klein et 
al., 2016; Zheng et al., 2016; data presented in Chapter 2). Additionally, Zheng et al. 
showed the presence of cells with different DC markers, such as CCR6, DC-SIGN, 
CD1a+/CD207+ and CD123+/BDCA-2+ (CD303), sparsely distributed within the in-
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terstitial compartment of the normal human testis (Zheng et al., 2016). However, the 
functions of DCs in the human testis under physiological conditions are not yet un-
derstood (Klein et al., 2016; Zhao et al., 2014). Existing data indicate that these DCs 
are immature, based on detection of specific, single markers such as CCR6, DC-
SIGN, CD1a (Zheng et al., 2016). These findings are in agreement with observations 
in rats, where testicular DCs are not able to activate lymphocytes under normal con-
ditions (Guazzone et al., 2011). Nevertheless, in man, the numbers of DCs and T-
lymphocytes are very low in comparison to rat or mice testes (Pöllänen, 1993; Rival 
et al., 2006, Pérez et al., 2013; Klein et al., 2016; Zheng et al., 2016). This suggests 
that some functionalities of testicular immune cells vary between species. 
 
1.2.3 The immunosuppressive role of cytokines and chemokines in the 
testis  
 
Cytokines exert control of immune cell functions, driving either immune-stimulatory or 
immune-suppressive reactions. Control of cytokine synthesis and activity is neces-
sary, otherwise the immune system would produce an uncontrolled pro-inflammatory 
response, especially after an inflammatory insult. To regulate inflammation, cytokines 
and chemokines in the local environment can control macrophage phenotypes by 
differentiating them into pro-inflammatory (M1) or anti-inflammatory (M2) phenotypes 
(Sica and Mantovani, 2012). For instance, formation of M1 cells is typically promoted 
by pro-inflammatory interferon-γ, TNF-α and LPS, whereas M2 differentiation can be 
driven by IL-4 and IL-13. Additional factors are involved in the prevention and modu-
lation of DC subsets and M2 formation, including vascular endothelial growth factor 
(VEGF), macrophage colony-stimulating factor (M-CSF), TGF-β, IL-10, IL-6, and 
prostaglandin E2 (PGE2) (Sica and Mantovani, 2012; Genin et al., 2015; Heusinkveld 
et al., 2011a); Gottfried et al., 2008). The adult mammalian testis has an immune-
suppressive environment partly build by the presence of anti-inflammatory cytokines 
such as IL-10, TGF-β, and activin A (Zhao et al., 2014). Therefore, these cytokines 
can influence macrophage and DC polarization, and control their differentiation into 
different functional phenotypes in the testis to protect germ cells from autoimmune 
attack.  
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1.2.4 Complexity of signaling pathways: TGF-β and IL-10 influence pro-
inflammatory cytokine expression 
 
Testicular expression of the cytokines TGF-β and IL-10 is important to maintain the 
immunosuppressive environment. Both cytokines are known as negative regulators 
of pro-inflammatory cytokine synthesis, restricting production of key molecules such 
as IL-1, IL-2, IL-6, IL-12, IFN-γ, TNF-α, as well as MHCII molecules (Fig. 4, A/B) 
(Gratchev, 2017; de Waal Malefyt et al., 1993; Fiorentino et al., 1991; Steensberg et 
al., 2003; Couper et al., 2008), and thus they are generally known to have the capaci-
ty to resolve pro-inflammatory cytokine reactions (Yoshimura et al., 2003). TGF-β 
and IL-10 have been detected in the human testis as well as in testicular germ cell 
neoplasia, as described later in this thesis (Chapter 2). TGF-β has been shown to be 
associated with disease progression in lung and pancreatic cancer (reviewed by 
Miyazono et al., 2018). The capability of macrophage subsets to contribute to testicu-
lar germ cell tumour progression via their expression of TGF-β will be analysed in 
Chapter 3 and Chapter 4. 
The transforming growth factor beta (TGF-β) superfamily of ligands consists of struc-
turally related dimeric signalling molecules that exhibit the characteristic feature of 
signalling via transmembrane receptors that have intracellular serine/threonine ki-
nase activity. There are three TGF-β isoforms: TGF-β1, -2, and -3, each with a ho-
modimer of a distinct gene product (Lui et al., 2003). These proteins, produced by 
multiple cell types, are secreted by circulating monocytes and tissue macrophages 
(Assoian et al., 1987; Grotendorst et al., 1989). In the testis, TGF-β1 is produced by 
Sertoli cells, peritubular cells and immune cells (e.g. mast cells and resident macro-
phages) (Skinner and Moses, 1989; Pöllänen et al., 1988; Dobashi et al., 2002; Zhao 
et al., 2014). The TGF-β monomers feature 3 intermolecular disulphide bonds and 
dimerise through a separate single intermolecular disulphide bond. Monomers are 
synthesized with a 5’ pre-region that is cleaved following entry into the endoplasmic 
reticulum. The pro-region, which is directly attached to the mature ligand is cleaved 
after dimerization but remains associated with the TGF-β signalling protein. This ‘la-
tency-associated peptide’ (also known as LAP) blocks interaction between TGF-βs 
and the receptors; these ligands are activated by environmental changes such as pH 
shifts that cause the LAP to dissociate (Harrison et al., 2011). After secretion, TGF-
βs can bind to first a Type II receptor subunit, TβRII, and then to a Type 1 receptor 
moiety, TβRI (ALK5), ultimately forming a hetero-tetrameric receptor complex for ca-
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nonical signalling (Sanz-Rodrigues et al., 2004; Chen et al., 2008; Gratchev, 2008; 
Loveland and Hedger, 2015). The binding of a TGF-β molecule enables the constitu-
tively active type II receptors to recruit and phosphorylate type I receptors. Inside the 
plasma membrane, SMAD anchor for receptor activation (SARA) mediates presenta-
tion of the signal transducers Smad2 and/or Smad3 to the type I receptor kinase. The 
phosphorylation of Smads leads to a conformation change that causes dissociation 
of the type I receptor and SARA. Phosphorylated Smad2 and Smad3 form dimers 
(either homo- and hetero-dimers, depending on cellular context and signal input) that 
oligomerize with the co-Smad, Smad4. The trimeric complex translocates into the 
nucleus to activate various target genes through binding to co-factors that determine 
which signalling outcomes are effected (Hill, 2016).  
TGF-β is widely regarded as a therapeutic target to inhibit inflammation (reviewed in 
Walton et al., 2017). It has also been reported to block the synthesis of pro-
inflammatory target genes in macrophages (Fig. 4, A) (Gratchev, 2017). Additionally, 
in human kidney, TGF-βs can inhibit RANTES expression, which is necessary for 
expression of pro-inflammatory cytokines such as TNF-α (Dai et al., 2011). Other 
studies have reported that inhibition of pro-inflammatory cytokines such as IL-1, IL-2, 
IFN-γ and a reduction of MHCII molecules are mediated by TGF-βs (Ding et al., 
1990; Dubois et al., 1990; Dong et al. 2001; Romieu-Mourez et al., 2007). A recent 
study provided evidence that, in human M2 macrophages with high levels of TGF-
βRII, TGF-β can also activate the non-canonical Smad signaling pathway by activat-
ing Smad1/5, rather than Smad 2/3 (Gratchev, 2017). It is interesting to speculate 
that, during the progressive development of testicular neoplasia, an inhibition of 
Smad signaling pathways could affect anti-inflammatory cytokine expression, which 
in turn may increase local production of pro-inflammatory cytokines. Dias et al. (2009) 
have reported the upregulation of inhibitory Smads, as well as the activin A inhibitory 
inhibin and betaglycan molecules, within seminomas in a subset of patients, provid-
ing a rationale for further studies to test this hypothesis (Dias et al., 2009).  
IL-10 is an anti-inflammatory cytokine, which has also been called “cytokine synthesis 
inhibitory factor” (CSIF), as it can influence immune cells (T-cells, macrophages) and 
alter cytokine expression. For example, IL-10 can be expressed by M2 macrophages 
and inhibit the production of the pro-inflammatory cytokines IL-1α/β, IL-6, IL-8, and 
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TNF-α (Fig. 4, B) (de Waal Malefyt et al., 1993; Fiorentino et al., 1991; Steensberg et 
al., 2003).  
To effect signalling, IL-10 can bind to the extracellular domains of IL10R1, which di-
merizes with IL10R2. In human T-cells and monocytes, cell surface binding of IL10 
leads to recruitment of the cytoplasmic proteins, JAK1 and TYK2, which phosphory-
late and thereby activate STAT1α and STAT3 (Finbloom and Winestock, 1995). 
STAT3 forms a homodimer that translocates into the nucleus to mediate transcrip-
tional regulation of IL-10-responsive genes by high-affinity binding of the activated 
STAT to target genomic sequences.  
The signalling pathway of IL-10 and other cytokines can vary between different im-
mune cell subtypes, due to formation of STAT homo- and heterodimers; this is con-
sidered as an important mechanism for providing cell- and context-specificity for gene 
induction (Finbloom and Winstock, 1995; Zhang et al., 1995; Ma et al., 2015). Inter-
estingly, STAT3 is also important in mice for activation of pro-inflammatory IL-6 sig-
nalling. STAT3 can induce the expression of SOCS3 that regulates various cytokine 
signaling pathways including that of IL-6 (O'shea and Murray, 2008). For both cyto-
kines, STAT3 is required (Yasukawa et al., 2003). However, the IL-10 inhibitory effect 
of IL-6 has to be elucidated. SOCS3 feedback in mouse eye macrophages has also 
been shown to be permissive for IL10/STAT3 signalling that promotes alternative 
macrophage activation (M2) (Nakamura et al., 2015). A definite role for these factors 
in the immune-suppressive environment of the adult mammalian testis remains to be 
elucidated. 
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Fig. 4: Signaling pathways of TGF-β and IL-10. (A) TGF-β-signaling via Smads 2 and 3 
suppresses pro-inflammatory cytokine production and reduces cell-mediated immunity. (B) 
IL10 actions, mediated via JAK–STAT signaling, inhibit pro-inflammatory cytokines and 
induce anti-inflammatory responses (e.g., IL1RA production). From Loveland et al., 2017. 
 
1.2.5 Functional macrophage polarization by cytokines, chemokines and 
hormones 
 
The testis as an immune-privileged organ has a specific immune-suppressive milieu 
partly provided by the local synthesis of anti-inflammatory cytokines including IL-10, 
TGF-β and activin A. These cytokines have the capacity to influence macrophage 
and DC differentiation into different functional phenotypes, depending on the local 
environment formed by characteristic cytokine profiles (Sica and Mantovani, 2012). 
Formation of cells with the M1 phenotype is enhanced by the actions of interferon-γ, 
TNF-α and LPS, each of which is considered to be pro-inflammatory. The emergence 
of the immune-suppressive M2 macrophage phenotype is driven by the actions of IL-
4 and IL-13. Additionally, the formation and modulation of DC subsets and M2 mac-
A 
B 
  CHAPTER 1 
  15 
rophages can be influenced by VEGF, macrophage colony-stimulating factor (M-
CSF), TGF-β, IL-10, IL-6, and PGE2 (Sica and Mantovani, 2012; Genin et al., 2015; 
Heusinkveld et al., 2011a; Gottfried et al., 2008). Within the murine testis, it appears 
that in addition to IL-10 and TGF-β, immune complexes and glucocorticoids play a 
role in M2 polarization (Bhushan and Meinhardt, 2017). Macrophage treatment with 
glucocorticoids can lead to upregulation of CD163 (an M2 marker) (Schaer et al., 
2002). It was also reported that human macrophages upregulate the TGF-βRII follow-
ing glucocorticoid stimulation, leading to an activation of TGF-β-specific gene ex-
pression in response to TGF-β1 (Gratchev et al., 2005; Gratchev et al., 2008). This 
phenomenon has been proposed to be of relevance for patients undergoing treat-
ment for atherosclerotic lesions and may have important implications for understand-
ing tissue-dependent features of macrophage polarization. 
1.3. Testicular germ cell tumours  
1.3.1 Classification and epidemiology 
 
Testicular cancer can be classified according to histopathological features into germ 
cell tumours derived from non-invasive germ cell neoplasia (GCNIS) and those unre-
lated to GCNIS (>95%) versus non-germ cell tumours (<5%) (Fig. 5) (Raijpert-De 
Meyts et al., 2016; Moch et al., 2016). Among GCNIS-derived testicular germ cell 
tumours (TGCT), approx. 60% of cases are morphologically homogeneous semi-
nomas. 
 
TGCT are the most common cancer type in young men in the range of 19-43 years of 
age (Richiardi et al., 2004; Chia et al., 2010; Jørgensen et al., 2014). In non-
seminomatous TGCT, the peak incidence is at 25 years, compared to 35 years in 
seminoma (Raijpert-De Meyts et al., 2016). The incidence of TGCT diagnosis is in-
creasing worldwide, particularly in regions located in North America, Europe and 
Oceania. Denmark and Norway have the highest incidences, with rates above 10 
cases per 100,000 inhabitants (World Standard Population) (Huyghe et al., 2003; 
Richiardi et al., 2004; Chia et al., 2010; Myrup et al., 2010).  
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Fig. 5: Classification of testicular tumours. From McGinley and Rampersaud, 2014. 
 
1.3.2 Pathogenesis 
 
TGCTs develop from a precursor, germ cell neoplasia in situ (GCNIS) cell (Berney et 
al., 2016). Although there is no direct observation of its onset, GCNIS is understood 
to arise from primordial germ cells or gonocytes that fail to differentiate properly dur-
ing fetal life, based on their expression of molecular markers characteristic for these 
cells, and on their highly similar morphology (Rajpert-De Meyts, 2006; illustrated in 
Fig. 6). As consequence of either intrinsic or environmental factors that prevent nor-
mal differentiation, these pre-GCNIS cells remain as developmentally arrested germ 
cells through childhood. The aetiology of this disease and the relative contribution of 
genetic and environmental factors to GCNIS formation and disease progression is 
not fully established, and both are likely to contribute (Myrup et al., 2010). Associa-
tions with cryptorchidism, hypospadias, and impaired spermatogenesis, both at the 
individual and population level, have led to the postulation of a testicular dysgenesis 
syndrome, which probably originates in utero (Skakkebaek et al., 2001; Raijpert-De 
Meyts et al., 2016). Furthermore, a family history of testicular cancer has to be con-
sidered as significant risk factor (Hemminki and Li, 2004). Although the cure rate is 
reported as 90-95% (Mortensen et al., 2014), the co-morbidities associated with this 
condition, and the frequency of relapse remain as clinical challenges (Daugaard et 
al., 2016). 
During puberty, the normal alteration of hormones and behaviour of testicular somatic 
cells is considered to be responsible for the increased proliferation rate of GCNIS and 
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their transformation into a neoplastic cell with the capacity for unchecked proliferation 
and invasion (Rajpert-De Meyts, 2006; Rajpert-De Meyts et al., 2016). TGCT are 
manifested in young men as one of two predominant subtypes, seminomas, which 
are homogeneous and appear similar to gonocytes, or as non-seminomas, in which 
heterogeneous tissue types differentiate from the neoplastic precursors (Fig. 6).  
Other rare germ cell tumour subtypes, classified as pediatric and spermatocytic sem-
inomas are not discussed further here, as their origins and biology is different (re-
viewed in Boublikova et al., 2014).  
It has been predicted that approximately 70% of patients who have GCNIS will de-
velop homogeneous seminoma and/or heterogeneous non-seminoma during a peri-
od of 7 years (Giwercman and Skakkebaek, 1993; Rajpert-De Meyts et al., 2016). 
However, it is not well understood why GCNIS develops into either seminoma or non-
seminoma. Genetic changes such as chromosome 12p abnormalities, including the 
presence of an isochromosome of 12p and chromosome 12p overrepresentation, 
have been implicated by experimental evidence, as have SNPs in several genes en-
coding proteins central to germline differentiation (Pyle and Nathanson, 2016). Addi-
tional studies of the genome revealed undermethylation of 5-methyl cytosine in both 
GCNIS and seminoma specimens. Interestingly, in non-seminomas which typically 
contain a mixture of differentiated tissue types, only a small number of imprinted 
genes and LINE1 are demethylated (Rajpert-De Meyts et al., 2016; Kawakami et al., 
2006; Smiraglia et al., 2002; Netto et al., 2008; Almstrup et al. 2010; Wermann et al. 
2010; Ushida et al., 2012). These features highlight the complexity of these germline 
cells and have led investigators to anticipate that a sequence of unique events may 
determine how TGCTs arise and develop that is distinct for each individual. Whether 
the immune cell milieu contributes to these outcomes is an area of high interest and 
of relevance to TGCT as well as other solid tumours. 
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Fig. 6: Development of testicular germ cell tumours (TGCTs). Gonocytes that fail to 
differentiate properly but survive past birth can develop into the precursor germ cell 
neoplasia in situ (GCNIS) cells, most probably following more than one developmental insult 
that converts a non-neoplastic, dormant pre-GCNIS cell into a more proliferative GCNIS. 
During puberty, an alteration of the somatic environment, including those in response to 
hormones, may be permissive for increased proliferation of GCNIS and allow certain cells to 
transform into homogenous seminoma or heterogeneous non-seminoma that will be 
diagnosed as forming TGCTs. Adapted from K. L. Loveland. 
 
 
1.3.3 Immune cells associated with testicular cancer 
 
The testicular neoplasia subtypes GCNIS and seminomas frequently contain immune 
cell infiltrations (Bell et al., 1987; Nakanoma et al., 1992; Wei et al., 1992; Bols et al., 
2000). Recent studies have shown that several different immune cell types can be 
present simultaneously in the testicular germ cell tumour environment. This includes 
T-cells (CD3), B-cells (CD20) and various antigen-presenting macrophage and DC 
subsets (Klein et al., 2016; Zheng et al., 2016). Zheng et al. identified two distinct 
macrophage subtypes, CD68+/CD163- and CD163+/CD68-, in seminoma specimens 
(Zheng et al., 2016), however these were not further characterised, nor was the rela-
tionship between different immune cell types thoroughly explored. Zheng et al. identi-
fied CD11c+cell aggregates around seminoma tumour cell clusters and postulated 
that these cells are CD11c+mDCs that could recruit CD68+ macrophages (Zheng et 
 
  CHAPTER 1 
  19 
al., 2016). However, CD11c is also expressed by M1 macrophages (Hume, 2008), 
thus additional analysis to resolve this is required, and respective new results are 
described in this thesis (Chapter 2). 
Among DC subsets, myeloid DCs, can exhibit stimulatory functions, whereas 
plasmacytoid DCs are reportedly involved in immune suppression and tolerance (Ma 
et al., 2013). Both types are characterised as immune-suppressive DC (Ma et al., 
2013; Tran Janco et al., 2015). In general, different DC subsets are involved in 
tumour progression and anti-tumour immunity, and their functions appear to be 
complex and potentially context-dependent (Ma et al., 2013). Typical markers for 
human pDCs are CD123, CD303 (also known as BDCA-2) and CD304 (BDCA-4), 
whereas mDCs are stratified into two subclasses depending on their surface antigen 
profiles; mDC1 express CD1c and CD11c, and mDC2 have CD11c and CD141 (Tran 
Janco et al., 2015). Zheng et al. identified different markers for mDCs in the testis, 
such as CD11c and DC-SIGN (Zheng et al., 2016). Additionally, other DC subsets 
such as CD1a+/CD207+ and pDCs (CD123+/CD303+ (BDCA-2+) were detected 
within seminoma specimens (Zheng et al., 2016); a third pDC marker, CD304 
(BDCA-4) was not included in that study.  
The importance of providing a clear documentation of antigen-presenting cell sub-
types is demonstrated from investigations of other cancer types, such as breast can-
cer and melanoma, in which various DC subsets (CD11c, CD141 (BDCA-3) and 
CD11c, CD1c (BDCA-1)) are present (Broz and Krummel, 2015). Of significance, 
tumours which contain CD141+DC cells show a better clinical outcome (Broz et al., 
2014; Sluijter et al., 2015; Broz and Krummel, 2015). The recruitment of DCs is most 
likely the consequence of local chemokine secretion, since the receptor for CCL20, 
CCR6, is expressed on the myeloid DCs present in these tumours. Further investiga-
tion in these tumour subtypes as well as in TGCTs is warranted to specifically identify 
the cytokine and chemokine receptors which are expressed by DCs. However, it 
must be recognized that a detailed analysis of DC populations that includes determi-
nation of how their functional polarization is associated with cancer is challenging, 
due to their diversity. Developments including the application of single cell RNA-
sequencing of patient-derived samples obtained following surgery should aid clarifi-
cation of the frequency and function of different immune cell subtypes. 
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1.3.4 Function of tumour-associated macrophages and dendritic cells  
 
In their role as antigen presenting cells, DCs and macrophages can provide crucial 
information about the physiological state of the individual to the immune system. Ma-
ture DCs and M1 macrophages are known to be potent killers of tumour cells (Man-
tovani et al., 2002; Koh and DiPietro, 2011; Mills et al., 2000). Tumour cells have the 
capability to alter their microenvironment and, thus, influence adjacent macrophage 
and DC phenotypes (Sica et al., 2002). Tumour infiltrating dendritic cells (TIDC) in 
breast cancer and tumour associated macrophages (TAM) are mostly immune-
suppressive and known to indicate a poor patient prognosis (Mantovani et al., 2002; 
Tran Janco et al., 2015). In this respect, TAMs are relatively well characterized in 
cancers other than TGCT. For instance, TAMs are functionally similar to M2 macro-
phages, which can express CD163 and CD206, and they can modulate their im-
mune-suppressive properties by producing higher level of anti-inflammatory cytokines 
(Sica et al., 2008 a); Yang and Zhang, 2017). In contrast, significant diagnostic chal-
lenges posed by DC diversity are clinically important to resolve in cases of cancer, 
because the presence of TIDCs can indicate a poor or good prognosis that depends 
on the cancer type (Tran Janco et al., 2015). TIDCs can exhibit low costimulatory 
molecules and subsequently low antigen cross-presentation capacity and high ex-
pression of regulatory molecules and receptors, which are associated with immuno-
suppression (Harimoto et al., 2013; Krempski et al., 2011; Tran Janco et al., 2015) 
Another important aspect of DC contributions to cancer development is their matura-
tion stage. Immature DCs are immune-suppressive, and in certain cancer types it has 
been shown that a high density of immature DCs correlated with a poor outcome and 
a low survival rate in animal models (Van Beek et al., 2014). Interestingly, in many 
cancer types such as breast cancer, neck and head cancer, and melanoma, pDCs 
display an immature DC phenotype which tends to be tolerogenic with low production 
of IFNγ (Tran Janco et al., 2015). pDC can express Indoleamine-pyrrole 2,3-
dioxygenase (IDO) that induces Treg expansion or produce inducible T-cell co-
stimulator ligand (ICOSL), that can control Treg expansion and be permissive for 
breast cancer progression via Treg-related IL-10 (Redpath et al., 2013; Veglia and 
Gabrilovich, 2017). Importantly, in the testis, tumour associated mDC (CD11c+DC-
SIGN+CCR6+HLA-DR-CD83-) are postulated to comprise immature DC subsets 
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(Zheng et al., 2016). These findings indicate that mDC in the testis and pDC in other 
cancer types are immature and may exert immune-suppressive effects. 
Zheng et al. have shown that mDC express CCR6, which can bind CCL20 when ex-
pressed by immature DCs (Schutyser et al., 2003). It has been reported that eosino-
phils, dendritic cells and macrophages, including TAMs, can also express CCL20 
(Caux et al., 2002; Mantovani et al., 2002). Furthermore, the recruitment and pheno-
type of DCs seems to be completely individual, when different tumour growth stages 
are compared (Krempski et al., 2011; Scarlet et al., 2012). However, this has to be 
further investigated in TGCT by the identification of the full suite of cytokine and 
chemokine receptors which can be expressed by DC subsets.  
 
1.3.5 Contribution of tumour cells to macrophage and DC polarization  
 
As described above, chemokines and cytokines play an important role in macro-
phage and DC recruitment and polarization in various types of cancers (Section 
1.3.5). In recent years it has been recognized that tumour cells are a key contributor 
to the tumour cell immune microenvironment, through the secretion of macrophage 
recruitment and polarization factors. The functional polarization of macrophages into 
an immunosuppressive phenotype may occur in response to IL-6 and CCL-2 secret-
ed by tumour cells (Conti and Rolens, 2004; Roca et al., 2009; Sierra-Filardi et al., 
2014). 
Interestingly, both IL-6 and CCL-2 are highly expressed in the testicular cancer mi-
croenvironment where macrophages (CD68, CD163) and DC subsets such as 
CD11c+mDCs are detectable, providing evidence that neoplastic germ cells directly 
drive macrophage and DC functionality (Klein et al., 2016; Zheng et al., 2016). How-
ever, the cellular origin of IL-6, CCL-2 and other key factors, as well as the respon-
sive cell types remains to be determined and will be described later in this thesis 
(Chapters 2, 3 and 4).  
Another potential polarization factor is CCL5, which can also be expressed by cancer 
cells and might be associated with testicular neoplasia (Azenshtein et al., 2002; Soria 
and Ben-Baruch, 2008; Klein et al., 2016). In other cancer types, CCL5 is known as a 
monocyte/macrophage activation and recruitment factor for immature DC (Scarpino 
et al., 2000; Locati, 2002). CCL17 and CCL22 can be expressed by tumour cells 
(Mantovani et al., 1992) and can affect T-cell polarization. The detection of chemo-
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kines CCL2, CCL18, CCL17 in different tumours has been linked to the functional 
polarization or presence of immune-suppressive M2 macrophages (Roca et al., 2009; 
Kim et al., 2009; Erler et al., 2009; Mantovani et al., 2008). The production and locali-
zation of these chemokines in testicular neoplasia may be important to both the in-
nate and adaptive immune responses at different phases of TGCT development. 
CCL17 was recently described as being highly upregulated in Sertoli cells surround-
ing GCNIS but not in later stages, as well as present in a subset of cells within the 
interstitium with morphological characteristics of immune cells (Szarek et al., 2018).  
The functional impact of this chemokine on tumour cells or somatic cells present in 
testicular neoplasia remains unknown. 
Tumour cells have the capability to elude strong immune reactions by expression of 
cytokines that drive macrophage and DC polarization and subsequently inhibit the 
function of these antigen-presenting cells (Gabrilovich, 2004). Interestingly, in carci-
noma of the cervix, tumour-derived IL-6 and PGE2 can drive M2 macrophage polari-
zation (Heusinkveld et al., 2011a/b), demonstrating the potential of tumour cells to 
drive macrophage polarization by their production of cytokines and chemokines. 
However, much remains to be learned about the cytokine and chemokine profiles 
associated with recruitment and polarization of macrophage and DC subsets in the 
human testis, reflecting their putative pathological roles in testicular neoplasia. These 
topics are addressed by the experiments presented in this thesis.  
 
 
1.3.6 Immune checkpoints 
 
Innate and adaptive immune responses play important roles in controlling and sup-
pressing tumour cell growth (Schreiber et al., 2011). For instance, APCs belonging to 
the innate arm of the immune system can recognise and present antigens to T cells, 
thereby activating the adaptive immune system (Janeway, 2001). This can enable an 
effective immune reaction to be mounted against cancer cells that will restrict tumour 
growth or progression. However, synergistic immune reactions must be orchestrated 
by immune cells that can be influenced by so called immunologic regulators. Several 
negative immunologic regulators, e.g. TIM-3/Galectin-9, PD-1/PD-L1, can suppress 
effective immune reactions to subsequently enhance tumour growth (Fig. 7).  
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One of the best understood pathways is that used by cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4) and the programmed cell death protein 1 (PD-1/PD-
L1). A blockade of CTLA-4 by antibodies leads to strong immune responses against 
tumour cells (Leach et al., 1996; van Elsas et al., 1999). However, PD-1 is expressed 
by activated T-cells and can bind to the ligands PD-L1 and PD-L2. Interestingly, the-
se ligands are negative regulators of T-cell activation and are expressed by both, 
APCs and tumour cells, with the functional outcome being repression of T-cell effec-
tor functions (Postow et al., 2015) (Fig. 7). In TGCTs, particularly seminoma, PD-L1 
was identified as present in approximately 73% of cases (n=208) but absent from the 
pre-invasive GCNIS (Fankhauser et al., 2015). Seminomas are mostly associated 
with an increase in macrophage and DC subsets which could correlate with this re-
ported detection of PD-L1 in most seminoma samples. In mouse models, tumour 
cells, macrophages and DCs (cells with CD11c, CD11b (CD1c counterpart of mouse 
CD11b), Gr1 and F4/80) can express PD-L1 (Deng et al., 2014). Additionally, in mice, 
DCs can also express PD-1 (Lim et al., 2016). This suggests that DCs might interact 
with tumour cells by binding PD-L1 through PD-1 which means that TCs could sup-
press DCs in addition to T cells However, in healthy human donors, some DC sub-
sets express PD-L1 (CD141+ mDC and CD123+pDC), while others do not 
(CD1c+mDC). In contrast, in hepatocellular carcinoma (HCC) patients, all three DC 
subsets, CD141+ mDC, CD123+pDC and CD1c+mDC, are able to express PD-L1 
(Lim et al., 2016).  
In mice the expression of PD-L1 by DC can inhibit T cell proliferation and activation 
through downregulation of NF-kB (Krempski et al., 2011). NF-κB pathway can aner-
gize the immune system and subsequently promote tumour growth (Xia et al., 2014). 
Lim et al. showed that PD-1 deficient mice (DCs) have increased IL-2 and IFN-γ cy-
tokine expression in vitro; this suggested that PD-L1 expressed by DCs is responsi-
ble for the immune-suppression of T-cells by decreasing IL-2 and IFN-γ cytokine ex-
pression and antigen-specific CD8+ proliferation in vivo. Additionally, in a hepatocel-
lular carcinoma (HCC) patient, Lim et al. have shown that PD-1 can be expressed by 
CD11c+cells (Lim et al., 2016). Therefore, treatment with anti-PD-1 antibodies could 
have an effect on circulating DC, an outcome that has yet to be directly documented. 
However, revealing DC and macrophage subsets which express high levels of PD-L1 
and/or PD-1 and are associated with testicular cancer could be a helpful avenue for 
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development of evidence-based therapies that capitalize on new knowledge about 
immune checkpoints to reinforce anti-tumour immunity.  
Furthermore, the immune checkpoint TIM-3 is also known as regulator of immune 
reactions and is expressed by macrophages and dendritic cells as well as Galectin-9 
(Das et al., 2017). A binding of TIM-3 to Galectin-9 leads to a suppression of the in-
nate immune system (Das et al., 2017). 
 
 
Fig. 7: Immune checkpoints and the immune-suppressive role of TIDCs. DCs can 
migrate to the tumour environment and upregulate the expression of molecules such as T 
cell Ig and mucin domain 3 (TIM-3), programmed cell death protein (PD-1) and programmed 
death-ligand 1 (PD-L1) that are known as immune checkpoints. TIDCs can interact with T 
cells by binding of PD-1 and PD-L1 which leads to an immune-suppression of T cells. TIDCs 
activate the production of retinoic acid that induces Treg differentiation. Additionally, TIDCs 
upregulate the expression of TIM-3 by tumour-induced IL-10, TGF-b1, VEGF-A, IDO. A 
binding of TIM-3 and High mobility group box 1 protein (HMGB1) leads to an 
immunosuppressive or non-immunogenic phenotype. From Tran Janco et al., 2015. 
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CONCLUSION 
 
Macrophages and DCs display phenotypic plasticity that exhibit completely different 
functions. Macrophages can be involved in tissue remodelling, cell homeostasis and 
play an important role in the testis to maintain an immunosuppressive milieu that pro-
tects germ cells from autoimmune attack. In contrast, macrophages and DCs can 
also be involved in tumour progression and tumour destruction. TGCTs are most fre-
quently associated with immune cell infiltrations that include macrophages and DCs. 
Thus, we characterised macrophages and DC subsets that are associated with 
pathological alterations such as testicular neoplasia (Chapter 2). Additionally, we in-
vestigated how tumour cells modulate immune cell responses (addressed in Chap-
ters 3 and 4). In conclusion, it is important to understand how immune cells, which 
serve an immune-protective role in the healthy testis, may contribute to the emer-
gence or progression of TGCTs using strategies that reflect their diversity and func-
tional flexibility. 
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Chapter 2 
 
Detailed analysis of immune cells in the human testis in normal physio-
logical and pathological conditions, with a focus on macrophage and 
dendritic cell subsets  
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CHAPTER 2: Detailed analysis of immune cells in the human testis 
under physiological and pathological conditions, with a focus on 
macrophage and dendritic cell subsets  
2. INTRODUCTION 
 
This study was conducted to analyse immune cells that are specifically associated 
with TGCTs, with a focus on antigen-presenting-cells (APCs) such as macrophages 
and dendritic cells. Macrophage and dendritic cell subsets show different phenotypic 
characteristics and can change their functional state depending on the environment 
(Stout et al., 2005). Tumour cells can alter the local microenvironment by their pro-
duction of cytokines and chemokines, thus affecting the function of APCs (Schraml 
and Reis e Sousa, 2015); subsequent functional polarization of APCs into immune-
suppressive phenotypes under the influence of tumour cell products is therefore pos-
sible (Mantovani et al., 2002).  
In this study, an identification of macrophage and DC subsets associated with testicu-
lar neoplasia (GCNIS and seminoma), in comparison with those present in clinical 
specimens with normal spermatogenesis was conducted. The tumour-immune-cell 
environment was evaluated to assess potential factors such as chemokines and cy-
tokines that may recruit and promote differentiation of macrophages and DCs under 
pathological conditions. In addition, we examined chemokine receptor expression in 
macrophages to confirm that these cells are potential targets of the previously de-
tected chemokines. We also characterized M1 and M2 macrophage cytokine expres-
sion profiles, revealing pro-inflammatory (M1: IL-12, TNF-a) and anti-inflammatory 
(M2: IL-10, TGF-b) cytokines, underpinning the concept that there is a dual function 
of immune cells, such as macrophages, in the testis.  
This is the first comprehensive study to reveal a functional polarization and recruit-
ment of macrophage and dendritic cell subsets associated with neoplasia (GCNIS 
and seminoma) caused by the alteration of the cytokine and chemokine milieu. Out-
comes from this study contribute to understanding the pathological development of 
GCNIS into seminoma by revealing the characteristics of immune cell subsets and 
how they contribute and respond to the specific microenvironment of neoplasia in the 
human testis. 
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2.1 MATERIAL AND METHODS 
2.1.1 Patients 
 
Testicular tissue was obtained from men, who underwent testicular biopsies during 
andrological work-up for infertility (Bergmann and Kliesch, 2010; Marconi et al., 
2012), during vasectomy or vasectomy reversal, or during surgery for testicular can-
cer. Specimens were collected at the Department of Urology, Pediatric Urology and 
Andrology at Giessen University Hospital and at the Department of Clinical Androlo-
gy, Center for Reproductive Medicine and Andrology at the University of Münster. All 
patients had given their written informed consent to use archived tissue specimens 
for research purposes (approved by the ethics committee of the Medical Faculty of 
the Justus Liebig University Giessen; Ref. No. 100/07; 26/11; 156/16). 
2.1.1.1 Routine Histology 
 
Testicular tissue specimens were immediately fixed by immersion in Bouin’s solution 
overnight and embedded in paraffin for further histological and immunohistochemical 
analyses. Depending on the material (e.g. sample size) available, a fraction was also 
snap-frozen using liquid nitrogen and cryopreserved for RNA extraction, cDNA syn-
thesis, and RT-qPCR. For histological evaluation, 5μm thick sections were prepared 
and stained with hematoxylin and eosin (HE) according to standard protocols. After-
wards, the HE-stained tissue sections were analysed to assess spermatogenic status 
and histopathological alteration, including a score count evaluation of spermatogene-
sis according to Bergmann & Kliesch (2010). Score counts (SC) can range from 10 to 
0, which reflects the frequency of tubules containing elongated spermatids, with an 
SC 10 corresponding to elongated spermatids being present in every tubular cross-
section and SC 0 corresponding to the complete absence of elongated spermatids. 
Subsequently, pathological conditions such as germ cell neoplasia in situ (GCNIS) 
and homogeneous seminoma specimens were identified. Testicular tissue specimens 
were grouped as follows: Group 1: normal spermatogenesis (nsp) without immune 
cell (lymphocytic) infiltrates (n=12; median age: 32 years, range 18-46 years; range 
of score count 9–10, median 10). Group 2: GCNIS associated with inflammatory infil-
trates (n=17; median age: 32 years, range 28–45 years). Group 3: manifest semi-
noma associated with immune cell infiltration (n=17; median age: 34 years, range 
21–61 years). 
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2.1.2 Immunohistochemistry  
 
Bouin’s fixed, paraffin-embedded tissue samples from human testis were evaluated 
by immunohistochemistry (IHC) and immunofluorescence (IF) (see Tab. 2.1.2.1, list 
of antibodies). Markers used were (1) for M1 macrophages: CD11, CD68; (2) for M2: 
CD163, CD206; (3) for mDC1: CD1c, CD11c; (4) for mDC2: CD11c, CD141; (5) for 
pDC: CD123, CD303, CD304; (6) for T cells: CD4, CD8; (7) for B cells: CD19. Anti-
bodies recognising IL-6 (cytokine), Rab7 (phagocytosis marker), and CCR1, CCR2, 
CCR3, CCR4, CCR5 and CCR8 (chemokine receptors) were also used. 
 
IHC staining was performed using 5 µm sections of Bouin’sfixed and paraffin-
embedded samples. Every section was deparaffinised in Xylol (2x 10 min.) and rehy-
drated using an ethanol gradient (100%, 96%, 80%, 70%, ddH2O, 5 min each). Af-
terwards, heat-mediated antigen retrieval by Tris-EDTA treatment or Citrate-treatment 
was conducted using a microwave oven (15 min, 460 Watt)(see Appendix). Wash 
steps were performed after each antibody incubation using wash buffer containing 
0.1%Tris-EDTA, TritonX100 in ddH2O. Endogenous peroxidase activity in tissue sec-
tions was blocked by exposure to 3% (v/v) H2O2 at room temperature (RT) for 30 min. 
After washing, a blocking solution (5% BSA in wash buffer) was applied for 30 min at 
RT, then tissue sections were treated with the primary antibody (Tab. 2.1.2.1, antibod-
ies and dilution) overnight at 4°C in a humid chamber. sections were washed, incu-
bated with secondary antibodies (Tab. 2.1.2.2) at room temperature for 1 h, then 
washed and exposed to peroxidase-conjugated streptavidin (Vectastain Elite ABC 
Kit; Vectorlabs, Burlingame, CA, USA) for 30 min at RT. Visualization was performed 
by using 3-Amino-9-Ethylcarbazole (AEC) (Biologo, Kronshagen, Germany) or 3,3′-
Diaminobenzidine (DAB) (Biologo, Kronshagen, Germany) solution, depending on 
the antibody sensitivity. Nuclear counterstaining employed hematoxylin (Carl Roth 
GmbH & Co. KG, Karlsruhe, Germany). Afterwards slides were treated with Kaiser’s 
glycerin gelatine (Merck, Darmstadt, Germany). For negative controls, treatment with 
primary antibodies was omitted. The visual evaluation was made with an upright mi-
croscope (Leica DM750 with Leica ICC50 HD, Solms, Germany). 
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Tab. 2.1.2.1 List of primary antibodies 
Primary antibody Manufacturer Dilution 
monoclonal mouse anti-
human CD11c antibody  
Novocastra, 
Germany,  
NCL-L-CD11c-563 
1:100 
monoclonal rabbit anti-
human CD11c antibody  
10 µl at 0.103 mg/ml 
Abcam 
ab52632 
 
1:100 
monoclonal mouse anti-
human CD68 antibody  
DAKO, Denmark  
MO876 
1:100 
rabbit polyclonal anti-human 
CD163 
0.6mg/ml 
DB biotech, Slovakia 
DB045-0.5 
1:100 
monoclonal mouse anti-
human CD206  
200µg/ml 
Santa cruz 
sc-376108 
 
1:100 
monoclonal mouse anti-
human CD123 
0.5mg/ml 
BD pharmingen 
555642 
1:100 
anti-human CD141  
 
Sigma ALDRICH 
HPA002982 
1:50 
rabbit anti-human CD303 
(ANTI-CLE4C)  
0.5mg/ml 
Sigma ALDRICH 
HPA029432 
 
1:20 
rabbit anti-human CD304 
(ANTI-NRP1)  
0.2mg/ml 
Sigma ALDRICH 
HPA030278 
 
1:20 
monoclonal rabbit anti-
human CD4, Clone OKT4 
25µg 
Abcam 
ab133616 
 
1:250 
monoclonal mouse anti-
human CD8 
0.5mg/ml 
Ebioscience 
Cat:14-0008-80 
Clone lc1 
1:250 
monoclonal mouse anti hu-
man CD19 
0.5mg/ml 
Ebioscience 
Cat:14-0190-80 
Clone lc1 
1:500 
monoclonal mouse anti-
human IL-6 
500µg 
invitrogen 
AHC0762 
1:100  
monoclonal mouse anti-Rab7 
2.1 mg/ml 
Abcam 
ab50533 
1:100  
rabbit anti-human CCR1 
0.5mg/ml 
Novus 
NB100-56334ss 
1:20 
rabbit anti-human CCR2 
1mg/ml 
Novus 
NBP1-48337ss 
1:50 
rabbit anti-human CCR3 
1mg/ml 
Novus 
NBP1-77065 
1:100 
goat anti-human CCR4 
1mg/ml 
Novus 
NB100-717 
1:50 
monoclonal mouse anti-
human CCR5 
25ug 
R&D 
MAB181 
 
1:50 
goat anti-human CCR8 
1 mg/ml 
Novus 
NB100-710 
1:50 
  CHAPTER 2 
  31 
Tab. 2.1.2.2 List of secondary antibodies 
Secondary antibody Manufacturer Dilution 
Biotinylated rabbit anti-
goat 
E0466 
Dako, Glostrup, 
Denmark 
 
1:200 
Biotinylated goat anti-
rabbit 
E0432  
Dako, Glostrup, 
Denmark 
 
1:100 
Biotinylated goat anti-
mouse 
E0433 
Dako, Glostrup, 
Denmark 
 
1:100 
 
 
2.1.3 Semi-quantitative analysis of infiltrating immune cells 
 
The ratio of M1 to M2 macrophage numbers was analyzed and quantified by visual 
inspection of slides from every patient group which had been stained with M1- and 
M2-specific markers (IHC). Patient samples from every group were separately ana-
lyzed for each marker and scored as follows: 0, no cells with signal detected; 1, indi-
vidual cells detected; 2, multiple cells detected, scattered distribution; 3, moderate 
frequency of cells detected, sparse infiltrate; 4, high frequency of cells with positive 
staining, dense infiltrate. Data are expressed as mean ± SD by GraphPad (Prism 5). 
Statistical significance was evaluated using One Way Anova followed by Tukey post-
test. A p-value less than 0.05 indicated a statistical significance. 
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2.1.4 Immunofluorescence 
 
IF staining was performed as described above (Section 2.1.2), up through the incuba-
tion with primary antibodies. Subsequently, slides were washed 3x 5 min on a shak-
er, and the secondary antibodies diluted in washing buffer added for IF double stain-
ing (detection of two marker for one section) and incubated for 1 h at RT (Tab. 
2.1.3.1). Afterwards, sections were incubated with 4′,6-diamidino-2-phenylindole 
(DAPI, 0.2 µg/ml, diluted in washing buffer) (Merck, Darmstadt, Germany) for 10 min, 
washed and mounted using Fluoromount™ Aqueous Mounting Medium (Merck, 
Darmstadt, Germany). The visual evaluation was conducted by means of a fluores-
cence microscope (Olympus, Center Valley, PA, USA). 
 
Tab. 2.1.3.1 List of secondary antibodies (IF) 
Secondary antibody Manufacturer Dilution 
Alexa 488 donkey anti-
rabbit 
Thermo Fisher 
R37118 
1:100 
FITC goat anti-mouse 
 
Sigma ALDRICH 
F0257-1ML 
1:100 
Cy3 donkey anti-  1:200 
Alexa donkey 594 anti-
rabbit 
Thermo Fisher  
R37119 
1:100 
 
 
2.1.5 RNA extraction, cDNA synthesis, RT-PCR and quantitative real-time 
PCR 
 
Snap-frozen testicular biopsies were cryopreserved until RNA extraction and used for 
cytokine and chemokine expression profiling. The same patient groups as for IHC/IF 
experiments (nsp n=4, GCNIS n=6, seminoma=10) were used. For CCL15 analysis, 
six additional nsp samples were used to subsequently confirm the presence of 
CCL15 in the testis under normal conditions (nsp=10, GCNIS=4, seminoma=6). Total 
RNA was extracted using TRizol® (Sigma Aldich, St. Louis, MO, USA) according to 
the manufacturer`s protocol. cDNA was synthesized using MultiScribe® Reverse 
Transcriptase (50 U/µl, Applied Biosystems, Waltham, MA, USA). For RT-PCR, spe-
cific primers were designed to analyze cytokines/chemokines, chemokine receptors, 
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prostaglandin synthase E2 and distinct immune checkpoint molecules (Tab. 2.1.5.1, 
primer list). Five µl of cDNA plus 20 µl master mix according to Tab. 2.1.5.2 were 
prepared and PCR run was performed (Appendix, Chapter 2). PCR products were 
visualized using a 1.5% agarose gel (Appendix, Chapter 2) for 75 min at 130 V. 
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2.1.5.1 Tab. of designed primer 
Target Accession 
number 
Used as: Forward pri-
mer, 5’- 3’ 
Reverse primer, 5’- 3’ 
GAPDH  NM_002046.6 Housekeeper TGACAACAG
CCTCAA-
GATC 
TCCTTCCACGATAC-
CAAAG 
Bactin  NM_001101.4 Housekeeper TTCCTTCCT
GGG-
CATGGAGT 
TACAGGTCTTT-
GCGGATGTC 
IL-6 NM_000600.4 
 
Potential 
macrophage 
polarization 
factor 
TACCCCCAG
GAGAAGAT-
TCC 
AGATGCCGTCGAG-
GATGTAC 
PTGES 2 NM_004878.4 
 
Potential 
macrophage 
polarization 
factor 
GGAC-
GGAGGA-
GATGAAGTG 
GCGGACAATGTAG-
TCAAAGG 
TIM-3 AB924452.1 Immune 
checkpoint 
CCTATCTGC
CCTGCTTC-
TAC 
TCACATCCCTTTCAT
CAGTC 
Galectin-9 NM_009587.2 Immune 
checkpoint 
TCAATGG-
GAC-
CGTTCTCAG 
 
TTGAAGTG-
GAAGGCAATGTC 
 
CCR1  NM_001295.2 chemokine 
receptor 
AAA-
GCCCCAGAA
ACAAAGAC 
TTGCATCCCCA-
TAGTCAAAC 
CCR2  NM_0011230
41.2 
chemokine 
receptor 
GACCCACAA
GATAAA-
GAAGC 
TTGAGGTCTCCAGA
ATAGG 
CCR3  NM_001837.3 chemokine 
receptor 
GTGGTGGTG
GTGATGATC
C 
ATGCCCCCTGACAT
AGTGG 
CCR4  NM_005508.4 chemokine 
receptor 
CTGCTCTTC
GTGTTTTCC
C 
AAAGCCCAC-
CAAGTACATCC 
CCR5  NM_000579.3 chemokine 
receptor 
TAGTGG-
GATGAG-
CAGAGAAC 
GGCGAAAA-
GAATCAGAGAAC 
CCR8  NM_005201.3 chemokine 
receptor 
GTTTGG-
GACTG-
TAATGTGC 
TGATCGTCCTCAC-
CTTTAG 
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                      Tab. 2.1.5.2 Master mix for RT-PCR 
Reagents Per attempt 
MgCl2  
25 mM 
1 µl 
PCR buffer 10x 2 µl 
RNAse free H2O 15.37 µl 
dNTPs  
10 mmol 
0.5 µl 
Primer rev.  
10 pmol/ µl 
0,5 µl 
Primer for.  
10 pmol/ µl 
0,5 µl 
Gold Amplitag  
5U/ ml 
0,13 µl 
Total  20 µl 
 
 
For quantitative analysis of mRNA expression, real-time PCR amplification was per-
formed using specific Taqman Gene Expression Assays (Tab. 2.1.5.3) (LifeTechnolo-
gies, Carlsbad, CA, USA). For each specimen, triplicate determinations were per-
formed using 2 µl cDNA (diluted 1:20 in RNAse free H2O) plus 5 µl TaqMan® Gene 
Expression Master Mix (LifeTechnologies), 0.5 µl TaqMan® Gene Expression Assay 
(Tab. 2.1.5.3, specific Taqman Probe) and 2.5 µl RNAse free H2O (per well). qRT-
PCR was performed on a CFX96 RealTime cycler (Bio-Rad, Munich, Germany). Rel-
ative gene expression was calculated using CFX Manager Software 3.0 (Bio-Rad). 
For statistical analysis, a one-way-ANOVA test was performed followed by a Tukey's 
Multiple Comparison Test (GraphPad, Prism 5.01). Relative gene expression was 
calculated using the ΔΔCT method. Data were expressed as fold-change, normalized 
to ACTB as well as calibrated to nsp. 
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                                 2.1.5.3 Table of TaqMan probes 
Target Product No. 
Human ACTB Hs01060665_g1 
Human GAPDH  Hs02758991_g1 
Human IL-1b  Hs01555410_m1 
Human IL-12a Hs01073447_m1 
Human TNFα Hs00174128_m1 
Human IL-6 Hs00174131_m1 
Human IL-10 Hs00961622_m1 
Human TGFβ1 Hs00998133_m1 
Human CCL2 Hs00234140_m1 
Human CCL5 Hs00982282_m1 
 
2.1.6 Protein isolation, SDS-PAGE and western blot 
2.1.6.1 Protein isolation from cryopreserved testis tissue 
 
Snap-frozen biopsies were washed twice with PBS, before 1 ml lysis buffer (APL 
buffer, Qiagen) was added and specimens were incubated for 5 min at RT. After-
wards, the tissue was homogenized by a Homogenizer (IKA® T-10 basic Ultra Turrax 
Homogenizer IKA® Werke GmbH & CO. KG, Staufen, Germany) for 6x 30 sec., then 
protein was extracted by using AllPrep® RNA/ Protein Kit (Qiagen) according to the 
manufacturer’s protocol. Protein concentration was measured using a Bicinchoninic 
Acid Protein Assay Kit (Sigma Aldrich) according to the manufacturer’s protocol. The 
absorbance of the solution was measured with a photometer at a wavelength of 562 
nm.  
2.1.6.2 Protein isolation from paraffin-embedded testis tissue 
 
Paraffin-embedded tissue was cut and 4 sections (with a thickness of 10 µm) were 
collected into an Eppendorf tube. Afterwards, protein isolation was performed using 
Qproteome FFPE Tissue Kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s protocol. The protein concentration was measured as described above 
(2.1.6.1).  
2.1.6.3 Gel electrophoresis 
 
For the gel electrophoresis, 11.7 µl of the sample (total concentration between 30 
and 40ng/ml, diluted in RNase free water) plus 4.5 µl NuPAGE® sample buffer and 
1.8 µl NuPAGE® Reducing agent were suspended and incubated for 10 min at 72°C. 
In the meantime, a NuPage® Novex 4–12% Bis–Tris gels (Invitrogen) was prepared 
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in the gel apparatus (BioRad) filled with diluted 3-(N-morpholino)propanesulfonic acid 
(MOPS) buffer (50 ml NuPAGE® MOPS Running Buffer 10x and 950 ml ddH2O) 
then samples were loaded into the wells, alongside a molecular size ladder (Page 
Ruler™Plus, Thermo Scientific). The electrophoresis was initially run at 50V (collect-
ing phase). After 15 min, electrophoresis speed was increased by running the gel at 
200V for an additional 45 min (separation phase). 
 
2.1.6.4 Protein transfer 
 
The apparatus for protein transfer was prepared and filled with transfer buffer (50 ml 
NuPAGE® transfer buffer, 1 ml NuPAGE® antioxidant, 200 ml Methanol, 749 ml 
ddH2O). Polyvinylidene difluoride (PVDF) membrane (Thermo Fisher) was activated 
for 2 min by soaking in methanol; sponges and whatman filter (BioRad) were incu-
bated in transfer buffer. Protein transfer was performed at 30 V for 1h 15 min. 
After the successful protein transfer, non-specific binding sites were blocked using 
blocking buffer (1.5 g BSA, 1.5 g milk powder in 30 ml PBS) for 30 min on a shaker at 
RT. In the meantime, primary antibodies against Rab7 (dilution 1:2000), p65 (dilution 
1:500), and β-Actin (dilution 1:5000) were incubated overnight at 4°C. Antibody dilu-
tion was performed using washing buffer containing 1% BSA, 0.1% Tween in PBS. 
On the next day, primary antibodies were discarded and PVDF-membranes were 
washed 3 x times with washing buffer. Afterwards, unspecific binding sites were 
blocked with goat or mouse serum (5% of the serum, diluted in washing buffer) for 15 
min at RT. The solution was discarded, replaced with secondary antibody (PO-anti 
mouse, 1:5000; PO-anti rabbit, 1:5000) diluted in washing buffer and incubated for 1 
h at RT. After the incubation, the membrane was washed 2 x times using PBS/ 0.1% 
Triton and finally washed with PBS. Antibody staining was visualized by using Lumi-
nata (Immobilon Forte Western HRP substrate, Merck). Luminata was incubated for 1 
min and developted by x-ray film (Amersham Hyperfilm ECL, GE Healthcare) and x-
ray cassette (Henry Schein). Development solution (TETENAL) was added until the 
protein bands were visible. Afterwards, the visible protein bands were fixed with fixa-
tion solution (TETENAL). The development was stopped with 3% acetic acid. 
 
 
 
 
  CHAPTER 2 
  38 
Tab. 2.1.6.5.2 List of primary antibodies (WB) 
Primary antibody Manufacturer Dilution 
monoclonal mouse anti-
human Rab7 
2.1 mg/ml 
Abcam 
ab50533 
1:2000 
Monoclonal rabbit anti-
human p65 (NF-κB subu-
nit) 
1 mg/ml 
Sigma Aldrich 
SAB5600083-100UL 
1:500 
 
Tab. 2.1.6.5.2 List of secondary antibodies (WB) 
Secondary antibody Manufacturer Dilution 
Biotinylated goat anti-
rabbit 
E0432  
 
Dako, Glostrup, 
Denmark 
 
1:100 
Biotinylated goat anti-
mouse 
E0433 
Dako, Glostrup, 
Denmark 
 
1:100 
 
2.1.7 Analysis of immune cells in testes of Gilz KO and WT mice  
2.1.7.1 Histology  
 
The following protocol was adapted from Sivanjah Indumathy, Monash University, 
Clayton, Australia. The testis tissue was collected and fixed in PBS with 4% para-
formaldehyde (PFA) for 5 hours. Afterwards, the testis tissue was placed in 15% su-
crose solution diluted in PBS and incubated overnight at 4°C. On the next day, su-
crose solution was discarded, replaced with 30% sucrose diluted in PBS and incu-
bated overnight at 4°C. Testis tissue was washed 3x in PBS for 5 min and dried us-
ing tissue paper. Then the testis tissue was transferred in a plastic mold and slowly 
filled with Tissue-Tek OCT and put on dry ice. The testis tissue was stored in -80°C 
until slides were cut. Upon use, the tissue was cut in 5 µm-10 µm thick sections using 
a sliding microtome (Leica SM2000 R, Solms, Germany) and transferred to micro-
scope slides. Afterwards, the slides were stored at -20°C until needed. 
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2.1.7.2 Flow cytometry  
 
The mechanical dissociation of the testes was conducted immediately after the dis-
section. The tubules were gently separated and transferred in a 15 ml Falcon tube 
containing DMEM. The tubes were inverted twice and after 15 min, supernatant was 
transferred into a fresh Falcon tube and centrifuged at 1000rcf. Then the supernatant 
was discarded and the cell pellet resuspended in 1 ml FACS buffer. The cells were 
counted, splitted into Eppendorf tubes and stained (see antibody list 2.1.7.2 and 
2.1.7.3). For flow cytometric analysis, ten thousand events were acquired for each 
sample using the BD LSR Fortessa x20 flow cytometer (BD Bioscience, San Jose, 
USA). Data were analysed using FlowJO Version 10 (Tree Star, Ashland, USA) in the 
following manner. 
 
Table 2.1.7.2: List of direct conjugated antibodies (Myeloid panel) 
 
Immune cell type Antibody Dilution Fluorophore 
All immune cells CD45 (BD) 1:100 Pe-Cy7 
Macrophages (pan) F4/80 (Affymetrix) 1:100 APC 
DC CD11c (Biolegend) 1:100 Pacific blue 
M1 MHCII (Biolegend) 1:100 BV710 
M2  CD206 (Biolegend) 1:100 BV610 
Macrophages (pan) CD11b (Biolegend) 1:100 FITC 
 
Table 2.1.7.3: List of direct conjugated antibodies (Lymphoid panel) 
Immune cell type Antibody Dilution Fluorophore 
All immune cells CD45 (BD) 1:100 Pe-Cy7 
T cells CD3 complex (Bio-
legend) 
1:100 AF647 
NK cells NK1.1 (Biolegend) 1:100 BV421 
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2.2 RESULTS 
2.2.1 Human testis: Assessment of immune cells under physiological 
and pathologic conditions 
2.2.1.1 Anti-inflammatory M2 macrophages detectable in the normal testis 
whereas pro-inflammatory M1 macrophages were absent 
 
Testicular biopsies with normal spermatogenesis (range of spermatogenesis score 
counts 7-10) contained cells bearing macrophage specific markers such as CD68 
(monocytes, macrophages), CD163 and CD206 (M2 macrophages). In contrast, 
CD11c+ cells (macrophages and DC) were hardly present under normal conditions 
(single cells in three of twelve patient samples) (Fig. 2.2.1.1/ 2.2.1.3). Other dendritic 
cell markers such as CD123, CD141, CD303, CD304 as well as a B-cell marker 
(CD19) were not detectable in the non-inflamed tissue (Fig. 2.2.1.1). However, posi-
tive for CD4 and CD8 on single cells (T-cells) could be identified. All detectable im-
mune cells were scattered and located in the interstitial compartment.  
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2.2.1.2 IHC analysis revealed increased immune cell populations associated 
with testicular germ cell neoplasia 
 
In contrast to the normal human testis, neoplasia (e.g. GCNIS and seminoma) is as-
sociated with increased numbers of infiltrating immune cells, showing a maximum in 
seminoma (Fig. 2.2.1.2, hematoxylin-staining, white arrows). The presence of differ-
ent macrophage and dendritic cell markers such as CD68 (monocytes, macrophag-
es), CD11c (macrophages and DC), CD163 and CD206 (M2 macrophages) and 
CD11c, CD123, CD141, CD303, CD304 (DC) were revealed. Additionally, sections of 
all GCNIS and seminoma tissue specimens contained cells of the adaptive immune 
system such as T-cells (CD4, CD8) and B-cells (CD19)(Fig. 2.2.1.2, A/B).  
CD68 CD11c CD163 CD206 
CD304 CD303 CD141 CD123 
CD19 CD4 CD8 
Fig. 2.2.1.1: Analysis of immune cell populations in non-inflamed human testis tissue 
showing normal spermatogenesis (see hematoxylin-staining, nsp = normal 
spermatogenesis) by immunohistochemistry (IHC, 40x). Exemplary hematoxylin staining 
showed the testis histology under normal conditions. For a detailed immune cell analysis, 
different CD markers were used such as: CD68 (macrophages and monocytes), CD11c 
(dendritic cells and macrophages), CD163, CD206 (M2 macrophages), CD123, CD141, 
CD303 and CD304 (dendritic cells), CD4 and CD8 (T-cells) as well as CD19 (B-cells). Nsp 
samples contained cells of the innate immune system such as CD68+cells, M2 macrophages 
(CD163+ and CD206+) and sparse CD11c+ cells as well as few cells of the adaptive immune 
system, e.g. T-cells (CD4+, CD8+). Dendritic cell marker such as CD123+, CD141+, CD303+, 
CD304+ and B-cells (CD19) were not detectable. All detectable immune cells were highlighted 
using black arrows and shown with a higher magnification (see insets). H= hematoxylin.       
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The main focus of this study was the detection of macrophage and dendritic cell 
markers by IHC. In GCNIS samples, CD68+ and CD11c+ cells were detectable and 
localized in the interstitial compartment as well as within seminiferous tubules (Fig. 
2.2.1.2, A). Particularly, the detection of CD68+ and CD11c+ cells revealed a co-
localization of these markers in close proximity to GCNIS cells (Fig. 2.2.1.2, A). In 
seminoma samples, CD68+ and CD11c+ cells were found around and within tumour 
cell clusters (Fig. 2.2.1.2, B). Furthermore, of M2-specific markers such as CD163 
and CD206 could be identified in samples of all three patient groups (nsp, GCNIS, 
seminoma). Additionally, the following markers were used for the identification of 
DCs: CD11c, CD123, CD141, CD303, CD304. Of note, all markers were detectable 
in neoplasia samples. However, in GCNIS only single cells exhibiting dendritic cell 
markers were detectable, whereas in seminoma samples these markers were fre-
quently present (Fig. 2.2.1.2, A/B). To sum up, in human testicular neoplasia (GCNIS/ 
seminoma), a detection of increased macrophage and dendritic cell markers such as, 
CD163, CD206 (M2), CD68 (monocytes, macrophages), CD11c (DC, macrophages) 
and CD123, CD141, CD303, CD304 (DC) was observed (Fig. 2.2.1.2, A/ B). 
 
A semi-quantitative scoring analysis revealed a significant increase of M2 macro-
phage marker (CD163) associated with testicular neoplasia compared to the normal 
testis (Fig. 2.2.1.2/ 2.2.1.3.1). Additionally, GCNIS and seminoma samples showed a 
significant increase of other macrophage markers such as CD68 and CD11c (Fig. 
2.2.1.3.1, A). 
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CD11c 
CD11c 
CD68 
CD68 
CD163 
CD163 
CD206 
CD206 
CD304 
CD304 CD303 
CD303 CD141 
CD141 CD123 
CD123 
CD19 
CD19 
CD4 
CD4 
CD8 
CD8 
Fig. 2.2.1.2: Analysis of inflammatory immune cell infiltrates associated with testicular 
neoplasia (GCNIS, seminoma) by IHC (40x). Samples of two different patient groups were 
analysed: germ cell neoplasia in situ (GCNIS) (B) and seminoma (C). Exemplary hematoxylin- 
staining revealed mainly focal infiltrates in GCNIS, compared to a disseminated pattern in 
seminoma samples (20x). For IHC staining, different CD markers were used such as: CD68 
(macrophages and monocytes), CD11c (dendritic cells and macrophages), CD163 and CD206 
(M2 macrophages), CD123, CD141, CD303 and CD304 (dendritic cells), as well as T- and B-
cell cells (CD4+, CD8+, CD19). IHC staining of GCNIS specimens revealed increased numbers 
of CD11c+ and CD68+ cells, which were detectable within the seminiferous epithelium around 
GCNIS cells and in the interstitial compartment. Additionally, single cells exhibiting dendritic cell 
markers such as CD123+, CD141+, CD303+, CD304+ were detectable (B). Seminoma samples 
showed a further increase of all immune cell types mentioned above (C). Respective immune 
cells were highlighted by black arrows and were shown with a higher magnification (see insets). 
H= hematoxylin.     
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2.2.1.3 Identification of DC and macrophage subsets associated with testicular 
germ cell neoplasia by immunofluorescence (IF) double-staining  
 
In non-inflamed testis tissue, we detected M2 specific markers such as CD163 and 
CD206 as well as CD68 (monocyte and macrophage marker) in the interstitial com-
partment (IHC, Fig. 2.2.1.2, B). An IF double staining was conducted to confirm the 
presence of M2 macrophages (CD163+/CD206+) in normal testis (nsp) as well as 
neoplasia specimens (GCNIS, seminoma) (Fig. 2.2.1.2, B). An identification of M2 
macrophages (CD163+/CD206+) was possible in all three patient groups (nsp, 
GCNIS, seminoma).  
Particularly, CD68+ and CD11c+ cells were co-localized in the neoplasia specimen 
as shown by IHC (Fig. 2.2.1.2, B) supported by a double-detection of CD68+/CD11c+ 
cells (M1 macrophages) (Fig. 2.2.1.3.1, B). Of note, CD68+/CD11c+ cells were not 
detectable in nsp  
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Furthermore, besides M1 macrophages, two different immune cell phenotypes were 
observed using CD68 and CD11c markers: CD68+/CD11c- (macrophages) and 
CD68-/CD11c+ (DC). As CD11c is also a specific marker of different dendritic cell 
subsets, an analysis of additional DC markers such as CD1c, CD11c, CD123, 
CD141, CD303, CD304 was conducted by IHC and IF (for IHC, refer to Fig. 2.2.1.2 B 
and C). A detailed analysis by IF revealed the presence of three different DC sub-
sets: mDC1 (CD1c+/CD11c+), mDC2 (CD11c+/CD141+) and pDC 
(CD123+/CD303+/CD304+) (Fig. 2.2.1.3.2). 
 
 
 
Fig. 2.2.1.3.1: Identification of markers compatible with M1 and M2 macrophage sub-
sets (nsp, GCNIS, seminoma). (A) Semi-quantitative scoring of immunohistochemical data 
revealed M1 and M2 macrophage-specific markers which were identified as M1 and M2 
macrophages associated with testicular neoplasia by (B) IF double staining. (nsp n= 12, 
GCNIS n=17 and seminoma n=17; score of 0=not detected, 1=single cells, 2=scattered, 3= 
sparse, 4=dense). Conducting IF double-staining confirmed the presence of M1 (CD11c+ 
(green)/ CD68+(red), merged: orange) and M2 (CD163+(red)/CD68+(green) in seminoma 
sample, merged: orange (white arrow). Significance tested by one-way ANOVA 
(*P<0.05,**P<0.01,*P<0.001).  
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2.2.2 Potential function of immune cells in the human testis 
2.2.2.1 M2 macrophages as contributors of the immune suppressive milieu in 
the testis 
 
The testis is known as an immune-privileged organ where germ cells are protected 
from autoimmune attack. Immune suppressive Treg cells, mast cells and macro-
phages can contribute to this immune suppressive environment by cytokine expres-
sion. For instance, in the non-inflamed testis, immune cells compatible with the phe-
notype of M2 macrophages (CD163+/CD206+) were frequently found and the re-
spective cytokine expression profile revealed immune suppressive properties relating 
to this phenotype, reflected by the presence of IL-10 and TGF-β (Fig. 2.2.2.1). In con-
trast, immune cells compatible with the phenotype of pro-inflammatory M1 macro-
phages (CD11c+/ CD68+) could not be identified under normal conditions, whereas 
CD68+ (monocytes and macrophages) cells and single CD11c+ (macrophages and 
DC) cells were detectable (Fig. 2.2.1.2/ Fig. 2.2.1.3, A). In line with these IHC-based 
findings, transcript levels of M1-related cytokines such as TNFα and IL-12b were low 
compared to TGF-β or neoplasia samples (Fig. 2.2.2.1; 2.2.2.2).  
 
 
 
 
 
 
 
 
CD141 
CD11c 
CD303 
CD123 
CD304 
CD123 
CD1c 
CD11c 
Fig. 2.2.1.3.2: Different dendritic cell subsets detectable in seminoma specimen using 
IF double-staining. Observation of CD1c+ and CD11c+ (mDC1) (A), CD11c+/CD141+ cells 
(mDC2) (B) and CD123+/ CD303+ (C), CD123+/CD304+ (D) (pDC). merge: orange. 
A B C D 
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2.2.2.2 M1 and M2 macrophages balance pro- and anti-inflammatory cytokine 
milieu in testicular germ cell neoplasia 
 
Expression M1-related pro-inflammatory cytokines such as TNFα and IL-12b was 
detected in GCNIS and seminoma specimens (Fig. 2.2.2.2, A). In comparison to the 
normal testis, transcript levels of these cytokines were significantly increased in neo-
plasia samples. An analysis of M2-related cytokines such as IL-10 and TGF-β1 de-
termined a significant difference between normal testis and GCNIS (IL-10 and TGF-
β1), and also between GCNIS and seminoma specimens (Fig. 2.2.2.2, B). To sum 
up, the detection of M1 and M2 macrophages was associated with a milieu compris-
ing both, pro- and anti-inflammatory cytokines at the transcript level (Fig. 2.2.2.2, A 
and B).  
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Fig. 2.2.2.1: Analysis of M1 (pro-inflammatory: TNFα and IL-12b) and M2 (anti-
inflammatory: TGF-β1 and IL-10) related cytokine transcript levels in normal testes (nsp; 
n=4). Anti-inflammatory cytokines such as TGF-β1 and IL-10 were detectable whereas pro-
inflammatory cytokines were hardly expressed. Relative gene expression normalised to β-actin 
and human placenta.  
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2.2.2.3 M1 macrophages: Indication of phagocytosis and antigen presenting 
capabilities  
 
M1 macrophages are also capable to eliminate pathogens by phagocytosis. There-
fore, Rab7 (phagocytosis marker for late stage phagosome maturation) was used to 
study this potential function of M1 macrophages in the human testis. Both, 
Rab7+/CD11c+ and Rab7+/CD68+ cells could be identified by means of IF in semi-
noma. Interestingly, not all CD11c+ and CD68+ cells expressed Rab7 (Fig. 2.2.2.3.1, 
A). Additionally, a western blot was conducted to compare all three categories of tes-
tis specimens. A detection of Rab7 (23kDa) was possible in normal testis, GCNIS 
and seminoma, but in the GCNIS specimen expression was lower (preliminary data) 
(Fig. 2.2.2.3.1, B). Additionally, a comparison between cryo-preserved tissue and 
Fig. 2.2.2.2: Comparative analysis of human testis samples (nsp, GCNIS, 
seminoma) to reveal (A) M1 (pro-inflammatory) and (B) M2 (anti-inflammatory) 
related cytokine expression. Transcript levels of M1 and M2 related cytokines showed a 
significant increase of both pro- and anti-inflammatory molecules in testicular neoplasia 
(nsp n=4, GCNIS n=6, seminoma=10). Relative gene expression normalised to β-actin 
and human placenta. Significance tested by one-way ANOVA (*P<0.05,**P<0.01).  
 
* 
** 
* ** 
* 
* 
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paraffin-embedded tissue was conducted using the same patient sample (Fig. 
2.2.2.3.1, B, seminoma, lane 3 (cryo) vs. lane 4 (paraffin)). A band compatible with 
Rab7 was detected in both samples, however the band obtained from the paraffin-
embedded material was not exactly at 23kDa.  
 
 
Fig. 2.2.2.3.1: Protein expression analysis of Rab7 (phagocytosis marker for late stage 
phagosome maturation) using M1 macrophage markers (CD11c and CD68) by (A) IF 
(seminoma) and (B) western blot (nsp, GCNIS, seminoma). (A) Rab7+/CD11c+ and 
Rab7+/CD68+ cells were detected in a seminoma sample. IF double detection is shown by 
white arrows (merge: orange). (B) Rab7 was detected by western blot in all three patient 
groups. For western blot analysis, cryopreserved tissue was used for protein isolation (1, 2, 
3, 5) and compared with a protein extract obtained from paraffin embedded tissue (4). 1= 
NSP, 2= GCNIS, 3= seminoma, 4= seminoma, 5= positive control (human placenta), 6= 
negative control. 
 
 
After the phagocytosis of pathogens, antigen presenting cells (macrophages and DC) 
can present antigens to T-cells. A detection of CD11c, CD68 (M1 marker) and 
CD4+T-cells revealed the same alignment pattern in seminoma samples (IHC, Fig. 
2.2.1.2). Thus, an IF double-staining of CD4+ cells and CD68+ or CD11c+ macro-
phages revealed that both cell types in close contact (IF, Fig. 2.2.2.3.2, B). However, 
the antigen presenting ability of macrophage and DC subsets to T-cells remains to be 
elucidated. For further functional analysis, APC functional marker should be consid-
ered. 
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2.2.3 Recruitment of immune cells by chemokine signalling in the human 
testis 
2.2.3.1 Possible recruitment of CD68+ macrophage precursors by CCL15  
 
Chemokine expression is associated with inflammation to recruit circulating immune 
cells into the inflamed tissue. Additionally, chemokines are partly responsible for a 
functional polarization of immune cells, especially macrophages. In contrast to non-
immune privileged organs, CD68+ macrophages as well as resident M2 macrophag-
es (CD163+/CD206+) were present in the testis under physiological conditions. . 
Therefore, an identification of chemokines and specific chemokine receptors was 
conducted to understand the recruitment and functional polarization of CD68+ and 
M2 macrophages in the normal human testis. Chemokines typically required for mac-
rophage recruitment such as CCL2, CCL5, CCL17, CCL18, and CCL22 were not ex-
pressed in the non-inflamed human testis (see 2.2.3.2.1). Interestingly, CCL15 
(mRNA transcript level) was detectable in samples exhibiting nsp, whereas in neo-
plasia CCL15 was downregulated (Fig. 2.2.3.1.1, A). CCL15-specific receptors 
(mRNA transcript level) such as CCR1 and CCR3 were detectable in all three cate-
gories of testis tissue specimens, indicating that corresponding immune cells could 
be present (Fig. 2.2.3.1.1, B). Furthermore, CD68+ macrophages were identified as 
possible targets of CCL15 due to the double-staining of CCR1 by IF (Fig. 2.2.3.1.1, 
C). A detection of CD68+ and CCR3+ cells was also possible.  
 
Fig. 2.2.2.3.2: Indication of antigen presentation by detection of CD68+ or 
CD11c+ cells (M1 macrophages) and CD4+ cells (T cells) by IF. A CD4+ cells are 
in close contact to CD11c+ cells (A) and CD68+ cells (B), highlighted by white arrow. 
A and B shows the same magnification. 
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2.2.3.2 Chemokine and chemokine receptor expression analysis in testicular 
germ cell neoplasia 
 
Testicular cancer (GCNIS, seminoma) is associated with infilration of different im-
mune cell populations (see Fig. 2.2.1.2). An identification of chemokines that might 
be responsible for newly detected macrophages and DCs as non-resident immune 
cell populations) associated with testicular germ cell neoplasia was conducted. 
Therefore, a detailed analysis of chemokine (CCL2, CCL5, CCL15, CCL17, CCL18, 
CCL22) as well as chemokine receptor (CCR1, 2, 3, 4, 5, 8) expression profiles was 
conducted to reveal significant alterations associated with neoplasia compared to the 
non-inflamed, normal testis (nsp). In testis samples revealing germ cell neoplasia 
(GCNIS, seminoma), significantly increased transcript levels of CCL2 (p<0.05), CCL5 
CCR1 CCR3 A 
Fig. 2.2.3.1.1: Differences in CCL15 (A) and respective chemokine receptor (B) 
expression in human testis samples (nsp, GCNIS, seminoma). A) CCL15 mRNA 
expression was almost absent in neoplasia whereas CCL15 was highly expressed in nsp 
(relative gene expression normalised to β-actin and NSP; nsp n=4, GCNIS n=6, 
seminoma=10; significance tested by one-way ANOVA (***P<0.001). B) Transcripts of 
CCL15-corresponding receptors CCR1 and CCR3 were detectable in all patient groups 
(PCR). C) Identification of CD68+ cells in nsp, co-staining for CCR1 and CCR3 (white 
arrows). 
 
B 
C 
  CHAPTER 2 
  52 
(p<0.001), CCL18 (p<0.05) and CCL22 (p<0.05) were detected in comparison to nsp. 
Chemokines such as CCL15 and CCL17 were either not detectable or not significant-
ly increased in neoplasia. The CCR mRNA expression profile determined the pres-
ence of all six corresponding receptors binding the chemokines investigated, namely 
CCR1, CCR2, CCR3, CCR4, CCR5 and CCR8 in all three categories of human testis 
specimens (Fig. 2.2.3.2.1).  
 
 
Fig. 2.2.3.2.1: Difference in chemokine and chemokine receptor expression profiles in 
normal human testis (nsp, n=4) compared to germ cell neoplasia (GCNIS, n=6; semi-
noma, n = 10). Transcript levels of chemokines CCL2, CCL5, CCL18 and CCL22  were sig-
nificantly increased in neoplasia samples (CCL22: not significant in GCNIS) (A-E; qRT-PCR; 
relative gene expression was normalized to ACTB as well as NSP; significance tested by 
one-way ANOVA (*P < 0.05, **P < 0.01, ***P < 0.001). Detection of corresponding chemo-
kine receptors was possible in all three patient groups (F; RT-PCR; M= marker, 1= NSP, 2= 
GCNIS, 3= seminoma, 4= negative control). 
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2.2.4 Tumour-/immune cell interaction and functional polarization of 
macrophages  
2.2.4.1 Potential macrophage polarization factors  
 
Local environmental changes caused by cytokines and chemokines associated with 
testicular cancer can influence functional polarization of macrophages since macro-
phages can switch their phenotype due to a stimulus. Therefore, potential macro-
phage polarization factors such as prostaglandin, TGF-β1, IL-10, and IL-6 can help to 
elucidate their role in the human testis. Therefore, a detailed analysis was conducted 
to reveal the presence of these factors in different testis specimens (normal testis, 
GCNIS and seminoma). As previously mentioned, M2 macrophages were detectable 
in non-inflamed, normal testis tissue, where also prostaglandin E synthase2 
(PTGES2) and IL-10 were expressed (Fig. 2.2.4.1.1/ Fig. 2.2.2.2). Additionally, in 
GCNIS and seminoma specimens, mRNA expression of PTGES2, IL-10 as well as 
IL-6 was shown (Fig. 2.2.4.1.1). Interestingly, it could be observed that M2 macro-
phages express IL-6, whereas in nsp, M2 macrophages were not able to express IL-6 
(Fig. 2.2.4.1.2). Additionally, a detection of PTGES2 (mRNA) was possible in both 
tumour cell clusters as well as immune cell infiltrates obtained from seminoma sam-
ples (Fig. 2.2.4.1.1).  
 
 
Fig. 2.2.4.1.1: Analysis of potential macrophage polarization factors IL-10, IL-6 and 
PTGES2 in human testis by RT-PCR. Prostaglandin E synthase (PTGES2) was expressed 
in nsp as well as tumour cluster and immune cell infiltrates dissected from seminoma (laser-
assisted picking). IL-10 was expressed in all three categories of specimens (nsp, GCNIS, 
seminoma) whereas IL-6 was only detectable in GCNIS and seminoma specimens. Human 
placenta was used as a positive control. M= marker, PTGES2: 1= negative control, 2= tu-
mour cluster , 3= immune cell infiltrate, 4= positive control, 5= normal spermatogenesis, 
GAPDH: 6= tumour cluster, 7= immune cell infiltrate, IL-10: 1= normal spermatogenesis, 2= 
GCNIS, 3= seminoma, 4= negative control, IL-6: 5= normal spermatogenesis, 6= GCNIS, 7= 
seminoma, 8= negative control, GAPDH: 9= normal spermatogenesis, 10= GCNIS, 11= sem-
inoma, 12= positive control. 
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Fig. 2.2.4.1.2: IL-6 expression by CD163+ macrophages (M2) in normal human testis 
(nsp), GCNIS and seminoma. Co-localization of M2-related marker (CD163, red) and IL-6 
(green) in germ cell neoplasia but not in nsp. IL6+/CD163+cells were highlighted by white 
arrow, merged=orange).  
 
 
Additionally, an analysis regarding specific prostaglandin receptors was conducted to 
confirm the presence of target cells in specimens from all three patient groups select-
ing prostaglandin E receptors EP1, EP2, EP3 and EP4 (Fig. 2.2.4.1.3). In all three 
categories of specimens (nsp, GCNIS and seminoma) mRNA expression of EP2, 
EP3 and EP4 was detectable (Fig. 2.2.4.1.3). However, the role of prostaglandin as a 
macrophage polarization factor has to be further investigated.  
 
 
Fig. 2.2.4.1.3: Analysis of specific prostaglandin E receptors (EP1, EP2, EP3, EP4) in 
human testis by RT-PCR. EP2, EP3 and EP4 was expressed in all three categories of 
specimens (nsp, GCNIS, seminoma), whereas EP1 was not detectable. GAPDH was used 
as housekeeper. M= marker, 1= NSP, 2= GCNIS, 3= seminoma, 4= negative control. 
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2.2.4.2 Identification of potential prognostic testicular cancer marker: Signal-
ling pathways (p65, NF-κB) and immune checkpoints T-cell immunoglobulin 
mucin-3 (TIM-3) and Galectin-9 associated with testicular cancer 
 
An analysis of immune checkpoint TIM-3/Galectin-9 and NF-kappa-B p65 subunit 
was performed in normal testis tissue as well as specimens with germ cell neoplasia. 
A detection of p65 (protein) was possible in GCNIS and seminoma samples, whereas 
p65 was not expressed in nsp (Fig. 2.2.4.2.1). Additionally, an analysis of TIM-3/Gal-
9 known as immune checkpoints was conducted revealing TIM-3 and Galectin-9 ex-
pression in nsp and neoplasia specimens (GCNIS and seminoma) (Fig. 2.2.4.2.2).   
 
 
 
 
 
 
 
 
Fig. 2.2.4.2.2: Analysis of immune checkpoint T-cell immunoglobulin mucin-3 (Tim-3)/ 
Gal-9 expression in normal human testis as well as germ cell neoplasia by RT-PCR. 
Tim-3 and Galectin-9 were detectable in all nsp (n=2) and seminoma specimens (n=3), 
whereas in GCNIS (n=3) only one of three samples was positive. M= marker, 1= NSP1, 2= 
NSP2, 3= GCNIS1, 4= GCNIS2, 5=GCNIS3, 6=seminoma1, 7=seminoma2, 8=seminoma).  
Fig. 2.2.4.2.1: Protein expression of p65 (NF-κB pathway) in normal human testis as 
well as germ cell neoplasia by western blot. p65 was detectable in GCNIS and seminoma 
specimens but not in nsp. 1= GCNIS, 2= seminoma, 3=nsp, 4= negative control, 5= positive 
control (human placenta). 
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2.2.4.3 Impacted spermatogenesis in glucocorticoid-induced leucine zipper 
protein (GILZ) KO mice influenced testicular immune cell populations 
 
This preliminary study was conducted to elucidate the influence of Glucocorticoid-
Induced Leucine Zipper (GILZ) on immune cell populations in the testis. Thus, the 
effect of Gilz on spermatogenesis was examined by histological evaluation, whereas 
flow cytometry was performed to study the effect on immune cell populations in Gilz 
knock-out (KO) mice versus wildtype (WT) animals.  
Gilz KO mice showed a reduced testis weight in comparison to the WT (Fig. 
2.2.4.3.1, A, B). Additionally, a histological analysis (HE-staining) of Gilz KO mouse 
testis (week 8-12) revealed that the seminiferous epithelium was strongly affected. 
Furthermore, the cells in the seminiferous epithelium (SE) were visually identified as 
tubules with complete loss of germ cells (Fig. 2.2.4.3.1, C, D).  
 
 
Fig. 2.2.4.3.1: Analysis of testes weight and testis histology in Gilz KO mice (8-12 
weeks). After dissection, testes of WT and Gilz KO mice were measured (A, B). Gilz KO 
mice testis showed a significantly reduced weight compared to Gilz WT mice (WT n=6, Gilz 
KO n=5). Afterwards, the testes were prepared for cryo-cutting. 5µm slides were cut and 
stained with Hematoxylin for histological analysis (C, D). WT: n=6; Gilz KO: n=5. Abbrevia-
tions: L=lumen, SE=seminiferous epithelium, IC=interstitial compartment. Significance tested 
by one-way ANOVA (*P < 0.05, **P < 0.01, ***P < 0.001).   
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Additionally, we analysed immune cells populations in this mouse model by flow.Gilz 
KO vs. WT immune cell populations were compared to reveal a potential role of Gilz 
on immune cell populations and factors which were expressed during the spermato-
genesis and were absent in the Gilz KO due to the impaired spermatogenesis. Im-
mune suppressive M2 macrophages were frequently found in the WT testis, whereas 
Gilz KO testis contained less M2 macrophages (CD206+ cells: 25.4%) than the WT 
(CD206+ cells: 58.9%) (Tab. 2.2.4.3.1). Moreover, a reduction of the macrophage 
population expressing F4/80+ (pan-macrophage marker) was associated with Gilz 
KO (F4/80+ cells: 14.9% in Gilz KO vs. 57.5% in WT mice). Similar effects were seen 
with CD11c+ cells (DC, NK, macrophages) (CD11c: 34.6% in Gilz KO vs. 55.1% in 
WT mice) (Tab. 2.2.1.4). A detection of CD11b and MHCII positive cells showed no 
difference in Gilz KO (CD11b: 75.2%; MHCII: 18.9%) and WT testes (CD11b: 77.8%; 
MHCII: 17.4%) (Tab. 2.2.4.3.1). Our preliminary data showed also a difference in 
lymphoid immune cell populations compared between Gilz KO and WT animals (Tab. 
2.2.1.4.2). T-cells such as CD3+ and NK1.1+ cell numbers were increased in the Gilz 
KO in comparison to the WT (CD3: 33.8% (Gilz KO) vs. 18.3% (WT); NK1.1:19.2% 
(Gilz KO) vs. 9.73% (WT) (Tab. 2.2.4.3.2). This suggests a strong effect of GILZ on 
immune cell populations and subsequently the immune privileged testis.  
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Tab. 2.2.4.3.1: Preliminary analysis of myeloid immune cells (ICs) using a testes pool 
of two animals. Immune cell populations were shown in percentages of all gated 
CD45+ immune cells. 
 
Tab. 2.2.4.3.2: Preliminary analysis of lymphoid immune cells using a testes pool of 
two animals. Immune cell populations were shown in percentages of all gated CD45+ 
immune cells.
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2.3 DISCUSSION 
 
In the present study, an analysis of immune cells in the normal human testis (nsp) in 
comparison to testicular germ cell neoplasia, i.e. GCNIS and seminoma, was per-
formed using IHC and IF.  
Additionally, an analysis of immune cells in mice testis in comparison to pathological 
altered tissue caused by the absence of Gilz was conducted. For instance, it has 
been shown that macrophages influence spermatogenesis (DeFalco et al., 2015). But 
can an impacted spermatogenesis also influence immune cell populations? Thus, the 
effect of Gilz on spermatogenesis was examined by histological evaluation and clear-
ly revealed a pathological alteration due to an impacted spermatogenesis. Further-
more, the absence of Gilz using Gilz KO mice revealed an affected immune cell ho-
meostasis since M2 macrophages were decreased whereas NK and T cells were 
increased compared to the WT. 
In the human, immune cells under physiological conditions are mainly, resident mac-
rophages (CD68+, CD163+) and mast cells, accompanied by few T-cells (CD3+) 
(Tung and Teuscher, 1995; Hvarness et al., 2013; Klein et al., 2016; Frungieri et al., 
2002; Winnal et al., 2011; Pérez et al., 2013; Fijak et al., 2018). Additionally, in this 
study, individual CD4+ and CD8+ T-cells are detectable in the normal, non-inflamed 
testis. It is known that CD4 is also expressed by Treg cells (CD4+/FoxP3+), which 
are considered to be important players maintaining the immune suppressive milieu in 
the testis (Jacobo et al., 2009; Bonelli et al., 2009). Further cell types, especially M2 
macrophages, with immunosuppressive functions have been described in studies of 
mouse testis (Bhushan & Meinhardt, 2017).  
The data shown here indicate, that M2 (CD163+/CD206+) macrophages are present 
in the human testis under physiological conditions. Both immune cell types, Treg and 
M2 macrophages, are immunosuppressive which explains the detection of anti-
inflammatory cytokines (IL-10, TGF-β) in nsp. Further immunosuppressive regulation 
mechanisms to be considered in the testis are immune checkpoints such as TIM-3 
and its ligand Galctin-9 (Loveland et al., 2017), which otherwise have been associat-
ed with autoimmunity and chronic viral infections (Sabatos et al., 2003; Golden-
Mason et al., 2009). TIM-3 can regulate effector pathways and act as a negative reg-
ulator of T cell activation and can be expressed by T cells as well as macrophages 
and dendritic cells (DC) (Ocaña-Guzman et al., 2016). Interestingly, a detection of 
TIM-3 and Galectin-9 is possible in human testis specimens with nsp as well as germ 
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cell neoplasia. This result suggests that TIM-3/ Galectin-9 could play an important 
role to regulate T cell activation in the immunosuppressive testis as well as in testicu-
lar cancer.  
In nsp, besides M2 (CD163+ and CD206+) macrophages, CD68+/CD11c- macro-
phages and sparse CD11c+ DCs were detectable. 
However, the investigations of testicular germ cell neoplasia revealed a switch of im-
mune cell populations associated with a pro-inflammatory cytokine milieu. For in-
stance, in neoplasia there were considerable numbers of CD11c+ and CD68+cells 
detectable (Klein et al., 2016). Interestingly, in this study a co-localization of CD11c+ 
and CD68+ cells was possible. Zheng et al. showed the presence of aggregate unit 
forming myeloid CD11c+ DC and suggested a recruiting function of CD68+ macro-
phages due to their co-localization in seminoma (Zheng et al., 2016). Hume showed 
that CD11c can also be expressed by macrophages (Hume, 2008). Therefore, an IF 
double-staining was conducted and revealed CD68+/CD11c+ cells. These 
CD68+/CD11c+ cells can be classified as M1 macrophages since recent studies ob-
served M1 phenotypes that express CD11c+/CD68+ in different human tissues asso-
ciated with inflammation (Vianello et al., 2016; Li et al., 2017). The appearance of this 
M1 phenotype in the diseased human testis indicates a functional polarization of 
macrophages associated with testicular cancer. This suggests that CD68+/CD11c- 
macrophages detected in nsp can differentiate into either M1 (CD68+/CD11c+) or M2 
(CD163+/CD206+). For instance, CD68+/CD11c- macrophages might be driven by 
an altered cytokine and chemokine milieu associated with germ cell neoplasia. Previ-
ous results postulate that Th1 immune responses are important to drive the M1 polar-
ization. Klein et al showed a significant increase of IFN-γ as a cytokine of Th1-
immune responses in testis cancer (Klein et al., 2016). Interestingly, IFN-γ and TNF-
α have a strong impact on M1 polarization (Genin et al., 2015). Transcripts of both 
cytokines were detectable in testis tissue specimens with neoplasia in conjunction 
with M1 macrophages. Accordingly, there is suggestive evidence that increased 
numbers of macrophages of the M1 (CD11c+/CD68+) phenotype associated with 
neoplasia correlate with high expression of pro-inflammatory cytokine such as TNF-α 
and IL-12.  
Interestingly, not all CD11c+ cells express CD68. Therefore, further immune cell 
types that can express CD11c such as DCs were analyzed. Different DC subsets 
such as mDC1 (CD1c+/CD11c+), mDC2 (CD141+/CD11c+) and pDC 
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(CD123+/CD303+/CD304+) could be identified in the human testis, i.e. under patho-
logical conditions. Interestingly, a co-localization of CD4+ cells and CD68+ or 
CD11c+ cells could be observed by means of IF, suggesting that CD68+ and CD11+ 
cells are able to present antigens to CD4+ T cells. This could explain the increased 
detection of CD19+ B cells in neoplasia samples (Klein et al., 2016), which require 
activation by T cells. Besides antigen presentation, different DC subsets may have an 
influence on macrophage differentiation. Zheng et al. showed that CD11c+/DC-
SIGN+/CCR6+ DC can express IL-4 which is besides IL-10, IL-13, PGE2 one of the 
cytokines leading to an M2 polarization (Zheng et al., 2016; Chen and Smyth, 2011; 
Genin et al., 2015; Martinez et al., 2009; Schraufstatter et al., 2012). However, the 
polarization and functional role of pDC and mDC in testicular germ cell neoplasia as 
well as other testicular pathologies is still largely unclear and needs to be further ex-
amined.  
Furthermore, a detection of M2 macrophages as well as M2-related anti-inflammatory 
cytokines (IL-10 and TGF-β) is possible in nsp as well as in GCNIS and seminoma 
specimens, with a significantly higher expression in neoplasia compared to nsp (e.g. 
CD163, IL-10 and TGF-β). Notably, both M2-related cytokines have been associated 
with cancer progression and surveillance in different cancer types (Sica et al., 2006; 
Derynck et al., 2001). Interestingly, IL-10 was significantly higher expressed in 
GCNIS specimens (p<0.01). GCNIS is the precursor of (homogenous) seminoma 
development in approx. 60% of affected patients (Rajpert-De Meyts et al., 2016). 
Therefore, it could be postulated that the secretion of IL-10 and other cytokines main-
tains an immune suppressive milieu and favours seminoma formation and progres-
sion by avoiding an effective anti-tumour (tumoricidal) immune response. However, 
testicular cancer is associated with the presence of both, M1 and M2 macrophages, 
as well as a pro- and anti-inflammatory cytokines. Thus, previous results indicating a 
balanced action of pro-inflammatory M1 and anti-inflammatory M2 macrophages as-
sociated with testicular cancer.  
The investigation of functional macrophage polarization could be helpful to better un-
derstand the control of cancer progression by a specific immune environment. Sub-
sequently, potential macrophage polarization factors such as IL-10, PTGES2, TGF-
β1 and IL-6 were revealed in line with earlier results indicating a pivotal role of IL-6 in 
the development of testicular germ cell neoplasia (Klein et al., 2016). An identification 
of IL-6 expressed by M2 macrophages in the neoplasia specimen but not in nsp un-
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derpinning previously hypothesis from Klein et al. (Klein et al., 2016). Additionally, 
mRNA level have confirmed that IL-6 is only associated with GCNIS and seminoma, 
but not in testicular inflammation due to other pathologies (Klein et al., 2016). Weagel 
et al. showed that macrophage polarization is a spectrum which depends on many 
different factors (Weagel et al., 2015). For instance, M2 macrophages can be classi-
fied into M2a, M2b, M2c and M2d. Among these, M2b macrophages can express IL-6 
(Weagel et al., 2015). Moreover, Chanmee et al. and Lu et al. have shown that M2c 
macrophages positive for CD163 and CD206 can express high amounts of TGF-β1 
and IL-10 (Chanmee et al., 2014; Lu et al., 2013). This M2c macrophage phenotype 
shares characteristics of M2 macrophages that were detectable in testis specimens 
with nsp and neoplasia. However, it could be that other macrophage subclass sub-
sets are associated with neoplasia since some M2 macrophages can express IL-6. 
This suggests that some M2 subclass macrophages drive the functional polarization 
of macrophages. Besides M2 macrophages, cancer cells themself might secrete im-
mune suppressive factors and, thus, control macrophage polarization. For instance, it 
has been shown that cervical carcinoma-derived IL-6 and PGE2 have an influence 
on M2 polarization (Heusinkveld et al., 2011b).  
Additionally, to understand the recruitment and differentiation of macrophages in the 
human testis, the presence of chemokines which are known as chemoattractants 
were investigated. Interestingly, a detection of the chemokine CCL15 was possible in 
nsp. This observation suggests that this chemokine might be important for the migra-
tion of CD68+ macrophages. This indicates that blood circulating CD68+ monocytes 
are precursors of macrophages recruited to the testis that can subsequently differen-
tiate into both M1 and M2 phenotypes, depending on the environment. This hypothe-
sis is supported by the expression of CCL15-related receptors such as CCR1 and 
CCR3 by CD68+ cells in normal testis tissue (nsp). Additionally, Wang et al. have 
shown that CD68+ macrophages are believed to originate from circulatory mono-
cytes/macrophages (Wang et al., 1994). This suggests that monocyte derived cell 
type can be recruited by CCL15 In the healthy testis, mediators such as IL-10, TGF-
β, prostaglandin and glucocorticoids play a role in macrophage polarization and 
might drive CD68+ cells into an immune-suppressive M2 phenotype (Martinez et al., 
2009; Wang et al., 2017).  
In contrast, there is a downregulation of CCL15 in testicular germ cell neoplasia and 
an upregulation of different other chemokines. Comprehensive analysis of the chem-
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okine gene expression profiles using qRT-PCR could reflect the interaction of differ-
ent immune cells and the recruitment of macrophages and DC associated with testic-
ular germ cell neoplasia. Especially chemokines are important for the migration and 
differentiation of monocytes/ macrophages in a tissue-dependent manner (Sica et al., 
2006). Interestingly, increased transcript levels of chemokines such as CCL2, CCL5, 
CCL18, and CCL22 were detectable in samples with neoplasia compared to nsp. 
These results are in line with reports concerning other cancer entities. Recent studies 
have shown an upregulation of CCL2 in primary prostate and invasive breast cancer 
associated with a recruitment of M2 macrophages (Fang et al., 2016; Mizutani et al., 
2009; Ueno et al., 2000). Fang et al. showed that an in vivo gene silencing leads to a 
tumour growth inhibition and reduced M2 recruitment in breast cancer (Fang et al., 
2016). Therefore, we speculated that CCL2 is one of the important M2 attractants. 
Furthermore, CCL18 expression levels have been shown to influence disease out-
comes in cancer patients, especially in cutaneous lymphoma and breast cancer 
(Miyagaki et al., 2013; Narita et al., 2011). Interestingly, CCL18 in colorectal cancer 
has the opposite effect, with high levels correlated with better survival (Yuan et al., 
2013). In contrast, Schraufstatter et al. have shown that CCL18 leads to a maturation 
of cultured monocytes to macrophages in the M2 spectrum (Schraufstatter et al., 
2012). Additionally, CCL18 increased the expression of other chemokines such as 
CCL2 and CCL22 and cytokines such as IL-10 which are also detectable in human 
neoplasia (Schraufstatter et al., 2012). Concerning the human testis, expression of 
IL-10 was significantly increased in GCNIS in comparison to nsp, where CCL18 tran-
script levels were virtually not detectable. However, it has been shown that CCL18 
and CCL22 can be expressed by M2 macrophages (Mantovani et al., 2002). Thus, it 
has to be considered that signals other than CCL18 and CCL22 support M2 macro-
phage polarization in the human testis under physiological conditions. On the other 
hand, recent studies revealed further evidences that chemokines such as CCL2, 
CCL18, and CCL17 can be expressed by different tumours (Roca et al., 2009; Kim et 
al., 2009; Erler et al., 2009; Mantovani, 2008). It can be assumed that tumour cells 
strongly influence immune cells polarization to drive them into immune-suppressive 
phenotypes, however a complete suppression of immune responses does obviously 
not occur. 
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CONCLUSION 
 
Human testicular germ cell neoplasia is commonly associated with infiltrating immune 
cells. Besides few T-lymphocytes, antigen-presenting-cells (APC) such as CD68+ 
and sparse CD11c+ cells were detected in normal testis (nsp). Both of these mark-
ers, CD11c (integrin glycoprotein) and CD68 (glycoprotein), are typically expressed 
by macrophages, whereas CD11c can also be expressed by DCs. Macrophage and 
DC subsets have different phenotypic characteristics. Both immune cell types can 
change their functional state depending on the environment. Especially M1 (classical-
ly activated) and M2 (alternatively activated) macrophages are known for their differ-
ent function in cancer development. Previous studies have shown that the critical 
immune suppressive M2 phenotype can be driven by tumour derived and T cell (Th1 
or Th2) derived cytokines. Therefore, a detailed analysis of different macrophage (M1 
and M2) and DC subsets which are might be driven by cytokines and chemokines 
associated with testicular germ cell neoplasia was conducted. In neoplasia speci-
mens a detection of macrophage subtypes such as M1 (CD68+/CD11c+, pro-
inflammatory properties), M2 (CD163+/CD206+, anti-inflammatory, pro tumorigenic), 
DCs such as pDC, mDC1 and mDC2 (plasmocytoid: CD123+/CD303+/CD304+; 
myeloid: CD1c+/CD11c+ and CD11c+/CD141+) is possible. In contrast, in specimens 
of normal, non-inflamed testes (nsp) CD68+/CD11c- macrophages, single 
CD11c+cells and M2 macrophages which seem to be important for maintaining the 
immune privilege were detectable. This suggested a recruitment and a functional po-
larization of macrophages from CD68+ cells (nsp) into M1 (CD68+/CD11c+) or M2 
(CD163+/CD206) under pathological conditions of neoplasia (GCNIS and seminoma) 
(Fig. 2.3.1/2.3.2). Furthermore, M1 related pro-inflammatory cytokines such as TNF-
α, IL12 and M2 related cytokines such as IL-10 and TGF-β were detectable in all ne-
oplasia samples. Additionally, potential factors (chemokines) for the recruitment and 
polarization of immune cells are revealed. Interestingly, an upregulation of chemo-
kines such as CCL2, 5, 18, 22 which are possibly responsible for monocyte/ macro-
phage recruitment and/ or differentiation is detectable in testicular germ cell neo-
plasia. Furthermore, in neoplasia samples a downregulation of CCL15 is observable. 
In the normal testis, CCL15 is detectable and might be important to recruit CD68+ 
cells which express the chemokine specific receptors, CCR1 and CCR3. Those mac-
rophages could then differentiate into another phenotype depending on the local en-
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vironment. Moreover, testicular cancer is associated with M2 polarization factors 
such as TGF-β1, IL-6 and PTGES2 (Fig. 2.3.2). Accordingly, elevated numbers of M2 
macrophages as well as increased expression of M2 related anti-inflammatory cyto-
kines was observed in neoplasia compared to nsp. However, besides M2 polarization 
factors we detected TNF-α as M1 polarization factor as well as an increased fre-
quency of M1 macrophages. We assumed that there might be a balance between 
tumour suppressive M1 macrophages and tumour progressive M2 macrophages in 
testicular cancer which can be easily influenced by cytokine and chemokine expres-
sion. This depends on the tumour environment that is influenced by different immune 
cell types and tumour growth and other immune cell interactions e.g. Th1 and Th2. 
However, tumour cells drive the M2 differentiation (Fig. 2.3.2). Subsequently, M2 
macrophages are the dominating immune cell population that support tumour grow. 
Therefore, as clinical outcome an inhibition of typical M2 polarization factors should 
be considered rather than an inhibition of recruitment factors (chemokines) since this 
would also influence the recruitment of M1 macrophages. A decrease of immunosup-
pressive M2 macrophages in this tumour environment would probably reinforce im-
mune reactions against cancer by pro-inflammatory M1 macrophages.  
 
 
 
 
 
 
  CHAPTER 2 
  66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.3.1: Summary of immune cell types detected in GCNIS and seminoma in compari-
son to normal testis tissue (nsp). Testes with nsp contain only M2 macrophages, mast cells 
(not shown), CD68+ macrophages, single CD4+ T cells and single CD11c+ cells. In GCNIS, 
M2 (CD163+/CD206) macrophages and also M1 (CD68+/CD11c) macrophages were detecta-
ble. Additionally, T cells such as CD4+ and CD8+, B cells (CD19) and CD11c dendritic cells 
were found. Interestingly, M1 macrophages and DCs form cell aggregations around the tumor 
cells. Immune cells:  T-lymphocytes: CD4+, CD8+, B-lymphocytes: CD19+, macrophages: 
CD163+, CD206+ (M2), CD68+, CD11c (M1), CD68+, dendritic cells/ macrophages: CD11c+, 
Somatic cells: Sertoli cells (SC), Leydig cells (LC), spermatogonia (Sg), spermatocytes(S), 
round spermatid (RS), elongated spermatid (ES). Basal lamina (BL), seminiferous epithelium 
(SE), blood testis barrier (*).  
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T-cell 
TC 
Fig. 2.3.2: Functional macrophage polarization in the tumour environment: Monocytes 
and macrophages can become either M1 or M2 macrophages depending on the stimuli pre-
sent in their microenvironment. Both pro-inflammatory M1 (producing TNF and IL-12) and 
anti-inflammatory M2 (producing TGF-β and IL-10) macrophage subsets are present in tes-
ticular germ cell neoplasia (GCNIS, seminoma). Note that tumour cells can secrete macro-
phage recruitment and polarization factors such as chemokines, cytokines and PTGES. T-
cells can influence the microenvironment by expression of different cytokines and influence 
macrophage polarization as well.  
TC=tumour cell, M1=M1 macrophages, M2=M2 macrophages. PTGES=prostaglandine E 
synthase. Black arrows indicate cytokine or chemokine expression by cell types; blue ar-
rows indicate the influence on cell differentiation or cytokine expression; grey arrows show 
differentiation of macrophages. 
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CHAPTER 3: Assessment of mono-cultured tumour and immune 
cells of relevance to testicular neoplasia: the TCam-2 seminoma 
and THP-1 macrophage cell lines 
3 INTRODUCTION 
 
In the healthy human testis with complete spermatogenesis, both 
CD68+macrophages and M2 macrophages were detected, whereas a new macro-
phage subtype, corresponding to the M1 macrophage phenotype, was identified in 
specimens with neoplasia. We hypothesized that a functional polarization of macro-
phages had arisen due to the environmental change associated with the emergence 
of neoplastic testicular germ cells. Thus, we proposed that in addition to the contribu-
tion of hormonal changes of puberty altering the testicular milieu, an important envi-
ronmental shift is driven locally by cytokines and chemokines which can influence 
immune cell recruitment and polarization. To understand this mechanism, our work-
ing group previously established a tumour/ immune cell co-culture model using semi-
noma cells and peripheral blood mononuclear cells (PBMCs) that included an analy-
sis of all immune cell types (Klein et al., 2017). The present study builds on this cell-
culture model to examine in more detail how macrophages and seminoma cells con-
tribute to the testicular tumour microenvironment (see chapter 4), by constructing a 
cell culture model using a human monocytic leukemia cell line (THP-1) and a human 
seminoma cell line (TCam-2), which are characterised in this chapter.  
THP-1 cells are a well-established human macrophages model, in which the progeni-
tor THP-1 cells (monocyte-derived) can be differentiated into M0, M1 and M2 macro-
phage subsets using protocols that involve progressive exposure to specific factors 
(Park et al., 2007; Lund et al., 2016; Genin et al., 2015). The evaluation of polariza-
tion outcomes has relied on a cohort of RNA and protein markers.  
TCam- 2 cells were originally derived from a human seminoma (Mizuno et al., 1993). 
It is the only robust model of human testicular germ tumour cells, retaining features of 
seminoma cells which are shared with human gonocytes evidenced by the expres-
sion of pluripotency markers e.g. OCT3/4, NANOG and LIN28 (deJong et al., 2008; 
Eckert et al., 2008). As shown by deJong et al., TCam-2 cells are the first well-
characterized seminoma-derived cell line, that features characteristic foetal germ cell 
responses to TGF-beta ligands and retinoic acid (de Jong et al., 2008; Young et al., 
2011).  
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With the objectives of revealing what cytokines and chemokines present in testicular 
germ cell tumours are potential macrophage polarization factors, and subsequently to 
understand their impact on the functional polarization of macrophages, THP-1 cells 
were first differentiated into M0, M1 and M2 macrophages using an established pro-
tocol, and afterwards validated by measuring both RNA and protein changes by qRT-
PCR, flow cytometry and a multiplex cytokine and chemokine analysis. The expres-
sion of receptors determined to be present in macrophages within TGCTs was evalu-
ated, and the influence on macrophage phenotype of signalling moieties present in 
tumours or associated with these specific receptors was measured. The potential for 
TCam-2 cells to synthesize factors that may recruit and alter macrophage function 
was also examined by qRT-PCR (recruitment factors e.g CCL2 and CCL5) a multi-
plex cytokine and chemokine analysis. 
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3.1 MATERIAL AND METHODS 
3.1.1 Cell cultures 
3.1.1.1 TCam-2 (human seminoma cell line)  
 
TCam-2 cells (human seminoma derived cell line) (Mizuno et al., 1993; deJong et al., 
2008) originally obtained from Prof Kitizawa, Japan) were cultivated in a T75-flask 
containing 1640RPMI (Gibco, Paisley, UK) with 1% Pen/Strep (Gibco, Paisley, UK) 
and 10% fetal calf serum (FCS; Quantum Scientific, Minto, Australia) at 37°C and 5% 
CO2 until the cells were approximately 90% confluent. The medium was replaced 
every 2 days. For the cell transfer, the cells were washed with 1 ml PBS and 1 ml 
0.1% trypsin/ versene solution (TV) (Gibco, Paisley, UK) added with the flask left for 
at least 2 min in the incubator. The cell detachment was visualized using an inverted 
brightfield microscope (Primo Vert, Zeiss). After successful detachment, the cell sus-
pension containing 0.1% TV was transferred in a 15 ml Falcon tube and centrifuged 
at 239rcf, RT for 2 min. Afterwards, the supernatant was discard and 2 ml of 
RPMI1640 (1% Pen/Strep and 5% or 3% FCS) was added, the cells were resus-
pended, counted and seeded at a density of 1x105 cells per well in a 6 well plate 
(Falcon®, Corning Life Science, Tewksbury, USA). After the experimental incubation, 
TCam-2 cells were collected for mRNA analyses into Trizol (see sections 3.1.3 and 
3.1.4) or were snap frozen immediately on dry ice and stored at 80°C for subsequent 
protein analyses (sections 3.1.5 and 3.1.6). 
 
3.1.1.2 THP-1 (human monocytic leukemia cell line)  
 
THP-1 cells (human monocytic leukemia cell line; provided by Dr. Ashley Mansell, 
Hudson Institute of Medical Research, Clayton, Australia) were cultivated as a non-
adherent cell line in T75-flask containing 1640RPMI with 1% Pen/Strep (Gibco) and 
10% FCS at 37°C and 5% CO2 until confluent. Media was changed every 2-3 days, 
with the cell suspension transferred into a 15 ml Falcon tube for centrifugation at 
239rcf, RT for 2 min. The cell pellet was resuspended in 2 ml of RPMI1640 (1% 
Pen/Strep and 10% FCS) and seeded for experiments at 1x105 cells per well in 6 well 
plates. To induce differentiation (see reagents, Tab. 3.1.1), cells were first treated 
with phorbol 12-myristate 13-acetate (PMA, 20 ng/ml, Biolegend) for 24 h (Fig. 3.1.2), 
then the newly adherent and differentiated M0 macrophages were treated with either 
Lipopolysaccharide (LPS, 10 pg/ml) and IFN-γ (20 ng/ml, Biolegend) for M1 differen-
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tiation, or with IL-4 (20 ng/ml, Biolegend) and IL-13 (20 ng/ml, Biolegend) for M2 dif-
ferentiation, for a further 43 h incubation (Fig. 3.1.2). After this incubation, the cells 
were designated for further treatments with cytokines, chemokines and TGF-β signal-
ing pathway inhibitor (e.g. IL-10, activin A, Transforming growth factor beta-1 (TGF-
β1), CCL2, CCL5, CCL15 (see Tab. 3.1.1) and/ or RNA extraction and subsequent 
cDNA synthesis (PCR)(see 3.1.3/ 3.1.4), protein isolation (SDS-PAGE, western blot) 
(see 3.1.5), multiplex (see 3.1.6) or the cells fixed for Flow cytometric analysis (see 
3.1.7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1.1.2: Schematic of the in-vitro THP-1 setup for macrophage differentiation. 
Human monocyte-derived THP-1 cells were treated with PMA and incubated for 24 h. 
Afterwards, the differentiated THP-1 cells (now activated M0 macrophages) were treated 
with either LPS (10 pg/ml) or IFN-γ (20 ng/ml) to differentiate them into M1 macrophages or 
with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) to differentiate into M2 macrophages. After the 
differentiation, cells were collected for the following procedures and analyses: RNA 
extraction, cDNA synthesis (qRT-PCR), protein isolation (SDS-PAGE, western blot), 
supernatant collection (multiplex) and cell fixation (Flow). 
 Cytokine and chemokine treat-
ment 
 RNA extraction, cDNA synthesis 
(qRT-PCR)                                          
 Protein isolation (SDS-PAGE, 
western blot) 
 Supernatant collection (multi-
plex) 
 Cell fixation (Flow) 
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3.1.1 Table of. Reagents for THP-1 treatment 
Protein name Manufacturer Cat. 
No. 
Phorbol 12-myristate 13-acetate (PMA) Biolegend 423301 
Lipopolysaccharide (LPS) Sigma 8630 
Recombinant Human IFN-γ (carrier-free) Biolegend 570202 
Recombinant Human IL-13 (carrier-free) Biolegend 571102 
Recombinant Human IL-4 (Animal-Free) Biolegend 714904 
Recombinant Human CCL15 (MIP-1δ) (car-
rier-free) 
Biolegend 587402 
Recombinant Human CCL5 (RANTES) (An-
imal-Free) 
Biolegend 717004 
Recombinant Human CCL2 (MCP-1) (Ani-
mal-Free) 
Biolegend 716504 
IL-10 Biolegend 715602 
Transforming growth factor beta 1 (TGF-β1) Cell Signaling 
8915LC 
Activin A Abcam ab50051 
SB431542 Cell Signaling 14775 
 
3.1.2 Cell migration 
 
Previously differentiated THP-1 cells (M0, M1, M2) were cultivated in 6 well plates 
until confluent. Cells were treated with CCL15 (20 ng/ml), CCL2 (20 ng/ml) or CCL5 
(20 ng/ml), and a cell-free gap created from one side of the culture well to the other 
with a pipette tip. For orientation and subsequent measurement of gap closure, lines 
were drawn along the edges of the initial gap, and the extent of gap closure was 
measured from photographs taken at different time points using ImageJ, an image 
processing program for scientific analysis (t= 0 h, 24 h, 48 h, 72 h)(Fig. 3.1.2). The 
area that was measured at each time point was compared to the starting gap size. 
The percentage of gap closure is presented relative to t= 0 h. 
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Fig. 3.1.2: Schematic of migration assay also called wound healing assay using differ-
entiated THP-1 cells (M0, M1, M2). THP-1 cells were treated with cytokines and LPS, and 
then differentiated into M0, M1 and M2 macrophages. Afterwards the cells were cultivated in 
6 well plates until confluent (90%). Then M0, M1 and M2 macrophages were treated with 
different chemokines such as CCL2 (20 ng/ml), CCL5 (20 ng/ml) and CCL15 (20 ng/ml)(n=3). 
Next a gap was scratched in each well by using a pipette tip. For orientation, lines were 
drawn directly on the well, and the extent of gap closure was measured at different time 
points using ImageJ (t= 0 h, 24h, 48h, 72h). The area that was measured at t= 24 h, 48 h, 72 
h and compared with t=0 h set to 100%, thus the percentage of gap closure is shown as a 
percentage relative to t= 0 h.  
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3.1.3 Reverse transcriptase PCR (with RNA isolation) 
 
For extraction of total RNA, cells were washed with PBS then 1 ml TRIZOL was add-
ed to each well and the plate incubated on a shaker for 10 min at RT. Afterwards, a 
cell scraper (BD Falcon, Bedford, USA) was used to remove all attached cells, with 
differentiated THP-1 cells being extremely tightly attached. The TRIZOL cell suspen-
sion was collected and frozen at -80° or processed immediately. Then 150 µl Chloro-
form was added, mixed (by shaking) and incubated for 5 min at RT. The solution was 
centrifuged at 4°, 10621 rcf for 15 min. Afterwards the aqueous phase was trans-
ferred into a new tube and precipitated with 500 µl 2-Propanolol, washed 2x with cold 
70% Ethanol afterwards the pellet was air dried and resuspenden with 21 µl RNAfree 
water. 
The DNase I kit (Ambion, LifeTechnologies) was used according to the manufactur-
er’s protocol (see Apendix). RNA was quantified using Nanodrop photometer (NP80, 
Implen). Synthesis of cDNA was performed using 500 ng DNA-free total RNA, 1 µl 
SuperScript® III reverse transcriptase (200 U/µl, LifeTechnologies, Grand Island, NY, 
USA), 4 µl 5x First Strand buffer (LifeTechnologies, Grand Island, NY, USA), 1 µl 
random hexamer primers (50 µM, Promega, Applied Biosystems), 1µl DTT (0.1M, 
Invitrogen), 1 µl dNTP mix (10 mM, Sigma-Aldrich, Castle Hill, Australia) and 1 µl Mo-
lecular Water (Carl Roth GmbH & Co. KG, Karlsruhe, Germany), per sample, accord-
ing to the enzyme manufacturer’s protocol. Negative control samples lacked Super-
Script® III (enzyme volume replaced with molecular water). The cDNA synthesis pro-
gram was conducted as in Tab. 3.1.3. 
 
Table 3.1.3: RT program for cDNA synthesis 
65°C 25°C 50°C 70°C 4°C 
5 min 10 min. 1 h. 15 min. hold 
 
3.1.4 Quantitative RT-PCR 
 
Quantitative real-time PCR was conducted for analyses of CD markers in macro-
phages and cytokine and chemokine mRNA transcript levels in M0, M1, M2 and 
TCam-2 cells. For the measurement of pro-inflammatory cytokines, such as IL1b, IL-
12, TNFa, and anti-inflammatory cytokines, such as IL-10, TGF-β1, as well as plei-
otropic IL-6 and chemokines including CCL2 and CCL5, Taqman probes (Thermo 
Fisher Scientific) were used (see Tab. 3.1.4.1) in a Taqman Assay, according to the 
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manufacturer’s protocol. The samples were prepared using 8 µl TaqMan® Gene Ex-
pression Assay and 2 µl sample (diluted 1:20 in Molecular water) (see Appendix, 
Chapter 3).  
For the analysis of CD markers to identify macrophage subsets, Oct3/4 to identify 
TCam-2 cells, Inhba (activin A, pleitropic cytokine), and chemokine receptors such as 
CCR1, CCR2, CCR3, CCR4 and CCR5, primers were designed using Oligo Explorer, 
Version 1.1.2 (see primer details, Tab. 3.1.4.2). The analysis was conducted using 
SybrGreen, according to the manufacturer’s protocol. The samples were prepared 
using 2 µl sample, 2 µl Molecular Water, 0.5 µl primer (10 pm, each forward and re-
verse) and 5 µl SYBRGreen (Thermo Fisher Scientific) and analysed by Applied Bio-
system 7900HT Fast Real-Time PCR machine. Each reaction was performed in 
technical triplicates which were averaged and calculated using SDS v2.4 (Applied 
Biosystems). For statistical analysis, a One Way ANOVA was performed followed by 
a Tukey post hoc test (GraphPad7.01). Data are shown as fold-change normalized to 
ACTB; term human placenta RNA (supplied by Ursula Manuelpillai) was used as a 
positive control. 
 
 
3.1.4.1 Table of TaqMan probes 
Target Product No. 
Human ACTB Hs01060665_g1 
Human GAPDH  Hs02758991_g1 
Human IL-1b  Hs01555410_m1 
Human IL-12a Hs01073447_m1 
Human TNFα Hs00174128_m1 
Human IL-6 Hs00174131_m1 
Human IL-10 Hs00961622_m1 
Human TGFβ1 Hs00998133_m1 
Human CCL2 Hs00234140_m1 
Human CCL5 Hs00982282_m1 
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3.1.4.2 Table of designed primers  
Tar-
get 
Accession 
number 
Utility Forward primer, 5’- 
3’ 
Reverse primer, 5’- 3’ 
GAPD
H  
NM_00125679
9.2 
House-
keeper 
AA-
GCCTGCCGGTGACTAAC 
CGCCCAATACGACCAAATC 
Bactin     NM_001101.4 House-
keeper 
GCATGGGTCAGAAGGAT
TC 
ACGCAGCTCATT-
GTAGAAGG 
CD11c  NM_00128637
5.1 
M1 AGACAGGAGCAG-
GACATTG 
GAACTGCATCAGGGAAAAC 
CD68  BT009923.1 M1 GCTGGCTGTGCTTTTCT
CG 
TCCTGTGGCTGGTTGTTCC 
CD163  DQ058615.1 M2 CTGTTTTGTCACCAG-
TTCTC 
CTCCAGCCATTATTACACAC 
CD206  NM_002438.3 M2 GGACTGGGTTGC-
TATCACTC 
AACCCGATCCCTTGTAGAG 
 
CCR1 NM_001295.2 chemokine 
receptor 
AAA-
GCCCCAGAAACAAAGAC 
TTGCATCCCCATAGTCAAAC 
CCR2  NM_00112304
1.2 
chemokine 
receptor 
GACCCACAAGATAAA-
GAAGC 
TTGAGGTCTCCAGAATAGG 
CCR3  NM_001837.3 chemokine 
receptor 
GTGGTGGTGGTGATGAT
CC 
ATGCCCCCTGACATAGTGG 
CCR4  NM_005508.4 chemokine 
receptor 
CTGCTCTTCGTGTTTTC
CC 
AAAGCCCAC-
CAAGTACATCC 
CCR5  NM_000579.3 chemokine 
receptor 
TAGTGGGATGAGCAGA-
GAAC 
GGCGAAAAGAATCAGA-
GAAC 
Inhba  NM_002192.3 Activin A TCGGAGATCATCAC-
GTTTGC 
GGGACTTTTAGGAA-
GAGCCAGAC 
 
3.1.5 Western blot 
3.1.5.1 Protein Isolation 
 
As described above, the media of the cultivated and differentiated M1 (THP-1) cells 
was collected by aspiration and frozen for further analyses by Multiplex, while the 
cells were washed with ice-cold PBS then 200 µl ice-cold cell lysate solution (10x 
Lysis buffer (Cell Signaling, #9803) diluted 1:10 in distilled water containing phospha-
tase (Cell Signalling, #5870S) and protease inhibitor (Cell Signalling, #5871S) diluted 
1:100 to prevent proteolytic degradation was added to each well. After 5 min on ice, 
cells were collected from individual wells using a cell scraper, then transferred to an 
Eppendorf tube, kept on ice for 20 min and vortexed every 5 min. Afterwards, the 
tubes were centrifuged at 10621rcf for 10 min. The supernatant was collected for pro-
tein concentration measurement against a standard of bovine serum albumin, and 
frozen at -80°C or directly used for SDS-PAGE. For SDS-PAGE, 30 µg of protein per 
lane was used. 
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3.1.5.2 SDS-PAGE 
 
The 10-12% running gel was cast 2 h before the protein transfer was conducted to 
allow an appropriate polymerization of the gel (see Appendix, Chapter 3). The sam-
ples were prepared by adding 2x SDS sample buffer (see appendix) plus β-
mercaptoethanol then mixed. The samples were boiled for 5 mins at 95°C for protein 
denaturation. Then 3 µl of a pre-stained protein molecular size ladder (PageRuler 
Prestained Protein Ladder, Fisher Scientific) was used and 10 µl in each gel, and 
each sample was loaded into a well. The gel was run at 30 mA until the loading dye 
entered the separating gel, and the voltage was increased to 50mA for at least 1 h 
until the loading dye reached the bottom of the gel. 
 
3.1.5.3 Protein transfer 
 
While the SDS-gel was running, transfer buffer (see appendix, Chapter 3), Whatman 
paper (BioRad, Hercules, California, USA) and membrane were prepared as follows. 
Four pieces of blotting paper were cut to a size slightly smaller than the gel and incu-
bated in transfer buffer along with 4x sponges. Then the PVDF-membrane (Millipore 
Immobilon P Transfer Membrane IPVH 00010 PVDF 0.45 µm pore size) was careful-
ly cut to the gel size, incubated in methanol for 30 sec then incubated in transfer 
buffer. Next the gel and PVDF membrane were incubated in transfer buffer. Then the 
gel and PVDF membrane were prepared for the protein transfer (see chapter 2, Fig. 
2.1.6.4, transfer assembly). Protein transfer proceeded with the transfer cassette im-
mersed in transfer buffer at 100 Volts for 2 h at RT. 
 
3.1.5.4 Protein detection 
 
After transfer, the PVDF membrane was carefully separated from the gel and washed 
twice with TBST (0.05% Tween in Tris-buffered saline TBS) for at least 5 min. All in-
cubations and washes were performed at RT. The membrane was blocked with 3-5% 
BSA/TBST for 1 h on a rocking plate, then the primary antibody (diluted in blocking 
buffer, 1:800) was added and incubated with rocking for an additional hour. The 
membrane was next washed three times using TBST buffer for 5-10 min. The sec-
ondary antibody (diluted in 3-5% BSA/TBST, 1:5000) was added and incubated for 1 
h with rocking, then the membrane was washed two times for 8 min using TBST. For 
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the chemiluminescent reaction, 400 µl of lumi-light western blotting substrate 1 and 2 
(Roche, Germany, Mannheim) were mixed, added and incubated for 2 min. Visualiza-
tion of antibody binding to target proteins was conducted using BIORAD Chemi 
Doc™ MP. 
 
3.1.5.4.1 Table of primary antibodies 
Primary Antibody Manufacturer Dilution Cat. No. 
pSmad2- 255  Cell Signaling 1:800 pS5255 
pSmad3-423/425 Cell Signaling 1:800 9513S 
Smad3 Cell Signaling 1:800 9520S 
a-tubulin Sigma-Aldrich 1:3000 T5168 
 
3.1.5.4.2 Table of secondary antibodies 
Secondary Antibody Manufacturer Dilution Cat. No. 
Anti-Rabbit IgG Pe-
roxidase 
Sigma-Aldrich 1:5000 A9169 
Anti-Mouse IgG Pe-
roxidase 
Sigma-Aldrich 1:5000 A9044 
 
 
3.1.6 Multiplex Cytokine /Chemokine analysis 
 
The medium from cultivated and differentiated THP-1 (M0, M1, M2) cells was collect-
ed for multiplex analysis. For cytokine and chemokine analysis, two separate Lu-
minex Multiplex Kits (Merck Millipore, Australia) were used (see Appendix, kits). 
Magnetic beads were used to isolate the reaction products for measurement in cell 
supernatants, that is more efficient and sensitive for analysis of small samples than 
traditional ELISA kits. The supernatants of cultivated cells exposed to factors to in-
duce THP-1 cell differentiation into M0, M1 and M2 cells, or without exposure (e.g. 
TCam-2 cells) that were used for this analysis were centrifuged at 239rcf for 2 min to 
exclude remaining cells, then collected in Eppendorf tubes for storage at -80°C or 
else immediately proceeded. Analysis was conducted using a Corning™ 96-Well Fil-
ter Plate Fluid Guard (Fisher Scientific), and samples were prepared according to the 
kit manufacturer`s protocol. The MULTIPLEX analysis (see Appendix) of each sample 
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(using triplicates) was conducted and the results visualized using Bioplex 200 (Bio-
rad).  
 
3.1.7 Flow  
3.1.7.1 Cell collection and fixation  
 
For analysis of cell surface markers by Flow cytometry, cultivated cells exposed to 
factors to induce THP-1 cell differentiation were grown to near confluency. After re-
moval of the supernatant (used for cytokine and chemokine analysis, described in 
3.1.6), 1 ml of 0.1% TV was added in each well for at least 3 min at 37°C in 5% CO2. 
Then each cell suspension was transferred into a Falcon tube and centrifuged at 
239rcf for 2 min, RT. The supernatant was removed, the cell pellet washed in 1 ml 
PBS and centrifuged again for 2 min. For fixation, the supernatant was discarded and 
1 ml of 4% PFA (in Millipore water) was added and incubated for 15-20 min at RT. 
The tubes were centrifuged at 239rcf for 2 min at 4°C. The supernatant was discard-
ed and replaced with 1% BSA/PBS. The cells were washed in BSA/PBS twice then 
stored for less than 10 days at 4oC for analysis. 
 
3.1.7.2 Staining of fixed cells 
 
The fixed cells were pelleted at 956rcf for 2 min at 4°C; all cell centrifugations were 
conducted using these conditions unless otherwise noted. The 1% BSA/PBS solution 
was discarded and 100 µl Perm/Wash (1x saponin-based permeabilisation reagent, 
ThermoFisher) containing 5% serum (species of origin varied depending on the pri-
mary antibody) was added and incubated for at least 10 min. Cells were pelleted by 
centrifugation, the supernatant removed, and cells were resuspended in Perm/Wash 
containing the primary antibody (Oct3/4, 1:100) and incubated for 1 h at RT. In the 
meantime, directly conjugated antibodies were prepared at appropriate dilutions in 
Perm/Wash (see 3.1.7.2.3). After blocking, cells were spun at 239rcf for 2 min at 4°C 
and the diluted direct conjugated antibody solution (see Tab. 3.1.7.2.3) was added 
and incubated for a 45 min in the dark. Next, the cells were pelleted at 239rcf. The 
supernatant was discarded and the diluted secondary antibody (Donkey anti-goat 
AF488, 1:300) was added and incubation for 45 min, at RT. Afterwards, 100 µl 
Perm/Wash was added to each tube and spun down at 239rcf. The supernatant was 
discarded and the cells were resuspended in Perm/Wash. This step was repeated 
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twice. The cells were finally resuspended in 150 µl Perm/Wash and stored for up to 6 
days at 4°C, until the flow analysis was conducted. 
 
 
3.1.7.2.1 Table of antibody used for TCam-2 detection (indirect staining) 
Antibody Manufacturer  Dilution Cat. No. 
Oct3/4 (primary 
antibody) 
Santa Cruz 1:100 sc-8629 
Donkey anti-goat 
AF488 (secondary 
antibody) 
Invitrogen 1:300 A11055 
 
 
3.1.7.2.3 List of direct conjugated antibodies (received from Dr B. Loveland, 
Burnet Institute, Melbourne, Australia) 
Direct conjugated 
Antibodies 
Manufacturer Dilution Cat. No. 
CD14 
PE  
BD Biosciences 
 
1:100 347497 
 
CD11c 
APCH7 
Biolegend 
 
1:20 337218 
 
CD68 
FITC 
Biolegend 
 
1:20 333806 
 
CD163 
PE 
Biolegend 
 
1:20 333606 
 
CD206 
APC 
Biolegend 
 
1:20 321110 
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3.1.7.3 Setting of the Flow cytometer and gating strategy  
 
Ten thousand events were acquired for each sample using the BD LSR Fortessa x20 
(BD Bioscience, San Jose, USA). Data were analysed using FlowJO Version 10 
(Tree Star, Ashland, USA) in the following manner. The first step was the selection of 
cells according to their physical properties; both debris and clumped cells were identi-
fied based on their position in the plot and subsequently excluded using Forward 
scatter (FSC) and Side scatter (SSC) setting made using the unstained control vs the 
stained control. Each antibody was detected using a different voltage setting that de-
pended on the cells being examined and the fluorophore (see list of voltage settings).  
 
 
3.1.7.3 Table: Voltage of each channel used for Flow analysis 
Antibody Voltage  
Oct3/4 (A488) B530: 550; 
SSC: 300; FSC: 640  
CD11c (APCH7) R780: 780; 
SSC: 300; FSC: 620 
CD14 (PE) RY586: 580; 
SSC: 300; FSC: 620 
CD68 (FITC) B530: 550; 
SSC: 280; FSC: 620 
CD163 (PE) Y586: 570; 
SSC: 300; FSC: 640 
CD206 (APC) R670: 700 
SSC: 300; FSC: 640 
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3.2 RESULTS  
3.2.1 Differentiation of THP-1 cells into M0, M1 and M2 macrophages after 
cytokine and LPS treatment 
 
For in vitro experiments to examine the functional polarization of macrophages asso-
ciated with testicular cancer (Chapter 2) we used M0, M1 and M2 macrophages ob-
tained by differentiation of THP-1 cells, a monocyte-derived cell line. To polarize the 
undifferentiated and non-adherent THP-1 cells, a treatment with PMA was first con-
ducted to activate them (black arrow). After every treatment, cells were observed us-
ing an inverted brightfield microscope. After this treatment, the previously round and 
non-adherent THP-1 cells became adherent and differentiated into a fibroblast-like 
M0 phenotype (Fig. 3.2.1.1, A/3.2.1.1, B, black arrow). Subsequent treatments with 
different cytokines and with LPS allowed M0 cell differentiation into M1 (LPS and 
IFNγ) or M2 (IL-4 and IL-13) macrophages. The M1 and M2 cells were more firmly 
attached and more fibroblast-like in appearance (Fig. 3.2.1.1, C, black arrow).   
 
Fig. 3.2.1.1: Analysis of differentiated human monocyte-derived THP-1 cells (M0, M1 
and M2 macrophages) by PMA, LPS and cytokine treatment. After the PMA treatment, 
the round non-adherent THP-1 cells (A) differentiate into adherent, fibroblast-like M0 macro-
phages (B, black arrow). After M0 macrophages were treated with cytokines (e.g. IFNγ, LPS 
or IL-4, IL-13) to differentiate them into M1 or M2 macrophages, respectively, the M1 and M2 
macrophages were more firmly attached to the wells and had a and more fibroblast-like ap-
pearance (C, black arrow). 
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An analysis measuring typical macrophage markers was conducted by qRT-PCR and 
Flow after the differentiation steps using PMA, cytokines and LPS. M1-specific mark-
ers are CD68 and CD11c, whereas M2 macrophages express CD163 and CD206.  
The determination of those markers at the transcript level revealed the success of the 
differentiation, since M1 macrophages expressed higher levels of CD68 and CD11c 
transcripts, but lower levels of the M2-specific markers, CD163 and CD206 than M2 
macrophages (Fig. 3.2.1.2, A). In contrast, THP-1 cells which were treated to differ-
entiate into M2 macrophages had a higher level of M2-specific marker transcripts 
than did M1 macrophages (Fig. 3.2.1.2, A). M0 macrophages expressed significantly 
lower levels of CD68 and CD11c (M1 markers) than did M1 macrophages, and had 
significantly lower levels of CD163 and CD206 (M2 markers) than M2 macrophages. 
To sum up, macrophages were successful differentiated. 
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Fig. 3.2.1.2: CD expression analysis of M0, M1 and M2 macrophages (differentiated 
THP-1 cells) by qRT-PCR and Flow analyses (FMI=Fluorescence Mean Intensity). THP-
1 cells treated with PMA (M0), then with either LPS and IFNγ (M1) or IL-4 and IL-13 (M2) 
were examined for expression of macrophage subtype-specific markers. The levels of M1 
markers, CD11c and CD68, and M2 markers, CD163 and CD206 were examined in each cell 
population by qRT-PCR (the value for each sample was normalised to b-actin) (A) and Flow 
(B) (n=3). Transcript levels of M1-specific markers were highest in M1 macrophages, M2-
specific marker transcripts were highest in M2 macrophages, and M0 macrophage transcript 
levels were closer to those in M1 cells (A). Flow analysis revealed that M0 macrophages ex-
pressed both M1- and M2-specific protein markers (B). M1 macrophages expressed high 
amounts of CD68 and CD11c, while M2 macrophages expressed high amounts of M2 (signif-
icantly higher than M2 marker expression by M1 macrophages) (B). Significance tested by 
one-way ANOVA (*P < 0.05, **P < 0.01). 
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3.2.2 Functional characterization of THP-1 derived M0, M1 and M2 mac-
rophages through analysis of cytokine expression and wound healing 
activity 
 
Macrophages of distinct phenotypes have different functions relating to pro-
inflammatory (in M1 macrophages) or anti-inflammatory and wound-healing actions 
(M2 macrophages). Following differentiation of THP-1 cells by PMA, LPS and cyto-
kine treatments into M0, M1 and M2 macrophage subtypes, their individual capacities 
for typical macrophage functions was evaluated by examining their cytokine expres-
sion profiles and migratory properties (functionally relevant to wound healing), using 
qRT-PCR, multiplex chemokine and cytokine assays (derivative of ELISA) and/or a 
‘scratch’ wound healing assay. The mRNA cytokine profiles revealed that M0 macro-
phages expressed transcripts encoding pro-inflammatory cytokines, including IL-12a 
and TNF-α, as well as the anti-inflammatory cytokines TGF-β1 and Inhba (dimerizes 
to form activin A; pleitropic cytokine) (Fig. 3.2.2.1). The ‘pro-inflammatory’ M1 macro-
phages contained relatively higher transcript levels for pro-inflammatory cytokines 
such as IL-12a, TNF-α, IL-6, in addition to Inhba and TGF-β1.  M2 macrophages ex-
pressed transcripts encoding anti-inflammatory cytokines e.g. IL-10, TGF-β1, Inhba 
and IL-6 (also pleiotropic) (Fig. 3.2.2.1). 
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Fig. 3.2.2.1: mRNA transcript profiles demonstrating relative pro-/ and anti-
inflammatory cytokine expression by M0, M1 and M2 macrophages (differentiated 
THP-1) (n=3). M2 macrophages expressed relatively higher levels of transcripts encoding IL-
6, Inhba, IL-10 and TGF-β1 (anti-inflammatory cytokines, A) whereas M1 macrophages ex-
pressed pro-inflammatory cytokines such as IL-12a, TNF-α and the pleiotropic cytokine IL-6 
(B). M0 macrophages showed transcript level of TGF-β (anti-inflammatory cytokine (A)) and 
pro-inflammatory cytokine (B) such as IL-12. Cytokines such as IL-6, IL-10, TGF-β1, IL-12a 
and TNF-α are relative to b-actin and human placenta (Taqman probes) whereas Inhba is 
relative to b-actin (individual primer design). Significance tested by one-way ANOVA (*P < 
0.05). 
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The cytokine protein profile in the M0 macrophage supernatant exhibited lower 
amounts of IL-10, TGF-β1, IL-12 and TNF-α relative to that from M1 and M2 macro-
phages; secretion of IL-6 from M0 cells was barely detected (Fig. 3.2.2.2). M1 mac-
rophages are known to express pro-inflammatory cytokines including IL-6, IL-12 and 
TNF-α (Martinez and Gordon, 2014). After differentiation of THP-1 cells into the M1 
subtype, specific pro-inflammatory cytokines were secreted (Fig. 3.2.2.2, B). Addi-
tionally, production of IL-6, IL-12 and TNF-α was higher in the supernatant of M1 
macrophages in comparison to M0 and M2 (Fig. 3.2.2.2, B). In contrast, higher levels 
of specific anti-inflammatory M2 related cytokines such as IL-10 and TGF-β1 were 
produced by M2 macrophages (Fig. 3.2.2.2, A). Collectively, these results highlight 
and confirm the expected functional differences between the M0, M1 and M2 macro-
phages generated from THP-1 cells (Genin et al., 2015).   
 
  
Fig. 3.2.2.2: Pro-/and anti-inflammatory cytokine profile of M0, M1 and M2 macrophag-
es (differentiated THP-1) by multiplex chemokine and cytokine assay (n=3). M2 macro-
phages expressed anti-inflammatory cytokines (A) such as IL-10 and TGF-β1 whereas M1 
macrophages expressed pro-inflammatory cytokines (B) such as IL-12, TNFα, IL-1a and 
the pleiotropic cytokine IL-6. M0 macrophages secreted besides anti-inflammatory cytokines 
(A) also pro-inflammatory cytokines (B) such as IL-12 and TNFα. Significance tested by one-
way ANOVA (*P < 0.05).   
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An additional analysis of the potential wound healing activity of individual macro-
phage subsets was conducted using a cell ‘scratch’ assay (method described in Sec-
tion 3.1.2). This is based on knowledge that M2 macrophages have additional prop-
erties such as contributing to angiogenesis and wound healing (Genin et al., 2015; 
Hagemann et al, 2009), activities that require these cells to migrate. A ‘wound’ was 
simulated in a plate of confluent cells by scratching a gap across the bottom of the 
well using M0, M1 and M2 macrophages (differentiated THP-1). After 24h the gap 
was slightly closed by M1 (1.98%) and M2 (3.56%) cells. After 48 h, there was an 
increase in the gap closure by M0 (6.33%) and M1 (3.39%) cells but a decrease by 
M2 (1.72%). Interestingly, after 72 h, M2 macrophages showed the greatest extent of 
gap closure (13.94%) in comparison to M0 (6.92%) and M1 (6.3%) cells (Fig. 
3.2.2.3). 
 
Fig. 3.2.2.3: A scratch assay measuring relative migration activity was conducted to 
reveal the potential wound healing activity of each macrophage subset (M0, M1 and 
M2). Individual macrophage subtypes were cultivated in a 6 well plate to 90 % confluence. A 
gap was created across the well with a pipet tip, and the extent of gap closure was measured 
daily (at t= 24 h, 48 h, 72 h) (n=3). After 24 h, M2 macrophages showed the strongest gap 
closure (3.56%) compared to M0 (0%) and M1 (1.98%) macrophages. M2 macrophages 
showed the strongest gap closure effect after 72 h (13.94%) whereas M0 and M1 macro-
phages reached a percentage of approximately 7%. Significance tested by one-way ANOVA 
(*P < 0.05).   
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3.2.3 Chemokine and chemokine receptor expression by THP-1 derived 
M0, M1 and M2 macrophages 
 
Examination of testicular neoplasia samples revealed the presence of the chemo-
kines CCL2 and CCL5 (see Chapter 2), which were previously identified as macro-
phage recruitment and polarization factors in other cancer types e.g breast cancer 
(CCL2, CCL5) and primary prostate cancer (CCL2) (Fang et al., 2016; Mizutani et al., 
2009; Ueno et al., 2000; Soria and Ben-Baruch, 2008). Interestingly, both tumour 
cells and macrophages can express these chemokines. Thus, we analysed the po-
tential for THP-1-derived macrophage subsets to produce both chemokines (CCL2, 
CCL5) and their specific chemokine receptor subunits (CCR1, CCR2, CCR3, CCR5), 
to determine if these macrophages could be the cellular targets of these particular 
chemokines.  
Both CCL2 and CCL5 mRNA transcripts were detected at relatively low levels in M0 
macrophages, and proteins encoded by both were detected in the multiplex analysis 
(Fig. 3.2.3.1, A/ B). M1 and M2 macrophages contained high levels of CCL2 and 
CCL5 transcripts relative to M0 cells, whereas the CCL2 protein level in M1 cells was 
significantly higher compared to M0 and M2 macrophages but CCL5 protein levels 
were not different between these cell types (Fig. 3.2.3.1, A).  
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Fig. 3.2.3.1: Chemokine transcript and protein expression profiles of M0, M1 and M2 
macrophages determined using qRT-PCR and Multiplex (n=3). Relative gene expression 
was normalised to ACTB and human placenta, with M0 cells containing relatively lower tran-
script levels than M1 and M2 subtypes. (A). M1 macrophages produced a significantly higher 
amount of CCL2 protein compared with M0 and M2 macrophages.  Significance tested by 
one-way ANOVA (*P < 0.05, **P < 0.01, ***P < 0.001).  
 
 
As previously mentioned, macrophages are targets of chemokines which can be ex-
pressed by tumour cells (Roca et al., 2009; Kim et al., 2009; Erler et al., 2009; Man-
tovani, 2008). The present study was conducted to assess which macrophage sub-
sets might be targets for these locally-produced chemokines by examining chemo-
kine receptor mRNA levels. M0 macrophages contained CCR1 and CCR2 tran-
scripts, whereas other chemokine receptors, CCR3 and CCR5 were not detected 
(Fig. 3.2.3.2). Similar to M0 macrophages, M2 and M1 macrophages also contained 
CCR1, whereas the CCR2 transcript was barely detected in M1 cells and undetecta-
ble in M2 cells (Fig. 3.2.3.2). Additionally, both M1 and M2 macrophages expressed 
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CCR3 and CCR5 (Fig. 3.2.3.2), however the levels of both were higher in M1 macro-
phages (Fig. 3.2.3.2).  
These outcomes have implications for the potential responsiveness of these cells to 
locally produced factors and highlight functional differences between these macro-
phage subtypes, as summarized here and presented in Tab. 3.2.3. M0 macrophages 
have the potential to bind CCL5 and CCL15 via CCR1 and to bind CCL2 through 
CCR2. In addition to the potential to bind CCL5 and CCL15 via CCR1 contrast, M1 
and M2 macrophages may also bind these ligands through CCR3 and CCR5 (CCL5) 
receptors. Thus, in summary, these results indicate that M0 and M1 macrophages 
can bind CCL2, CCL5 and CCL15, whereas M2 can bind CCL5 and CCL15 (see Tab. 
3.2.3). 
 
 
Fig. 3.2.3.2: Chemokine receptor transcripts measured in M0, M1 and M2 macrophages 
(differentiated from THP-1 cells) using qRT-PCR (n=3). M0 macrophages had detectable 
levels of CCR1 and CCR2 but not CCR3 or CCR transcripts, whereas M1 and M2 expressed 
CCR1, CCR3 and CCR5, and M1 cells had a barely detectable level of the CCR2 transcript. 
Relative gene expression was normalised to ACTB in each sample and human placenta 
which served as the positive control. 
 
 
 
 
Table 3.2.3: Summary of chemokine receptor transcripts detected in individual 
expression macrophage subsets. Receptor name in bold; ligands for each receptor 
listed below; tick = detected; n. d. = not detected)  
 M0 M1 M2 
CCR1 
   CCL5, CCL15 
      
CCR2  
   CCL2 
    n.d. 
CCR3 
   CCL5, CCL15 
n.d.     
CCR5  
   CCL5 
n.d.     
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3.2.4 M0, M1 or M2 macrophage (THP-1 derived) treatment with cytokines 
and chemokines 
 
Data presented in Chapter 2 identified that different macrophage subsets are detect-
able in neoplasia specimens when compared to healthy adult testis tissue with nor-
mal spermatogenesis. This indicates that a functionally distinct macrophage polariza-
tion state is associated with testicular neoplasia, and led us to the identification of 
potential macrophage polarization factors associated with testicular neoplasia. Exper-
iments were undertaken to determine the influence of these cytokines, such as IL-10, 
activin A, and chemokines, such as CCL2, CCL5 and CCL15, on individual macro-
phage subsets, with the objective of determining how they might change the synthe-
sis of subtype-specific markers and cytokines.  
Under normal culture conditions, M0 macrophages contain transcripts encoding both 
pro-inflammatory cytokines such as IL-1b, IL-12a and anti-inflammatory cytokine 
TGF-β. After exposure to either IL-10 (20 ng/ml) or activin A (25 ng/ml), only the 
IL12-a mRNA was decreased following exposure to IL-10; no other significant chang-
es were detected (Fig. 3.2.4.1).   
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Fig. 3.2.4.1: Effect of IL-10 (20 ng/ml)(A) or activin A (25 ng/ml) (B) treated M0 macro-
phages (differentiated THP-1) by analysing mRNA transcript profile of pro-/ and anti-
inflammatory cytokine expression. M0 macrophages (without IL-10 or activin A treatment) 
expressed transcript level of pro-/ and anti-inflammatory cytokines such as IL-12a, IL1b and 
TGF-β1. M0 macrophages that were treated with IL-10 and activin A showed an increased 
IL-12 transcript level whereas the levels of other cytokines did not change. Monoculture: n=1 
(preliminary data); co-culture: n=3). 
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M0 macrophages showed expression level of CCL5 and a hardly expression of 
CCL2. After a treatment with IL-10 (20ng/ml, A) or activin A (25ng/ml, B) M0 macro-
phages showed an increase of CCL-2 and CCL-5 expression (mRNA transcript lev-
els) (Fig. 3.2.4.2, A/ B). 
 
 
 
Fig. 3.2.4.2: Effect of IL-10 (20ng/ml) (A) or activin A (25ng/ml) (B) treated M0 macro-
phages (differentiated THP-1) by analysing mRNA transcript level of chemokine ex-
pression. M0 macrophages without IL-10 (A) and activin A (B) treatment expressed no tran-
script level of CCL2 whereas CCL5 was hardly detectable. M0 macrophages that were treat-
ed with IL-10 showed an increased transcript level of CCL2 and CCL5 (A) as well as activin 
A treated M0 macrophages (B). Monoculture: n=1 (preliminary data); co-culture: n=3). 
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After exposure to either CCL15 (20 ng/ml) or activin A (25 ng/ml), M1 specific CD11c 
and M2 specific CD206 marker (transcript level) were decreased whereas activin A 
treated M0 macrophages showed additional a significantly reduction of CD68. Tran-
script level of M2 specific CD163 was not detectable in both groups. 
 
Fig. 3.2.4.3: Effect of CCL15 (20ng/ml) (A) or activin A (25ng/ml) (B) treated M0 macro-
phages (differentiated THP-1) by analysing mRNA transcript level of specific macro-
phage marker as an indication of macrophage polarization (n=3). M0 macrophages 
without CCL15 (A) and activin A (B) treatment expressed transcript level of CD68, CD11c 
and CD206 but no transcript level of CD163. M0 macrophages exposed to CCL15 (A) and 
activin A (B) showed a reduction of m1 and m2 marker. Significance tested by student t-test 
(*P < 0.05).  
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Fig. 3.2.4.4: Effect of CCL2 (20ng/ml) (A) or CCL5 (20ng/ml) (B) treated M0 macrophag-
es (differentiated THP-1) by analysing mRNA transcript level of specific macrophage 
marker as an indication of macrophage polarization (n=3). M0 macrophages without 
CCL2 (A) and CCL5 (B) treatment expressed transcript level of CD68, CD11c and CD206 
but no transcript level of CD163. M0 macrophages exposed to CCL2 (A) and CCL5 (B) 
showed increased transcript level of m1 and m2 specific marker (excluded CD206 of CCL5 
treated M0). Significance tested by student t-test (**P < 0.01). 
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3.2.5 Inhibition of Smad2/3 signalling pathway of macrophage subsets by 
SB-431542 and Follistatin (inhibitors)  
 
TGF-β and activin A are known as macrophage polarization factors (Sierra-Filardi et 
al., 2007; Zhang et al., 2016). Their effect on the polarization of macrophages from 
M0 and M1 into the M2 subtype was confirmed after treatment with either TGF-β (20 
ng/ml) or activin A (25 ng/ml). In addition, inhibitors of activin A and/or TGF-β signal-
ling, SB-431542 (10 µM, can inhibit both ligands) and follistatin (250 ng/ml, specific to 
activin) were tested for their effect on this transition. Cells were pre-treated with these 
ligands to increase or with inhibitors to block Smad2/Smad3 activation, which medi-
ate activin A and TGF-β signalling pathway activity and thus enable the M0 and M1 
differentiation into M2 macrophages. At first, pathway activation was interrogated us-
ing antibodies to detect total Smad3, phosphorylated Smad3 (pSmad3) and pSmad2 
after a treatments with either TGF-β or activin A. Next, the impact of pre-treatment 
with inhibitors SB-431542 and follistatin on the extent of Smad2 and Smad3 phos-
phorylation arising from TGF-β and activin A treatment was assessed. Treatment of 
M0 macrophages with TGF-β (20 ng/ml, without inhibitor pre-treatment) activated 
Smad2 and Smad3, as evidenced by increased signals for the phosphorylated forms 
of these transcription factors (Fig. 3.2.5.1, B/ C, lane 1). Pre-treatment with 
SB431542 prior to TGF-β the pSmad2 and pSmad3 band signal was lower compared 
to that observed in MO cells lacking inhibitor pre-treatment (Fig. 3.2.5.1, B/ C, lane 2 
and 3). Additionally, the activin A treated M0 cells showed a strong pSmad2 and 
pSmad3 protein band (Fig. 3.2.5.1, B/ C, lane 4) while pre-treatment with SB-431542 
or follistatin showed a lower Smad2 and pSmad3 signals (Fig. 3.2.5.1, B/ C lane 5 
and 6). However, Smad3 was detected in all treated groups whereas the TGF-β1 
group showed the strongest protein band (Fig. 3.2.5.1, A, lane 1). 
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Fig. 3.2.5.1: Inhibition effect of Smad2/3 signaling pathway using TGF-β1 and activin A 
and SB431542 and Follistatin treated M0 macrophages (THP-1 derived) (preliminary 
data). M0 macrophages were treated with TGF-β (20ng/ml) or activin A (10ng/ml, without the 
inhibitor pre-treatment) and a strong detection of pSmad2 and pSmad3 was possible. 
Whereas, M0 macrophages which were pre-treated with inhibitors (e.g. SB431542 and Fol-
listatin), showed a decrease of the protein bands. All groups showed an expression of 
Smad3. 
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3.2.6 Migration assay reveals individual macrophage subsets as targets 
of specific chemokines  
 
Chemokines are recruitment factors of immune cells. As previously mentioned, we 
have detected CD68+macrophages and CD163+/CD206+ M2 macrophages in the 
human testis. Additionally, we revealed the presence of the chemokine CCL15 in the 
non-inflamed testis. Thus, we assumed that macrophage precursor and M2 macro-
phages can be recruited to the non-inflamed testis. In contrast, testicular neoplasia 
was associated with CCL2 and CCL5 (see chapter 2). Interestingly, there was an cor-
relation between the new revealed chemokine milieu and the increased macrophage 
populations associated with testicular cancer. Therefore, we assumed that CCL2 and 
CCL5 are recruitment factors of macrophages which can then differentiate into other 
phenotypes due to the tumour environment. Thus, we conducted a migration assay 
using M0, M1 and M2 that were treated with CCL15 and M1 and M2 macrophages 
were treated with CCL2, CCL5 and CCL15 to reveal the chemotaxis effect.  
After the CCL15 treatment, M0 macrophages showed a significantly increased migra-
tion effect in comparison to the untreated group after 24 h (M0 CCL15: 12.62%, M0: 
0%) (Fig. 3.2.6.1, A). After 48 h, CCL15 treated M0 macrophages showed a signifi-
cantly increased migration effect compared to the untreated group (M0 CCL15: 
16.25%, M0: 6.33%) (Fig. 3.2.6.1, A). The strongest effect of the treated group was to 
see after 72 h (22.8%) that was significantly increased compared to the gap closure 
of the untreated group which didn’t change after 48 h (6.03%) (Fig. 3.2.6.1, A). In 
contrast, the treated M1 macrophages showed after 24 h a gap closure of 6.9% 
whereas the untreated group reached 1.98%. After 48 h, the treated group showed a 
slight decrease (5.57%) and the untreated group a slight increase (3.39%) of the gap 
closure (Fig. 3.2.6.1, B). After 72 h the untreated group showed an increase and 
reached 6.3% gap closure in comparison to t= 24 h (1.98%) and t= 48 h (3.39%) 
whereas the treated group showed an decrease (0.72%)(Fig. 3.2.6.1, B). The treated 
M2 macrophages showed a gap closure of about 7.65% after 24 h and 7.93% after 
48 h whereas the control group showed less effect (t= 24 h: 3.56%, 48 h=1.71%) 
(Fig. 3.2.6.1, C). After 72 h either the control group or treated group showed an in-
crease of the gap closure of about 13.94% (control group) and 14.73% (treated 
group) (Fig. 3.2.6.1, C). 
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Fig. 3.2.6.1: A Scratch assay was conducted to reveal the recruitment activity of 
CCL15 using different macrophage subset (M0, M1 and M2). Macrophages were cultivat-
ed in a 6 well plate and after reaching a confluence of about 90%, a gap was scratched and 
the gap closure was measured at different time points (t= 24 h, 48 h, 72 h)(n=3). M0 macro-
phages treated with CCL15 showed the strongest migration effect in comparison to M1 (B) 
and M2 (C) macrophages. Comparing CCL15 treated M0 macrophages with the control 
group revealed a significantly increased gap closure effect (A). M1 macrophages showed the 
lowest migration effect of gap closure and after 72 h there was a decrease (0.72% gap clo-
sure). After 24 h, treated M2 macrophages showed a gap closure of 7.65% whereas the un-
treated group reached 3.56%. After 72 h both groups showed an increase (CCL15 M2: 
14.73%, M2: 13.97%). Significance tested by one-way ANOVA (*P < 0.05, **P < 0.01, ***P < 
0.001). 
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Interestingly, M1 macrophages which are treated with CCL2 showed a stronger mi-
gration effect than the group that were treatment with CCL15. After 24 h, the treated 
M1 macrophages showed a significant gap closure of about 11.92% whereas the un-
treated group showed a 2.94% gap closure (Fig. 3.2.6.2, A). After 48 h there was a 
slightly increase of both groups (M1 CCL2: 15.05%, M1: 4.93%) but the strongest 
effect was to see after 72 h (M1 CCL2: 21.13%, M1: 8.16%) (Fig. 3.2.6.2, A). All in 
all, M1 macrophages which were treated with CCL2 showed a significant increase of 
gap closure compared to the control group (A). In contrast, M2 macrophages showed 
no significant effect of the CCL2 treatment compared to the control group (Fig. 
3.2.6.2, B). 
 
 
 
 
Fig. 3.2.6.2: A Scratch assay was conducted to reveal the recruitment activity of CCL2 
using different macrophage subsets (M1 and M2). Macrophages were cultivated in a 6 
well plate and after reaching a confluence of about 90%, a gap was scratched and the gap 
closure was measured at different time points (t= 24 h, 48 h, 72 h)(n=3). The untreated M1 
macrophages showed a slight gap closure after 24 h (4%) which reached after 72 h a maxi-
mum of about 10% (A). M1 macrophages which were treated with CCL2 showed significant 
increase of gap closure compared to the control group (A). M2 macrophages showed a slight 
gap closure without the CCL2 treatment which was increased compared to the treated M2 
macrophages (B). Significance tested by one-way ANOVA (*P < 0.05, **P < 0.01, ***P < 
0.001). 
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Additionally, M1 and M2 macrophages were treated with CCL5. Treated and untreat-
ed M1 macrophages showed after 48 h a significant difference (M1 CCL5: 15%, M1: 
2%) (Fig. 3.2.6.3, A). After 72 h, CCL5 treated M1 macrophages showed a reduction 
of the gap closure whereas the untreated group reached 4% (Fig. 3.2.6.3, A). CCL5 
treated M2 macrophages showed after 24 h a significant increase compared to the 
control group (M2 CCL5: 13%, M2: 2%) (Fig. 3.2.6.3, B). After 48 h and 72 h, the 
treated group showed no significant difference compared with the control group (Fig. 
3.2.6.3, B). 
 
Fig. 3.2.6.3: A Scratch assay was conducted to reveal the recruitment activity of CCL5 
using different macrophage subset (M1 and M2). Macrophages were cultivated in a 6 well 
plate and after reaching a confluence of about 90%, a gap was scratched and the gap clo-
sure was measured at different time points (t=24 h, 48 h, 72 h)(n=3). Treated M1 macro-
phages showed a strong gap closure effect after 48 h (15%) which was significantly in-
creased compared with the untreated control group (2%) (A). After 72 h treated M1 macro-
phages showed a decreased migration effect. In contrast, M2 macrophages showed strong 
migration effects (B). After 24 h, CCL5 treated M2 macrophages showed a gap closure of 
about 13% which was slightly increased after 48 h (14%) whereas the untreated group 
showed also strong migration effects compared to M1 macrophages (A/ B). Significance 
tested by one-way ANOVA (*P < 0.05, **P < 0.01, ***P < 0.001). 
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3.2.7 Cytokine and chemokine expression by TCam-2 
 
It is known that tumour cells itself can express different cytokines and chemokines to 
recruit and influence immune cell functions. Therefore, we analysed if TCam-2 (mon-
oculture) can express cytokines and chemokines.  
We revealed that cultivated TCam-2 can express TGF-β1 (anti-inflammatory cyto-
kines) and IL-6 (pro/-and anti-inflammatory cytokine) that was significantly increased 
compared to other cytokines (IL-10, IL-1a, IL-12b and TNF-α (Fig. 3.2.7.1).  
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Fig. 3.2.7.1: TCam-2 analysis of anti-/ and pro-inflammatory cytokine expression of by 
Multiplex (n=3). Cultivated TCam-2 cells expressed the anti-inflammatory cytokine TGF-β1 
(anti-inflammatory) and the pleiotropic cytokine IL-6 which were significantly increased com-
pared with other cytokines such as IL-10 and IL-1a, IL-12b, TNF-α (pro-inflammatory). Signif-
icance tested by one-way ANOVA (*P < 0.05, **P < 0.01, ***P < 0.001). 
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Additionally, we analysed the expression of Chemokines such as CCL2 and CCL5 
(mRNA and protein). The cultivated TCam-2 cells showed a slight expression of 
CCL2 whereas CCL5 was not detectable (transcript level) (Fig. 3.2.7.2, A). The pro-
tein analysis revealed that CCL2 was secreted whereas CCL5 was hardly expressed 
(protein level) (Fig. 3.2.7.2, B).  
 
 
Fig. 3.2.7.2: TCam-2 analysis: Chemokine transcript expression level and protein ex-
pression by qRT-PCR (A) and Multiplex (B) (n=3). Cultivated TCam-2 cells showed tran-
script level of CCL-2 whereas CCL5 was hardly detectable. A protein analysis revealed the 
expression of CCL2 whereas CCL5 was hardly detectable as well. Relative gene expression 
was normalised to ACTB and human placenta. Significance tested by one-way ANOVA (*P < 
0.05). 
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 3.3 DISCUSSION 
 
Testicular germ cell tumours typically contain a variety of macrophage subtypes in 
close contact with the neoplastic cells. These macrophage subsets have contrasting 
properties, both anti- and pro-inflammatory, and are known to exhibit either tumour 
progressive (M2) or tumour destructive (M1) phenotypes in other neoplastic condi-
tions (Sica et al., 2006; Sica et al., 2008; Allavena et al., 2008; Biswas and Manto-
vani, 2010). Tumour cells can themselves control the functional polarization of mac-
rophages by producing cytokines and chemokines (Lewis and Pollard, 2006; Duluc et 
al., 2007; Heusinkveld et al., 2011b). In this thesis, potential macrophage polarization 
factors have been identified in specimens of human testicular neoplasia (see Chapter 
2). Thus, this study was conducted to establish components of a cell culture model 
that could be used to examine functional interactions between macrophages and 
TGCTs. The human monocyte-derived THP-1 and the TCam-2 seminoma cell lines 
were selected as well-established models of each cell type that could be manipulated 
and used to characterize macrophage-tumour cell interactions.  In the present chap-
ter, potential macrophage polarization factors are examined in detail, while in Chapter 
4 the TCam-2 and THP-1 cells are used in co-culture to model the testicular tumour 
environment and observe their interactions.  
In the present study, THP-1 cells are characterized regarding the presence of hall-
mark CD marker proteins and functional properties. A recently established protocol 
for THP-1 differentiation into specific macrophages subsets (Genin et al., 2016) was 
used to differentiate THP-1 cells into M0, M1 or M2 macrophages by successive ex-
posure to PMA, cytokines and LPS. In addition to characterization of subtype-specific 
CD markers, cytokine and chemokine expression and characterization of chemokine 
receptors were conducted to identify what potential recruitment factors may be influ-
encing the behaviour and/or phenotypes of these cells. Additional experiments treat-
ing the differentiated macrophages with cytokines and chemokines found in the tes-
ticular tumour environment (Chapter 2) identified potential macrophage polarization 
factors and examined whether one or more cytokines are necessary or sufficient to 
drive functional differentiation. To assess whether TCam-2 cells might be to influence 
macrophage polarization, cytokine and chemokine profiling of this cell line was also 
conducted. 
For an identification of different macrophages subsets following in vitro differentiation 
of the THP-1 cell line, the markers used were those described in human testis clinical 
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specimens in Chapter 2: M1, CD11 and CD68; M2: CD163 and CD206. CD68+ mac-
rophages were also detected which could not be classified as with M1 or M2 pheno-
types.   
In the present study, M0 macrophages were shown to contain high transcript and 
protein levels of CD68. This therefore indicates that M0 cells are a precursor of mac-
rophages which subsequently differentiate into another phenotype, either M1 or M2, 
depending on the cytokine milieu they encounter after the recruitment. In the healthy 
testis with normal spermatogenesis, the predominantly anti-inflammatory milieu is 
predicted to promote the M2 phenotype. Interestingly, the culture of M0 macrophages 
led to synthesis of both M1 (CD68 and CD11c) and M2 (CD163 and CD206) marker 
expression in these cells. This can be interpreted as an indication that M0 macro-
phages become poised to differentiate into either M1 or M2 macrophages, with their 
subsequent phenotype influenced by cytokine and chemokines. The presence of  
transcripts and proteins encoding both pro-/and anti-inflammatory cytokines in M0 
macrophages was demonstrated, including IL-10, TGF-β1, TNF-α, IL-12, CCL2 and 
CCL5. It could be that this cytokines and chemokines were secreted by macrophages 
due to the long incubation time (43 h). However, all detectable cytokines are known 
as potential M2 macrophage polarization factors such as IL-10, TGF-β1 whereas 
TNF-α is a potential M1 polarization factor (Urban et al., 1986; Hagemann et al., 
2006; Lu et al., 2013; Chanmee et al., 2014; Genin et al., 2015,).  
Both, M1 and M2 macrophages expressed specific CD markers, CD68 and CD11c 
(M1) and CD163 and CD206 (M2) whereas macrophages which were differentiated 
into M2 showed significantly increased M2 marker expression compared to M1 mac-
rophages. Additionally, both, M1 and M2 macrophages expressed nearly the same 
transcript level of pro-/and anti-inflammatory cytokines whereas the protein analysis 
clearly confirmed the anti-inflammatory property of M2 macrophages due to the ex-
pression of high amounts of IL-10 and TGF-β as well as the pro-inflammatory proper-
ty of M1 macrophages by the expression of high amounts of IL-12, IL-6, TNF-α 
(Biswas and Mantovani, 2010; Blagih and Jones, 2012; Haschemi et al., 2012; Cai et 
al., 2012). Interestingly, in vivo studies of murine macrophages revealed that M2 
macrophages can re-polarize into M1 due to the plasticity caused by cytokines ex-
pression (Guiducci et al., 2005). Therefore, the plasticity of macrophages could ex-
plain the transcript level of pro-/and anti-inflammatory cytokines expressed by M1 
and M2 macrophages. Another reason which should be discussed is the transition 
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ability. Furthermore, M2 macrophages are known for the wound healing property 
(Martinez et al., 2008). Therefore, an assay was conducted that simulated a wound 
by scratching a gap at the bottom of a confluent 6 well plate. All three macrophage 
subsets were analysed and M2 macrophages showed the strongest wound healing 
effect by measuring the area of the gap at different time points. This property that is 
M2 specific can be hereby confirmed. All in all, polarized and well characterized THP-
1 macrophages are a useful in-vitro model since M1 and M2 specific properties can 
be confirmed. 
Additionally, an analysis regarding chemokine and chemokine receptors expression 
by M0, M1 and M2 macrophages was conducted. The inflammatory chemokines 
CCL2, CCL5 and CCL15 and chemokine specific receptors were addressed due to 
the chemotaxis capability of immune cells especially macrophages and their potential 
role as macrophage polarization factors. We revealed clearly that M0 macrophages 
are targets of all chemokines (CCL2, CCL5 and CCL15) due to the specific receptor 
expression of CCR1 and CCR2 (transcript levels). However, a migration assay was 
conducted to confirm the macrophage recruitment effect of chemokines (CCL2, CCL5 
and CCL15). Interestingly, M0 and M2 macrophages showed a strong migration ef-
fect using CCL15 whereas M1 macrophages showed no migration effect after the 
treatment with CCL15. This result could probably explain why M2 (CD163, CD206) 
and macrophage precursor (CD68+) which might be similar to M0 macrophages are 
present in the human testis where a detection of CCL15 was also possible (Fig. 
3.3.1).  
In contrast, M1 macrophages expressed low transcript level of CCR2. CCR2 can bind 
CCL2 (Craig and Loberg, 2006) but it is unclear if protein levels are expressed to 
bind CCL2. We assumed that these chemokine are responsible for the recruitment 
and/or for the functional polarization of M1 macrophages since CCL2 was constantly 
present and associated with testicular neoplasia (see Chapter 2). Conducting a mi-
gration assay, M1 macrophages showed a strong migration effect by CCL2 treatment 
that confirmed our hypothesis (Fig. 3.3.2). Interestingly, a chemokine expression 
analysis revealed an expression of CCL2 by M1 macrophages. This suggested that 
M1 macrophages can recruit circulating M1 macrophages as well as M0 macrophag-
es since both subsets expressed specific chemokine receptors to bind CCL2. This 
would confirm the role of macrophages to reinforce immune reaction by a recruitment 
of circulating immune cells from the peripheral blood to the inflammatory environ-
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ment. However, M2 macrophages expressed other chemokine receptor types than 
M0, which can target CCL5 and CCL15 but no CCL2. A migration assay was con-
ducted in order to confirm these recruitment properties of CCL15 and CCL5. A con-
formation was possible since the M2 treatment with both cytokines revealed a strong 
migration effect (Fig. 3.3.1/3.3.2). Additionally, M2 were able to express CCL5 which 
indicates that M2 macrophages have an influence on the recruitment of themselves. 
To sum up, macrophages itself express chemokines such as CCL2 (expressed by 
M1) and CCL5 (expressed by M2) that can confirm the role of macrophages to rein-
force immune reaction by the recruitment of immune cells. However, tumour cells in 
other cancer types can influence macrophage recruitment by even CCL2 as well as 
CCL5 (Ueno et al., 2000; Mantovani, 2008; Mizutani et al., 2009; Roca et al., 2009; 
Kim et al., 2009; Erler et al., 2009; Fang et al., 2016). Interestingly, the cultivation of 
TCam-2 cells showed an expression profile of both chemokines (CCL2 and CCL5) 
that could suggest that TCam-2 cells as a seminoma cell line can recruit macrophag-
es and control probably macrophage polarization by tumour specific cytokine expres-
sion. Further macrophage polarization depends then on the environment which is 
given. 
We tested the polarization capability of these chemokines by treating M0 macro-
phages with different chemokines and cytokines such as CCL2, CCL5; CCL15 and 
activin A. As previously mentioned (Chapter 2), M0 macrophages are precursor of 
M1 and M2 macrophages. Those macrophages are present in the human testis and 
we hypothesized an recruitment by CCL15 but it was not clear if this chemokine is 
also responsible for a functional polarization or if the cytokine milieu in the testis 
drives functional macrophage polarization since M2 macrophages are mainly pre-
sent. Interestingly, we were able to show an impact of CCL15 treated macrophages 
on CD marker expression.since M1 specific CD11c was downregulated but also M2 
specific CD206. M1 macrophages (CD68+/CD11c+) were not detectable in the hu-
man testis that confirmed our in vitro results but M2 macrophages 
(CD163+/CD206+). However, M2 macrophage polarization can be driven by TGF-β 
(Zhang et al., 2016) that is constantly present in the testis and indicated that CCL15 
is not responsible for a functional polarization of M2 macrophages. This suggested 
that CCL15 is a recruitment factor of macrophages but also a polarization factor. Ad-
ditionally, CCL2 and CCL5 treated M0 macrophages expressed higher transcript lev-
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el of M2 specific marker (CD163, CD206) that suggested besides the recruitment 
effect of these chemokines also a polarization effect.   
 
Fig. 3.3.1: Schematic of chemokine and macrophage coherence in the human testis. 
Besides, CD68+macrophage precursor, anti-inflammatory M2 macrophages are detectable in 
the human testis. In vitro cell culture experiments revealed the chemotactic property of both 
macrophage subsets that subsequently confirmed those cells as targets of CCL15. IC= 
immune cells, SC= sertoli cell, RS= round spermatids, ES= elongated spermatids, SG= 
spermatogonia, BL= blood testis barrier, SE= seminiferous epithelium. As indicated by black 
arrows, CCL15 can recruit different macrophage subsets. 
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Fig. 3.3.2: Schematic of chemokine and macrophage coherence under 
pathological conditions e.g. testicular neopasia. Besides M2 macrophages, newly 
detected pro-inflammatory M1 macrophages are associated with testicular neoplasia. 
Additionally recruitment factors such as CCL2 and CCL5 were present under this 
conditions. Specific in vitro cell culture experiments revealed that M1 macrophages 
can be recruited by CCL2 and CCL5 while M2 are attracted to CCL5. As indicated by 
black arrows, chemokines can recruit different macrophage subsets. IC= immune 
cells. 
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CONCLUSION 
 
We differentiated THP-1 cells into different macrophage subsets (M0, M1, M2) by a 
specific treatment with cytokines and LPS. Subsequently, a confirmation of M1 (pro-
inflammatory) and M2 (anti-inflammatory) specific properties was possible. Addition-
ally, a detailed cytokine and chemokine profile of TCam-2 cells was conducted to un-
derstand the immune cell recruitment and polarization capability. To sum up, we es-
tablished and characterized a macrophage and seminoma cell model that can be fur-
ther used for co-culture analysis (see chapter 4). 
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CHAPTER 4: The impact of testicular germ cell tumour/ immune cell 
interactions on the functional polarization of macrophages: Analy-
sis using THP-1 and TCam-2 cells  
4 INTRODUCTION 
 
As described in Chapter 2, testicular germ cell neoplasia specimens commonly con-
tain different macrophage subsets with distinct properties, such as the tumour-
promoting M2 macrophages that produce anti-inflammatory cytokines and the tumor-
icidal M1 macrophages which synthesize pro-inflammatory cytokines. However in the 
normal human testis with complete spermatogenesis, M1 macrophages are not de-
tectable. Data presented in Chapter 2 addressed the hypothesis that an altered envi-
ronment arises with the progression of testicular neoplasia, such that abnormalities in 
local production of cytokines and chemokines may recruit and polarize macrophages. 
A detailed analysis of cytokines and chemokines in the testicular tumour environment 
revealed potential candidates for macrophage recruitment and polarization (dis-
cussed in Chapter 2). 
As presented in Chapter 3, cell culture models were established to mimic the condi-
tions present in human testicular neoplasia in which germ cell tumours are in direct 
contact with macrophages. Using the human monocyte-derived THP-1 cell line, dif-
ferentiation into M0, M1 and M2 macrophages could be driven by treatment of these 
cells with specific factors. Both M0 and M1 cells could be altered to adopt pheno-
types associated with immune-suppressive M2 macrophages. This demonstrates the 
utility of the THP-1 cells to model the functional plasticity of macrophages in the testis 
tumour environment. 
In addition, the seminoma-derived TCam-2 cell line was shown to synthesize cyto-
kines capable of altering macrophage functions. Data in this chapter presents the 
results from co-culturing the different THP-1-derived macrophage subsets with 
TCam-2 cells to simulate and therefore study the immune-/tumour cell interaction. 
The presence and potential changes in cytokine and chemokine production was 
measured using qRT-PCR and multiplex protein assays. Additionally, functional mac-
rophage polarization associated with tumour/immune cell interaction was analysed in 
regards to factors that were secreted in this co-culture. The relevance of Smad sig-
nalling pathways to macrophage differentiation and subsequent macrophage polari-
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zation was tested using the pathway inhibitor, SB431542, and the outcomes moni-
tored by Flow analysis. This co-culture model was also used to examine the phago-
cytic capability of each macrophage subset. The results illustrate a functional molecu-
lar dialogue between tumour and immune cells that is likely to exist in the adult hu-
man testis and change with the progression from GCNIS to neoplasia. 
 
4.1 MATERIAL AND METHODS 
4.1.1 Cell co-cultures 
 
TCam-2 cells (a human seminoma derived cell line {Mizuno et al., 1993; deJong et 
al., 2008}, originally obtained from Prof. Kitizawa, Japan) and THP-1 cells (human 
monocytic leukemia cell line; provided by Dr. Ashley Mansell, Hudson Institute of 
Medical Research, Clayton, Australia) were cultivated as described in Chapter 3 
(Sections 3.1.1.1 and 3.1.1.2). THP-1 cells were differentiated into M0, M1 and M2 
subtypes using phorbol 12-myristate 13-acetate (PMA, 20 ng/ml) for 24 h (Fig. 4.1.1), 
then either Lipopolysaccharide (LPS, 10 pg/ml) and IFN-γ (20 ng/ml) for M1 differen-
tiation, or with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for M2 differentiation, for a further 
43 h incubation (Fig. 4.1.1). 
The cells were counted and each cell type was individually seeded at a density of 
1x105 cells per well in a 6 well plate (Falcon®, Corning Life Science, Tewksbury, 
USA) (Fig. 4.1.1). For IF, glass cover slips were placed into each well before the cells 
were seeded. THP-1 inhibition of the TGF-β signaling pathway was conducted 1h 
before TCam-2 cells were added. After the co-culture, cells were designated for RNA 
extraction and cDNA synthesis (PCR) (see 4.1.2/4.1.3), multiplex (see 4.1.4), IF (see 
4.1.5) or fixed for Flow analysis (see 4.1.6).  
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Fig. 4.1.1: Schematic of the in-vitro THP-1 setup for macrophage differentiation and 
following co-culture with TCam-2 cells. Human monocyte-derived THP-1 cells were treat-
ed with PMA and incubated for 24 h. Afterwards, the differentiated THP-1 cells (into activated 
M0 macrophages) were treated with either LPS (10 pg/ml) and IFN-γ (20 ng/ml) for differen-
tiation into M1 macrophages or with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for differentiation 
into M2 macrophages. Then TCam-2 and THP-1 cells were co-cultured (at a density of 
1x105cells per well of each individual cell type. After co-culture following analyses were con-
ducted: RNA extraction and cDNA synthesis (for transcript analysis by qRT-PCR), superna-
tant collection (Multiplex for protein measurement) and cell fixation (Flow cytometry for cell-
specific marker enumeration). 
 
4.1.2 RNA extraction and reverse transcription 
 
For extraction of total RNA, cells were washed with PBS then 1 ml TRIZOL was add-
ed to each well and the plate incubated on a shaker for 10 min at RT. Afterwards, a 
cell scraper (BD Falcon, Bedford, USA) was used to remove all attached cells, with 
differentiated THP-1 cells being extremely tightly attached. The TRIZOL cell suspen-
sion was collected and frozen at -80° or processed immediately. The DNase I kit 
(Ambion, LifeTechnologies) was used according to the manufacturer’s protocol. RNA 
was quantified using Nanodrop photometer (NP80, Implen). Synthesis of cDNA was 
performed using 500 ng DNA-free total RNA, 1 µl SuperScript® III reverse transcrip-
tase (200 U/µl, LifeTechnologies, Grand Island, NY, USA), 4 µl 5x First Strand buffer 
(LifeTechnologies), 1 µl random hexamer primers (50 µM, Promega or Applied Bio-
systems), 1 µl DTT (0.1M, Invitrogen), 1 µl dNTP mix (10 mM, Sigma-Aldrich, Castle 
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Hill, Australia) and 1 µl Molecular Water (Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany) per sample, according to the enzyme manufacturer’s protocol. Negative 
control samples lacked SuperScript® III (enzyme volume replaced with molecular 
water). The cDNA synthesis program was conducted as in Chapter 3 (Tab. 3.1.3). 
 
4.1.3 Quantitative RT-PCR 
 
Quantitative real-time PCR was conducted for analyses of CD markers in macro-
phages, and of cytokine and chemokine transcript levels in M0, M1, M2 and TCam-2 
cells. For the measurement of pro-inflammatory cytokines, IL1b, IL-12, TNFa, and 
anti-inflammatory cytokines, IL-10, TGF-β1, as well as pleiotropic IL-6 and chemo-
kines, CCL2 and CCL5, Taqman probes (Thermo Fisher Scientific) were used (see 
Tab. 3.1.4.1) in a Taqman Assay, according to the probe manufacturer’s protocol. 
The samples were prepared using 8 µl TaqMan® Gene Expression Assay and 2 µl 
sample (diluted 1:20 in Molecular Water) (see Appendix, Chapter 3).  
For the analysis of CD markers to identify macrophage subsets, Oct3/4 to identify 
TCam-2 cells, Inhba (activin A, pleitropic cytokine), and chemokine receptors, CCR1, 
CCR2, CCR3, CCR4 and CCR5, primers were designed using Oligo Explorer, Ver-
sion 1.1.2 (see primer details, Tab. 3.1.4.2).  
The chemokine receptor expression was analysed by using two TCam-2 datasets 
that were accessed from Geoprofiles series GSE60138. This series included TCam-2 
datasets GSM1466229 and GSM1466230, deposited by (Irie et al., 2015). Raw data 
was collected, and Genebank accession numbers correlated to specific gene names 
using BioDBnet Db2db software. 
The qRT-PCR was conducted using SybrGreen, according to the manufacturer’s pro-
tocol, as follows. The samples were prepared using 2 µl cDNA sample, 2 µl Molecu-
lar Water, 0.5 µl primer (10 pm, each forward and reverse) and 5 µl SYBRGreen 
(Thermo Fisher Scientific) and analysed by Applied Biosystem 7900HT Fast Real-
Time PCR machine. Each reaction was performed in technical triplicates which were 
averaged and calculated using SDS v2.4 (Applied Biosystems). For statistical analy-
sis, a One Way ANOVA was performed followed by a Tukey post hoc test 
(GraphPad7.01). Data are shown as fold-change normalized to ACTB; term human 
placenta RNA (supplied by Ursula Manuelpillai) was used as a positive control. 
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4.1.4 Multiplex Cytokine /Chemokine analysis 
 
The medium from cultivated and differentiated THP-1 cells differentiated into M0, M1, 
and M2 subtypes was collected for Multiplex analysis. For cytokine and chemokine 
analysis, two separate Luminex Multiplex Kits (Merck Millipore, Australia) were used 
(Chapter 3, Table 3.1.6), as this method is more efficient and sensitive for analysis of 
small samples than traditional ELISA kits. The supernatants of co-cultivated cells 
were centrifuged at 239rcf for 2 min to exclude remaining cells, then collected into 
Eppendorf tubes for storage at -80°C or else immediately processed. Samples were 
prepared according to the kit manufacturer`s protocol using magnetic beads to isolate 
the reaction products present in cell supernatants for measurement. The MULTIPLEX 
analysis (see Appendix Chapter 3) of each sample was conducted in triplicates using 
a Corning™ 96-Well Filter Plate Fluid Guard (Fisher Scientific), and and the results 
visualized using Bioplex 200 (Biorad).  
4.1.5 Immunofluorescence staining 
 
Media was removed from cells grown on coverslips, the cells were washed with PBS 
then fixed in 4% PFA for 15 min on a platform shaker with gentle rotation. After fixa-
tion the cells were washed 3 x 5 mins with PBS, then permeabilised in 1 ml/well 0.1% 
Triton-X-100/PBS for 10 mins. Primary antibodies (Tab. 4.1.5.1) were diluted in 0.5% 
BSA/PBS and applied to each coverslip for overnight incubation at 4°C or for 1 h at 
RT. Coverslips were then washed in 1 ml PBS 4 x 5 min on a rotating platform . Sec-
ondary antibodies (Tab. 4.1.5.2) were diluted in 0.5% BSA/PBS, then applied to the 
coverslips for a 1 h incubation in the dark. Afterwards, cells were washed in 1 ml/well  
PBS (4 x 5 min) on a rotating platform, incubated for 10 min in DAPI solution 
(1:10000, diluted in 0.5% BSA/PBS), then washed in 1 ml/well PBS (4 x 5 min). Co-
verslips were mounted using GVA (Genemed Biotechnologies, South San Francisco, 
U.S.A.) on Superfrost Plus slides. The slides were stored protected from light at 4°C 
until analysis was conducted. 
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Tab.4.1.5.1 Primary Antibodies (IF) 
Primary Antibody Manufacturer Dilution Cat.No. 
CD45 Dako 1:100 IS75130-2 
Oct3/4 Santacruz 1:100 sc-8629 
 
Tab.4.1.5.2 Secondary Antibodies (IF) 
Secondary Antibody Manufacturer Dilution Cat.No. 
Rabbit anti-mouse 
A568 
Abcam 1:300 483566 
Donkey anti-goat AF488 Invitrogen 1:300 A11055 
 
 
4.1.6 Flow  
4.1.6.1 Cell collection and fixation 
 
For flow cytometric analysis of cell surface markers expressed by M0 and M1 macro-
phages, and of transcription factors expressed by TCam-2 cells, THP-1 cells were 
first exposed to factors to induce differentiation and grown to near confluency. For co-
cultures, each cell type were seeded at a density of 1x105 cells per well (1.6 cm2) in a 
6-well plate (Falcon®, Corning Life Science, Tewksbury, USA), cultured at 37°C in 
5% CO2, and collected at different time points (t= 0 h, 3 h, 6 h, 12 h, 24 h and 48 h). 
Monocultures were seeded at the same density, and cells collected at 48 h for com-
parison.  After removal of the supernatant for measurements of cytokines and chem-
okines as described in 4.1.4, 1 ml of 0.1% TV was added in each well for at least 3 
min at 37°C in 5% CO2. Cells were fixed in 1 ml of 4% PFA (in Millipore Water) for 
15-20 min at RT. The tubes were centrifuged at 239rcf for 2 min at 4°C, the superna-
tant was replaced with 1% BSA/PBS, and the process repeated. Cells were stored for 
less than 10 days in 1% BSA/PBS at 4oC prior to analysis. 
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4.1.6.2 Staining of fixed cells 
 
The fixed cells were pelleted at 956rcf for 2 min at 4°C; all cell centrifugations were 
conducted using these conditions unless otherwise noted. The 1% BSA/PBS solution 
was discarded and 100 µl BD Perm/Wash™ buffer (containing Fetal Bovine Serum 
and saponin, ThermoFisher) was added and incubated for at least 10 min at RT. 
Cells were pelleted by centrifugation, the supernatant removed, and cells were re-
suspended in 50 µl Perm/Wash containing the primary antibody (Oct3/4, 1:100) and 
incubated for 1 h at RT. In the meantime, directly conjugated antibodies were pre-
pared at appropriate dilutions in Perm/Wash (see 3.1.7.2.3). After blocking, cells 
were spun at 239rcf for 2 min at 4°C and 50 µl of the diluted direct conjugated anti-
body solution (see Tab. 3.1.7.2.3) was added and incubated for 45 min protected 
from light. The cells were pelleted at 239rcf, the supernatant discarded and the dilut-
ed secondary antibody (Donkey anti-goat AF488, 1:300) added and incubation for 45 
min, at RT. Cells were washed twice in Perm/Wash (100 µl in each tube, centrifuga-
tion at 239rcf), and the cells were finally resuspended in 150 µl Perm/Wash and 
stored for up to 6 days at 4°C, until the flow analysis was conducted. 
 
4.1.6.3 Gating strategy 
 
Ten thousand events were acquired for each sample using the BD LSR Fortessa x20 
(BD Bioscience, San Jose, USA). Data were analysed using FlowJO Version 10 
(Tree Star, Ashland, USA) in the following manner. The first step was the selection of 
cells according to their physical properties; both debris and clumped cells were identi-
fied based on their position in the plot and subsequently excluded using Forward 
scatter (FSC) and Side scatter (SSC) setting made using the unstained control vs. 
the stained control. Each antibody was detected using a different voltage setting that 
depended on the cells being examined and the fluorophore (Chapter 3, Tab. 3.1.7.3).  
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4.2 RESULTS 
4.2.1 Visualisation of TCam-2 and THP-1 interactions in co-culture 
 
Co-culture of TCam-2 and THP-1 cells was used to investigate the nature and speci-
ficity of tumour-immune cell interactions, with a focus on cytokine and chemokine 
expression. TCam-2 and THP-1 derived M0, M1 and M2 macrophages were ob-
served after 24 h co-culture using an inverted brightfield microscope (Fig. 4.2.1). M0 
macrophages (Fig. 4.2.1, A) were in close contact with TCam-2 cells, as were M1 
(Fig. 4.2.1, B) and M2 (Fig. 4.2.1, C) macrophages.  
 
 
Fig. 4.2.1: Visualisation of tumour-/immune cell interactions using TCam-2 and differ-
ent THP-1-derived macrophage subsets (M0 (A), M1 (B), M2 (C)) after 24h co-culture. 
TCam-2 cells, black arrows; macrophage subtypes, white arrows. 
 
4.2.2 Synthesis of immune cell modulators is altered by co-culture 
 
As shown in Chapter 3, cultivated M0 macrophages in monoculture produced detect-
able levels of the pro-inflammatory transcripts encoding IL-12a and IL-1b, whereas 
transcripts encoding anti-inflammatory proteins such as TGF-β1 and IL-10 were bare-
ly detectable (Fig. 4.2.2.1). Co-cultured M0/TCam-2 cells altered these cytokine tran-
script profiles. For instance, levels of transcripts encoding the anti-inflammatory cyto-
kines IL-10, TGF-β and Inhba were higher compared the levels detected in monocul-
tures of M0 macrophages and TCam-2 cells (Fig. 4.2.2.1). Pro-inflammatory cyto-
kines such as IL-1b and TNF-α were also highly expressed in this co-culture system, 
whereas IL-12a was decreased (Fig. 4.2.2.1). Additionally, detection of the transcript 
encoding the pleiotropic IL-6 was possible in co-cultures of M0 macrophages and 
TCam-2 cells (Fig. 4.2.2.1). The level of the TGF-β1 protein was also analysed in this 
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co-culture model. It was detected in after 3 h of M0/TCam-2 co-culture, and the 
amount of protein detected after 24 h and 48 h was significantly higher than at 3 h of 
co-culture and in TCam cells grown alone (mono-culture). 
Furthermore, mono-cultured M1 macrophages showed transcript level of pro-/ and 
anti-inflammatory cytokines (e.g. Inhba, IL-10, TGF-β1, IL-12a, TNF-α, IL-1b and IL-
6) (Fig. 4.2.2.1/4.2.2.2). A co-culture with M1/TCam-2 leaded to an alteration of pro-
inflammatory cytokine transcript level such as a downregulation of IL-12a, TNF-α 
(excluded IL-1b) and anti-inflammatory cytokine IL-10 whereas TGF-β was increased 
(Fig. 4.2.2.1). Interestingly, there was a tendency of increased IL-6 cytokine transcript 
level in this co-culture system (Fig. 4.2.2.1). A detection of TGF-β1 protein level was 
possible after 3 h M1/TCam-2 co-culture. Additionally, TGF-β1 protein level was ana-
lysed using M1/TCam-2 co-culture model. Detection of TGF-β1 protein level was 
possible after 3 h M1/TCam-2 (Fig.4.2.2.2). After 48 h, the protein expression of 
TGF-β1 was significantly increased in the M1/TCam-2 co-culture compared to co-
cultured M1/Tcam-2 (t= 3 h) and monocultured TCam-2 (Fig.4.2.2.2). However, an 
analysis of TGF-β1 protein level between both groups, M0/TCam-2 and M1/TCam-2 
cells revealed that co-cultured M1/TCam-2 showed a higher expression than 
M0/Tcam-2 (Fig.4.2.2.2). 
M2 macrophages (mono-culture) expressed transcript level of pro-/ and anti-
inflammatory cytokines (e.g. Inhba, IL-10, TGF-β1, IL-12a, TNF-α, IL-1b and IL-6) 
(Fig. 4.2.2.1). However, transcript level of anti-inflammatory cytokines such as IL-10 
and TGF-β1 and pro-inflammatory cytokines such as IL-12a and IL-1b as well as the 
pleiotropic cytokine IL-6 were decreased whereas Inhba and TNF-α were slightly in-
creased in the M2/ TCam-2 co-culture compared with the monoculture (Fig. 4.2.2.1).  
In summary, the outcomes of tumour/ immune cell interactions revealed in these co-
cultures indicate that synthesis of the immune modulatory factors persists in co-
cultures and this cellular crosstalk can influence macrophage function.  
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Fig. 4.2.2.1 Tumour/ immune cell interactions affect profiles of transcripts encoding 
pro- and anti-inflammatory cytokines. Monocultures and co-cultures were conducted with 
THP-1-derived M0, M1 and M2 macrophages and TCam-2 cells (all n=3, except M0: IL-1b, 
n=1). Analysis of cytokines with established functions and presence in the testis (A) and cy-
tokines associated with inflammation (B). M0 macrophages showed transcript level of Inhba, 
TGF-β1 (anti-inflammatory cytokines) and IL-12a and IL-1b (pro-inflammatory cytokines) 
which were altered after a co-culture with TCam-2 cells. M2 macrophages expressed tran-
script level of the pleiotropic IL-6 and Inhba, IL-10 and TGF-β1 (anti-inflammatory cytokines) 
whereas M1 macrophages expressed pro-inflammatory cytokines such as IL-12, TNFα, IL-1a 
and the pleiotropic cytokine IL-6 which were altered after a co-culture with TCam-2 cells. The 
fold change value presented for each culture was calculated by delta-delta-Ct method and is 
relative to b-actin and human placenta (Taqman probes), whereas Inhba is relative to b-actin 
(individual primer design).  
A 
B 
* 
* 
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Fig. 4.2.2.2: Analysis of tumour/immune cell interaction effects on TGF-β1 levels in co-
cultured M0 (A) or M1 (B) macrophages with TCam-2 cells (n=3). TGF-β1 was measured 
against a standard provided with the Multiplex Kit. At each time point examined, t= 3, 24, 48 
h, TGF-β1 levels were higher in in M0/TCam-2 and M1/TCam-2 co-culture in comparison to 
the TCam-2 monoculture and co-culture (t= 3 h). Significance tested by student t-test (*P < 
0.05, **P < 0.01).   
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4.2.3 Tumour-immune cell interactions reveal chemokine attractants and 
M0, M1 and M2 macrophages as target cells (co-culture) 
 
As reviewed in Chapter 2, macrophages are targets of different chemokines which 
are present under pathological conditions, including testicular neoplasia. Therefore, 
this co-culture model was used to interrogate the mechanism underpinning recruit-
ment and functional polarization of macrophages. Analysis of two chemokines identi-
fied as present in TGCT tumours and their receptors (Chapter 2, Section 2.2.3.2) was 
undertaken to address the potential recruit and function on immune cells. 
The co-cultured TCam-2 cells and THP-1-derived macrophage subsets were ob-
served to be in close contact (Fig 4.2.1). Measurement of chemokine transcript levels 
revealed the presence of the chemoattractants, CCL2 and CCL5, using this tumour 
(TCam-2)/ immune cell (M0, M1, M2) co-culture model (Fig. 4.2.3.1). The transcript 
level of CCL2 was significantly higher in the M0/TCam-2 and M1/TCam-2 co-culture 
compared to the monocultures. In contrast, M2 cells and co-cultured M2/TCam-2 
cells showed no significant difference in CCL2 transcript levels (Fig. 4.2.3.1). Addi-
tionally, the CCL5 expression profile was not different between monocultured and co-
cultured M0 macrophages, whereas monocultured M1 and M2 macrophages showed 
a non-significant but clear trend towards higher CCL5 transcript levels, compared to 
the co-culture with TCam-2. Due to time constraints, a time course was not possible, 
but the duration of this interaction could be an important feature which determines 
the outcome of the behaviours of these cells in vivo and in vitro. 
An assessment of chemokine proteins revealed that after only 3 h of co-culture, 
CCL2 and CCL5 proteins were detectable in M0/TCam-2 and M1/TCam-2 co-culture 
supernatants (Fig. 4.2.3.2). After 3 h, CCL2 was significantly higher in the M1/TCam-
2 co-culture compared to the TCam-2 monoculture (Fig. 4.2.3.2). After 24 h, co-
cultured M0/TCam-2 and M1/TCam-2 cells showed an upward trend of CCL2 and 
CCL5 protein levels that was measured as significantly increased in M0/TCam-2 co-
culture compared to monocultured TCam-2 cells (Fig. 4.2.3.2).  
In summary, the levels of both CCL2 and CCL5 were measurable after 3 h co-culture 
and elevated at the 24 h in co-cultures, with CCL2 significantly higher in M1/TCam-2 
co-cultures and CCL5 significantly higher in M0/TCam-2 co-cultures.   
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Fig. 4.2.3.1: Chemokine transcript expression profile of co-cultured M0/TCam-2, 
M1/TCam-2, M2/TCam-2 macrophages compared with monocultured cells by qRT-PCR 
(n=3). All co-cultured macrophage subtypes contained detectable levels of CCL2 and CCL5 
transcripts, whereas only CCL2 was detectable in TCam-2 cells at a low level. Co-cultures of 
either M0/TCam-2 or M1/TCam-2 exhibited significantly increased CCL2 compared with the 
monoculture of these macrophage subtypes. The CCL5 transcript appeared lower (non-
significant) in all three co-cultures (M0/TCam-2, M1/TCam-2, M2/TCam-2). The fold change 
value presented for each culture was calculated by delta-delta-Ct method. Relative gene ex-
pression was normalised to ACTB and human placenta. Significance tested by student t-test 
(n.s. not significant;*P < 0.05, **P < 0.01).    
 
 
 
 
 
 
 
 
 
 
 
* 
** 
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Fig. 4.2.3.2:  Chemokine protein levels in TCam-2 cell monoculture supernatants com-
pared to those from co-cultures of M0/TCam-2 (A) or M1/TCam-2 (B). Measurements 
obtained using the Multiplex assay (n=3). Levels of both CCL2 and CCL5 were measur-
able after 3 h co-culture and elevated at the 24 h in co-cultures, with CCL2 signifi-
cantly higher in M1/TCam-2 co-cultures and CCL5 significantly higher in M0/TCam-2 
co-cultures. Significance tested by student t-test (*P < 0.05, **P < 0.01, ***P < 0.001).   
 
As previously addressed in Chapter 3, the detection of several chemokine receptor 
transcripts was possible in monocultured macrophages. A comparative analysis be-
tween monocultured and co-cultured macrophages revealed a clear change in 
chemokine receptor expression, while TCam-2 cells do not express chemokine re-
ceptors evidenced by the RNA sequence data from two TCam-2 samples (dataset 1: 
CCR1: n.d., CCR2: n.d., CCR3: 5, CCR5: n.d.; dataset 2: CCR1: n.d., CCR2: n.d., 
CCR3: n.d., CCR5: n.d.; n.d.= not detected). Co-cultured M0 macrophages showed a 
decreased expression of CCR1, whereas CCR2 was not detectable and CCR3 was 
hardly present (Fig. 4.2.3.3). An analysis of co-cultured M1 and M2 macrophages 
revealed a decrease of CCR1, CCR3 and CCR5 transcripts compared to monocul-
tures. Interestingly, CCR2 was previously expressed by monocultured M1 but not 
detectable in the co-culture. 
B 
A 
  CHAPTER 4 
  128 
 
 
Fig. 4.2.3.3: Comparative analysis of monocultured and co-cultured M0, M1 and M2 
(differentiated THP-1) chemokine receptor expression by qRT-PCR (n=3). All receptors 
such as CCR1, CCR2, CCR3 and CCR5 were higher expressed in the monoculture com-
pared to the co-culture. Relative gene expression was normalised to ACTB. Significance 
tested by one-way ANOVA (*P < 0.05, **P < 0.01, ***P < 0.001).   
 
 
4.2.4 TCam-2 cells influence macrophage polarization towards an immu-
nosuppressive M2 phenotype 
 
Using this co-culture model, the impact of the tumour-immune cell interactions on 
functional macrophage polarization was assessed, with a focus on examining how 
M0, M1 and M2 specific macrophage marker synthesis was altered. A comparison of 
       M0                 M0/TCam-2 
       M1                    M1/TCam-2 
         M2                  M2/TCam-2 
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CD expression was conducted in monocultured macrophages vs. co-cultured macro-
phages using two approaches: qRT-PCR and Flow cytometry.  
Co-cultivation of M0 macrophages with TCam-2 cells altered the CD transcript level 
of M0 macrophages. For instance, compared to monocultured M0 macrophages, co-
cultured M0 cells showed a significantly higher level of the M1 marker, CD11c, with 
CD68 modestly but non-significantly elevated (Fig. 4.2.4.1, A). M2 specific markers 
CD163 and CD206 were barely detectable in the M0 cells cultured on their own, but 
co-culture with TCam-2 led significant elevation of the M2 marker, CD163 (Fig. 
4.2.4.1, A).  
Measurement of M1 and M2 specific markers by Flow cytometry was conducted to 
assess changes protein levels (Fig. 4.2.4.2, A). Co-culture of M0 cells with TCam-2 
cells resulted in significantly higher levels of both M2 markers, CD163 and CD206, at 
both 24 and 48 hours. M1 markers, CD68 and CD11c were significantly elevated at 
48 h in M0/TCam-2 co-cultures.  
Additionally, co-cultivation of M1 macrophages and TCam-2 cells altered M1-specific 
CD transcripts compared to monocultured M1 macrophages. Coculture led to a sig-
nificant decrease in both CD11c and CD68 (Fig. 4.2.4.1, B). The CD163 transcript 
could be amplified from monocultured M1 macrophages, while that encoding CD206 
was barely detectable; co-culture of the M1 cells with TCam-2 cells did not yield a 
significant change in either of these (Fig. 4.2.4.1, B). A preliminary assessment (n=1) 
of protein levels indicated that both M1 (CD68, CD11c) and M2 (CD163, CD206) 
markers were increased by TCam-2 co-culture (Fig. 4.2.4.3, B).  
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Fig. 4.2.4.1: Transcript expression level (mRNA) of M1 and M2 specific marker by co-
cultured M0/TCam-2 (A) and M1/TCam-2 (B) (qRT-PCR, n=3). (A) Co-cultured M0 macro-
phages showed a significant alteration of M1 (CD11c) and M2 (CD163) specific marker com-
pared with the M0 monoculture. (B) Co-cultured M1 macrophages showed a significantly 
decreased expression of M1 specific marker (CD11c, CD68). Relative gene expression was 
normalised to ACTB and human placenta. Significance tested by student t-test (*P < 0.05, 
**P < 0.01).   
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Fig. 4.2.4.2: Levels of M1- (A) and M2- (B) specific markers become elevated by co-
culture of M0 macrophages with TCam-2 cells. Co-cultures with M0 macrophages showed 
significantly higher levels of M1-specific protein markers at 48 h of co-culture (A) and signifi-
cantly higher levels of M2-specific markers at 24h and 48h of co-culture (B) measured by 
flow cytometry and shown as fluorescence mean intensity (FMI) (n=3). Significance tested by 
student t-test (*P < 0.05, **P < 0.01, ***P < 0.001).   
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Fig. 4.2.4.3: Levels of M1- (A) and M2- (B) specific markers may be altered following 
co-culture of M1 macrophages with TCam-2 cell. Markers measured by Flow cytometry 
(preliminary data, n=1) and shown as fluorescence mean intensity (FMI). Co-cultured M1 
macrophages appear to have higher levels of M1 (A) and M2 (B) markers after 48 h.  
 
 
4.2.5 TGF-β signalling pathway inhibitor (SB-431542) treatment decreas-
es differentiation of immune-suppressive M2 macrophages in M0/TCam-2 
and M1/TCam-2 co-cultures.   
 
As previously addressed (see 4.2.4), co-cultured M0/TCam-2 and M1/TCam-2 cells 
showed increased M2 marker expression compared to monocultured M0 or M1 mac-
rophages. Activin A, IL-10 and TGF-β1 are potential candidates for mediating this 
increased M2 marker expression since recent studies showed an association of 
those cytokines and M2 polarization (Mantovani et al., 2002; González-Domínguez et 
al., 2016). Activin A, IL-10 and TGF-β1 have been previously identified as macro-
phage polarization factors (Mantovani et al., 2002; Mia et al., 2014; González-
A
A
B
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Domínguez et al., 2016). Importantly, transcripts encoding each were detected in the 
M0/TCam-2 and M1/TCam-2 co-culture (Fig. 4.2.2.1).  
Because 48 hours of co-culture with TCam-2 cells of both M0 and M1 macrophages 
led to significantly increased expression of M2 specific markers (see 4.2.4), these 
conditions were selected to address the potential that these ligands contribute to the 
phenotypic change. Therefore, a study was conducted to investigate the effect of 
blocking TGF-β1 and activin A signaling, by preventing activation of the Smad signal-
ling pathway in conditions that were demonstrated as permissive for macrophage 
polarization. Before placing M0 and M1 macrophages in co-culture, the pathway in-
hibitor SB431542 was used to pre-treat them, 1 hour before TCam-2 cell additions. 
TCam-2 cells were added to pre-treated M0 or M1 macrophages, and the M2 specific 
markers, CD163 and CD206, measured at 0, 24 and 48 h. After 24 h, pre-treated and 
co-cultivated M0 macrophages showed a decreased expression of CD163 and a sig-
nificantly increased expression of CD206 compared to t= 0 h (Fig. 4.2.5, A). Co-
cultivated M1/TCam-2 cells showed slightly increased M2 marker levels (Fig. 4.2.5, 
B). After 48 h, pre-treated and co-cultivated M0 macrophages showed nearly the 
same level of M2 specific marker as measured t= 0 h, whereas M0/TCam-2 without 
SB431542 pre-treatment showed significantly increased expression level of CD163 
and CD206 (M2 marker) (Fig. 4.2.5, A). Co-cultivated M1 macrophages showed sig-
nificantly decreased M2 protein level compared to monocultured M1 macrophages 
(Fig. 4.2.5, B). 
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Fig. 4.2.5: M2 (CD163, CD206) specific Protein expression level (FMI) of co-cultured 
M0/TCam-2 (A) and M1/TCam-2 (B), treated with SB431542 (10 µM) and without 
SB431542 (control) by Flow (n=3). SB431542 treated M0 and M1 macrophages showed a 
slightly increase of M2 marker after 24 h and 48 h co-culture. Additionally, co-cultured M0 
and M1 macrophages showed significantly increased protein level of M2 specific markers 
after 48 h compared with the SB431542 treated group. Whereas pre-treated (SB431542) 
M0/TCam-2 cells showed a reduction of M2 specific marker after 48 h. Significance tested by 
student t-test (*P < 0.05, **P < 0.01, ***P < 0.001).   
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4.2.6 Co-cultured M0/TCam-2 and M1/TCam-2 reveal phagocytic activity 
of THP-1-derived M0 and M1 macrophages 
 
A crucial role of macrophages is their ability to phagocytise pathogens. Several anal-
yses employing flow cytometry and indirect immunofluorescence were conducted to 
identify the phagocytic activity of M0 and M1 macrophages in relationship to TCam-2 
cells. This study was conducted to address phagocytic activity of macrophage sub-
sets on tumour cells and how these macrophage responses are influenced by the 
presence of tumour cells over time. These outcomes could be helpful to reveal which 
subset could be exploited for therapeutics by inhibition of tumour derived cytokines 
that influence macrophage polarization and subsequently phagocytic activity.  
 
4.2.6.1 Flow cytometry used to monitor loss of TCam-2 cells during co-
culture with THP-1 derived macrophages 
 
The flow cytometric assay established to examine macrophage phagocytic activity in 
M0/TCam-2 cells and M1/TCam-2 co-cultures employed CD14 as a marker present 
on all macrophage subsets (see Appendix, Chapter 4). TCam-2 cells were identified 
using Oct3/4, which is also known as POU5F1, present in all TCam-2 cells (Young et 
al., 2011). The disappearance of Oct3/4+ TCam-2 cells during co-culture with M0 or 
M1 macrophages was presumed to occur via phagocytosis; this was monitored by 
measuring the percentage of cells present at different time points (t= 3, 24, 48 h) 
relative to the culture start, with t= 0 h set to 100% (Fig. 4.2.6.1.1). After 3 h, co-
cultured M0/TCam-2 showed no significant decrease in Oct3/4+TCam-2 cell numbers 
(Fig. 4.2.6.1.1). After 24 h, Oct3/4+TCam-2 cells were significantly decreased com-
pared with t= 0 h by approximately 10%. At 48 h of co-culture, the Oct3/4+TCam-2 
cell number remained significantly decreased compared to t= 0 h.  
The co-cultures of M1 macrophages and TCam-2 cells showed no significant reduc-
tion in Oct3/4+TCam-2 cell number at 3 h (Fig. 4.2.6.1.2), however at 24 h the signifi-
cant decrease in number of Oct3/4+TCam-2 cells was greater than that recorded in 
the M0/TCam-2 cell cultures, reaching a value approximately 30% lower compared 
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with t= 0 h. After 48 h, this number also remained significantly lower compared to t= 0 
h (Fig. 4.2.6.1.2).  
Thus, co-culture of phagocytic M0 or M1 macrophages and TCam-2 cells resulted in 
a loss of TCam-2 cells. The outcomes at both 24 and 48 hours provide evidence that 
M1 macrophages have a higher phagocytic activity than M0 macrophages. The trend 
towards a slight increase in TCam-2 numbers between 24 h and 48 h indicates that 
the remaining TCam-2 cells remain viable and are likely to be proliferating. 
 
 
Fig. 4.2.6.1.1: Percentage of Oct3/4+TCam-2 cells measured by flow cytometry in 
M0/TCam-2 co-cultures (n=3). Co-culture resulted in a significant decrease in 
Oct3/4+TCam-2 cells at 24 h and 48 h, as an indication of TCam-2 phagocytosis by M0 mac-
rophages. Measured number of Oct3/4+TCam-2 cells at indicated time points is presented as 
a percentage of the cell number at t0= 100%. Significance tested by one-way ANOVA (**P < 
0.01, ***P < 0.001).   
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Fig. 4.2.6.1.2: Percentage of Oct3/4+TCam-2 cells measured at different time points in 
the M1/TCam-2 co-culture as an indication of TCam-2 phagocytosis by M1 macro-
phages (n=3). Co-cultured M1/TCam-2 revealed a significant decrease of Oct3/4+TCam-2 
cells at 24 h and 48 h. Measured number of Oct3/4+TCam-2 cells at indicated time points is 
presented as a percentage of the cell number at t0= 100%.. Significance tested by one-way 
ANOVA (*P < 0.05).   
 
4.2.6.2 Flow cytometric tracking of macrophage granularity as an indicator of 
phagocytic activity 
 
Mutzke et al. showed that the flow cytometric measurement of side scatter in cells 
can be used as an indicator of macrophage phagocytic activity (Mutzke et al, 2015). 
In the present study, CD14+M1 macrophages were analysed, as these displayed the 
greater phagocytic activity towards TCam-2 cells compared to M0 cells (4.2.6.1).  
CD14+M1 macrophages were identified with altered granularity at specific time points 
of the co-culture (t= 3, 6, 12, 24, 48 h). At the beginning of the co-culture, most mac-
rophages had a similar granularity (SSC) (Fig. 4.2.6.2.1, t= 0 h), reflecting the ob-
served uniformity of shape of these cells. At 3 h, the co-cultured CD14+M1 macro-
phages showed a remarkable shift towards a broad range of granularities and the 
emergence of cells with a distinctively higher CD14 levels. At 6 h, some CD14+M1 
macrophages showed a similar but broad alignment along the x axis which, indicated 
that all cells have a different granularity (SSC) but the same CD14 expression profile 
(Y586) (Fig. 4.2.6.2.1). However, some M1 macrophages showed a consistent 
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alignment along the y axis (Y586) that indicated a variable CD14 expression between 
individual cells; this distribution pattern was generally the same at 12 h of co-culture. 
Remarkably at 24 h, CD14+M1 macrophages showed the same profile as observed 
at t= 3 h (Fig. 4.2.6.2.1), while at 48 h, CD14+M1 macrophages the profile was more 
similar to that present at t= 6 h. Additional experiments with sampling at t= 3 h, 24 h 
and, 48 h to capture the time points which showed the greatest alteration of granu-
larity, showed consistent profiles (data not shown). These samples were used for the 
immunofluorescence experiments reported below.  
 
 
Fig. 4.2.6.2.1: Flow cytometric analysis of CD14 expression (Y586) and granularity 
(SSC) as an indication of TCam-2 phagocytosis using co-cultured M1/TCam-2. 
M1/TCam-2 were co-cultured and analysed at different time points (t= 0, 3, 6, 12, 24, 48 h). 
The M1 population at the beginning of the co-culture (t= 0 h) was relatively consistent in 
granularity and exhibited no difference regarding CD14 expression. At 3 and 24 h, prominent, 
different M1 populations could be identified on the basis of CD14 levels and granularity. Dif-
ferent subpopulations are highlighted in distinct colours for ease of visualization. (N.B. Y-axis 
numbering overlap at ‘0’ value is the result of overlapping of three-dimensional graphs.) 
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Closer inspection of the 24 h data is shown in Fig. 4.2.6.2.1, the time point at which 
most distinctive shift was detected in the M1/TCam-2 co-culture. Three macrophage 
subpopulations with different granularity and CD14 expression were identified, de-
noted Population 1 (9.9%), Population 2 (58.7%) and Population 3 (15.9%). The re-
maining 15.54% of cells were scattered and therefore did not identify as a separate 
group (Fig. 4.2.6.2.2). On the basis of data provided by Mutzke (2015), Populations 2 
and 3 are predicted to be engaged in phagocytosis.   
This exciting result provided further evidence that THP-1 derived M1 macrophages in 
co-cultures with TCam-2 cells are actively phagocytic.  
 
Fig. 4.2.6.2.2: Flow cytometric analysis of CD14 expression (Y586) and granularity 
(SSC) as an indication of TCam-2 phagocytosis using co-cultured M1/TCam-2. 
M1/TCam-2 were co-cultured with TCam-2 cells and analysed at 24 h. Three different popu-
lations were identified: Population 1 (9.86%) showed the same granularity (SSC), Population 
2 (58.7%) showed a shift of the granularity relative to Population 1, and Population 3 (15.9%) 
showed a granularity shift compared with Population 1 and a different in CD14 expression 
compared with Population 2. This data is an extraction of the data reported in Fig. 4.2.6.2.1. 
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4.2.6.3 IF to visualise co-cultures reveals evidence of phagocytosis 
 
An indirect immunofluorescence analysis was conducted to visualize interactions be-
tween co-cultured phagocytic macrophages and TCam-2 cells. CD45 was used as a 
marker for the identification of macrophages of all subsets, and Oct3/4 was the 
TCam-2 marker. Co-cultured CD45+ M0 macrophages and Oct3/4+TCam-2 cells 
were in close contact (Fig. 4.2.6.3, A). An observation of the nucleus of TCam-2 cells 
and macrophages revealed a different nucleus size (DAPI staining). The nucleus of 
macrophages was smaller than TCam-2 cells. This allowed besides the specific anti-
body staining an additional identification feature of TCam-2 and macrophages. A de-
tection of CD45+/Oct3/4+ M0 was also possible whereas Oct3/4 was located in the 
cytoplasm of M0 macrophages (Fig. 4.2.6.3, B). A detection of Oct3/4+TCam-2 cells 
with a nucleus fragmentation and M0 macrophages (THP-1 derived) with an untypical 
CD45 expression was possible (Fig. 4.2.6.3, A). 
The same experiment was conducted using M1/TCam-2 co-cultured cells. CD45+M1 
macrophages showed a fibroblast like structure and were in close contact to 
Oct3/4+TCam-2 cells (Fig. 4.2.6.2.3, B). In this co-culture model an observation of 
CD45+/Oct3/4+M1 macrophages were possible as well macrophages with a frag-
mented nucleus or no nucleus (Fig. 4.2.6.2.3, B).  
In summary, phagocytic M0 and M1 macrophages were in close contact to TCam-2 
cells whereas some of the macrophages showed a detection of Oct3/4 (TCam-2 
marker) that indicates a phagocytic activity and confirmed previous results (4.2.6.1 
and 4.2.6.2).   
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Fig. 4.2.6.2.3: Identification of co-cultured Oct3/4+TCam-2 and CD45+M0 (A) or M1 (B) 
macrophages after 24 h by IF double-staining (n=3). Oct3/4+TCam cells and CD45+M0 
macrophages were identified by IF (A, white arrows). M0 and M1 macrophages were in close 
contact to TCam-2 cells (A/B, grey arrows). A double-detection of Oct3/4+/CD45+ macro-
phages was possible and a co-localization of CD45 (red) and Oct3/4 (green) is shown in or-
ange (merged). TCam-2 cells and M0 or M1 macrophages which showed a nucleus fragmen-
tation or which showed an atypical nuclear shape (lack of a nucleus) detection of CD45 or 
Oct3/4 are highlighted by yellow arrows (A/B).   
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4.3 DISCUSSION 
 
The widespread occurrence and nature of immune cell infiltrates in GCNIS and semi-
noma tumours indicates that the tumour microenvironment is permissive for immune 
cell maintenance. It also suggests that the immune cells may be contributing to tu-
mour survival, perhaps through establishment of a local milieu that supports their pro-
liferation or survival. In this study, a cell co-culture model was established in order to 
simulate the tumour/macrophage cell interactions observed in testicular germ cell 
cancers, with the goal of understanding the possible mechanisms behind develop-
ment and expansion of neoplastic germ cells in adult men. This system employed 
TCam-2 cells, a human testicular seminoma cell-derived line which exhibits many 
features of the primitive germ cells from which these tumours are considered to arise 
(de Jong et al., 2008; Young et al., 2011). The human monocyte cell line, THP-1, was 
used to generate three different macrophage subtypes following established differen-
tiation protocols to produce cells which were successful differentiated into M0, M1 
and M2 macrophages (Genin et al., 2015), as characterised in Chapter 3. The results 
of this study demonstrate how this approach can contribute to knowledge of the tu-
mour microenvironment, including how these macrophage responses are influenced 
by the presence of tumour cells. 
Co-cultures of TCam-2 cells and differentiated THP-1cells were used to investigate 
the influence of tumour cells on the functional polarization of macrophages, including 
through an exploration of the specific cytokine milieu that had been identified in pre-
vious literature (Klein et al., 2016) and extended in Chapter 2 of this thesis. In gen-
eral, cytokines and chemokines can control macrophages phenotypes and can dif-
ferentiate them into pro-inflammatory (M1) or anti-inflammatory (M2) phenotypes. M1 
macrophages can be activated by pro-inflammatory Interferon-γ, TNF-α and LPS, 
whereas M2 differentiation can be driven by IL-4, IL-13, macrophage colony-
stimulating factor (M-CSF), TGF-β, IL-10, IL-6, and PGE2 (Sica and Mantovani, 
2012; Genin et al., 2015; Heusinkveld et al. a)/b), 2011; Gottfried et al., 2008). Inter-
estingly, all three co-cultured macrophage subsets showed individual cytokine pro-
files.  
M0 macrophages co-cultured with TCam-2 cells showed an increased anti-
inflammatory response based on the production of IL-10, TGF-β1, Inhba, as well as 
an increased expression of pro-inflammatory cytokines IL-1b, TNF-α and IL-6; ex-
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pression of pro-inflammatory IL-12 cytokine was decreased compared to the level 
detected in M0 monoculture. Enhanced synthesis of anti-inflammatory cytokines such 
as IL-10 and TGF-β is associated with tumour cell progression and surveillance in 
several cancer types (Sica et al., 2006; Derynck et al., 2001). Furthermore, in the 
human testis, factors such as IL-10, TGF-β, prostaglandin and glucocorticoids play a 
role in M2 polarization and may drive macrophage precursor, M0 macrophages in 
this co-culture model that might be similar to CD68+macrophages in human testisinto 
immune-suppressive M2 macrophages (Martinez et al., 2009; Wang et al., 2017, dis-
cussed in Chapter 2). Another potential M2 macrophage polarization factor, IL-6, was 
detected using this co-culture model (Roca et al., 2009). Thus, there are likely to be 
several components present in the local testicular environment that favour the M2 
immuno-suppressive macrophage phenotype which are more highly expressed due 
to the interactions which occur between seminoma and immune cells. 
In addition to the various M2 polarization mediators identified, typical M1 polarization 
factors were also detected, such as TNF-a (Genin et al., 2015). Additionally, the co-
culture of M1 cells with TCam-2 cells led to a decrease in the typical M1-related pro-
inflammatory cytokines, IL-12 and TNF-α, with an accompanying increase in tran-
scripts encoding anti-inflammatory IL-6 and TGF-β1 (Zhang et al., 2016). Interesting-
ly, the production of both cytokines by TCam-2 cells (see Chapter 3, Section 3.2.7) 
further supports the understanding that TCam-2 cells influence the functional polari-
zation of macrophages and drives them into an immunosuppressive phenotype. In 
the M2/TCam-2 co-culture, levels of the transcripts encoding anti-inflammatory IL-10 
and TGF-β1 as well as IL-6 are decreased; the outcome of reduced IL-6 mRNA is 
different than observed for the other macrophage subsets, and distinguishes this tu-
mour/immune cell interaction.  
As previously mentioned, in human testicular germ cell neoplasia specimens exhibit-
ing GCNIS and seminoma, different macrophage subsets were observed in close 
contact to tumour cells. Using this in vitro co-culture model, a direct interaction be-
tween TCam-2 cells and cells from each of the differentiated THP-1 derived macro-
phage subsets was documented. We hypothesized that tumour cells can recruit mac-
rophages through their secretion of different chemokines and subsequently control 
functional polarization of macrophages by cytokine and chemokine expression. For, 
instance, it has been shown that tumour cells can express CCL2 and CCL5 chemo-
kine to recruit macrophages to the tumour environment (Weagel et al., 2015). Inter-
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estingly, we have detected CCL2 and CCL5 in vivo using testicular neoplasia sam-
ples and in vitro using this co-culture model (Chapter 2, Section 2.2.3.2 and Chapter 
4, Section 4.2.3). CCL2 transcript and protein were readily detectable, whereas CCL5 
was expressed at a barely detectable level by monocultured TCam-2 cells. This sug-
gests that, besides the seminoma cells themselves, another cell type is responsible 
for macrophage recruitment in vivo. Further analysis revealed that immunosuppres-
sive M2 macrophages can express CCL5; this suggests that, in the tumour environ-
ment M2 macrophages, which are also known as tumour associated macrophages 
(TAM) play an additional role in immune cell recruitment. TAMs have been shown to 
be similar to M2 macrophages, which can produce high amounts of anti-inflammatory 
cytokines, such as IL-10 and TGF-β (Sica et al., 2006; Sica et al., 2008). TAM infiltra-
tions indicate a poor prognosis in Hodgkin disease, glioma, cholangiocarcinoma and 
breast cancer (Steidel et al., 2010; Chen et al., 2011), as these conditions would 
more likely be permissive for uncontrolled tumour growth.  
In multiple tumour types, CCL5 (also known as RANTES) can recruit TAMs, Treg 
cells and supress the activity of both Th1 cells and cytotoxic T lymphocytes (Cook 
and Hagemann, 2013; Chang et al., 2012; Schlecker et al., 2012). This suggests that 
TAMs can recruit macrophages in neoplastic conditions to maintain the immune sup-
pressive milieu and supress the function of other immune cell types to avoid strong 
immune reactions. Thus, an investigation regarding chemokine receptor expression 
by macrophage subsets was made to identify which macrophages would likely be 
targets of specific chemokines found in testicular neoplasia. It is known that CCR1, 
CCR3 and CCR5 can bind CCL5, whereas CCR2 can bind CCL2. We identified that 
monocultured M0 and M1 macrophages are both potential targets of CCL2 and 
CCL5, whereas M2 macrophages are potential targets of CCL5 (Chapter 3; Section 
3.2.6). 
It was intriguing to note that the transcript level of the specific chemokine receptors 
CCR1, CCR3 and CCR5 expressed by M0, M1 and M2 macrophages were de-
creased in the co-culture with TCam-2 cells. The CCR2 transcript which was detect-
ed in monocultured M0 and M1 macrophages was not detected in the M0/TCam-2 
and M1/TCam-2 co-cultures. This suggested that M0 and M1 macrophages down-
regulate the expression of CCR2 after binding CCL2 to this receptor. However, co-
cultured M0 and M1 macrophages may express an additional CCL2 receptors; the 
atypical chemokine receptor 2 (ACKR2) is a receptor with CCL2 binding capability 
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that indicates a role in regulation of inflammation and immune responses (Bonavati et 
al., 2017). ACKR2 expression is associated with different disease e.g. chronic ob-
structive pulmonary disease, oral squamous cell carcinomas, colon cancer and 
breast cancer (Bonavati et al., 2017), but the potential presence and role of ACKR2 
expressed by macrophage subsets in this co-culture model, as well as in testicular 
cancer, remains to be determined.  
Additional, it has been shown that co-cultured M0 and M1 altered their phenotype, 
evidenced by the expression of M2 specific marker (Section 4.2.4). As previously 
shown M2 macrophages didn’t express CCR2 that suggest that after 43 h co-culture 
an expression of CCR2 was not possible since TCam-2 influenced M0 and M1 mac-
rophage differentiation into an M2 phenotype.  
Interestingly, recent studies have shown that an upregulation of CCL2 has also been 
demonstrated in primary prostate and invasive breast cancer and a positive associa-
tion with the recruitment of M2 cells has been documented (Fang et al., 2016; Mizu-
tani et al., 2009; Ueno et al., 2000). In vivo gene silencing has resulted in tumour 
growth inhibition and reduced M2 recruitment in a mouse model (Fang et al., 2016). 
Roca et al showed that CCL2 influence macrophage polarization into an M2 pheno-
type (Roca et al., 2009). This suggested that CCL2 is a macrophage recruitment fac-
tor as well as a polarization factor. These findings collectively indicate that CCL2 is 
one of the most important macrophage attractants in many tumour types, including, 
as shown to be likely here, in testicular neoplasia. 
 
Using this co-culture model, the potential polarization effect of TCam-2 cells on mac-
rophages was also analysed by flow cytometry to measure levels of cell subtype-
specific markers. As expected, monocultured M1 macrophages expressed M1-
specific markers CD11c and CD68, whereas M2 macrophages had higher levels of 
M2-specific markers, CD163 and CD206 compared to M1 macrophages. Intriguingly, 
cultivated M0 macrophages expressed relatively high levels of both M1 and M2 sub-
type markers, most likely reflecting their identity as a lineage precursor which can 
differentiate into either M1 or M2 macrophages. Co-culture of each macrophage sub-
set with TCam-2 cells demonstrated specific alterations of CD marker levels, showing 
that TCam-2 cells can influence macrophage polarization. M0 macrophages exhibited 
higher transcript and protein levels of immune-suppressive M2-subtype markers 
when co-cultured, compared to cells cultured on their own. The M0 cell type also dis-
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played an M1-specific marker and M1-related pro-inflammatory cytokines, including 
TNF-α, a known M1 polarization factor. Because both phenotypes were detected in 
co-cultured M0 cells, we hypothesize that TCam-2 cells can partly influence macro-
phage polarization into an immunosuppressive phenotype, but other local factors that 
determine the outcome of this process in vivo. Co-cultivated M1 macrophages also 
showed higher levels of M2 specific marker proteins, CD163 and CD206, when co-
cultured with TCam-2 cells, compared to when grown in monoculture.  
These findings from flow cytometry analysis indicated that TCam-2 cells influence 
macrophage polarization through their synthesis of cytokines and chemokines. Using 
this co-culture model, potential macrophage polarization factors have been identified 
as IL-10, TGF-β, activin A, IL-6 and CCL2. A preliminary experiment assessed the 
whether blocking TGF-β1 and activin A actions could alter the the polarization effect 
of co-culture with TCam-2 cells. Signaling by TGF-β1 and activin A normally occurs 
via specific cell surface receptor complexes which can be selectively and potently 
blocked by SB431542 (Inman et al., 2002). Co-culture of M0 or M1 macrophages 
with TCam-2 cells in the presence of SB431542 prevented the increase in M2 marker 
expression (CD163, CD206) documented in earlier co-cultures lacking this TGF-β1 
and activin A signaling inhibitor. This provides a preliminary indication that either 
TGF-β1 and/ or activin A are central to the process of macrophage polarization.  
There is considerable evidence supporting roles for several TGF-β superfamily lig-
ands in the emergence and progression of testicular germ cell neoplasia (reviewed in 
Loveland and Hedger, 2015). Evidence from murine studies demonstrates that Nod-
al, BMPs, TGF-β1 and activin A serve many essential roles in normal fetal testis de-
velopment (Young et al., 2015) during the stages when testicular germ cell tumours 
are considered to arise from spermatogenic precursor cells, gonocytes that do not 
develop normally. It will be important to explore if dysregulation of this signalling 
pathway maintains conditions permissive for inappropriate gonocyte maintenance 
into adult life by suppressing immune cell responses that would normally remove the-
se cells in infancy. 
A crucial function of macrophages is their role as patrolling cells that can recognise 
and phagocytise pathogens, including tumour cells. M1 macrophages have been 
previously described as highly phagocytic (Sica and Mantovani, 2012). The potential 
relevance of this macrophage function to germ cell tumour development was exam-
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ined using establishing several approaches. A newly established phagocytosis assay 
(Mutzke et al., 2015) was conducted to characterise the phagocytosis capability of 
different THP-1 derived macrophage subsets. Using flow cytometry to measure mac-
rophage granularity changes as alterations in side scatter, the co-culture of both M0 
and M1 macrophages with TCam-2 cells provided evidence of dynamic macrophage 
phagocytic activity. This method was developed using macrophage engulfment of 
latex beads, resulting an alteration of their granularity (Mutzke et al., 2015). Recent 
studies have shown that human monocytes can phagocytise 1-3 µm latex beads after 
only 6-8 min (Gu et al., 2014). We speculate that the phagocytosis of TCam-2 cells 
that are approximately 40 µm in diameter takes up to 3 h, since Cannon and Swan-
non showed that latex beads larger than 15 µm in diameter were completely phago-
cytised by murine bone marrow derived monocytes during an interval of 30 min 
(Cannon and Swannon, 1992). Interestingly, THP-1 derived macrophages in co-
culture with TCam-2 cells displayed a strong granularity shift at 3 h of co-culture, the 
earliest time point monitored in these experiments. The trend to decreased TCam-2 
cell numbers at 3 h co-culture offers further evidence of their phagocytosis by macro-
phages, but shift number was not significant until the 24 and 48 time points, the next 
ones measured in these experiments. At 48 h of co-cultivation with TCam-2 cells, the 
high levels of M2-specific markers on M0 and M1 macrophages indicated they are 
functionally polarized into an M2 phenotype. This could explain why TCam-2 cell 
numbers are increased after 48 h compared to at 24 h, since in other cancer types 
e.g. breast cancer, the immunosuppressive M2 macrophages are more permissive 
for tumour maintenance and thus play a significant role in tumour progression (Eiro, 
2012). This result, which indicates how tumour cells avoid immune reactions by con-
trolling macrophage polarization, would be highly relevant in the in vivo circumstanc-
es within a testicular germ cell neoplasia, which potentially develops over a period of 
months or years. The visualization of apparent phagocytosis was enabled through 
immunofluorescent double-staining, since Oct3/4 was detectable in the cytoplasm of 
macrophages. Thus, the phagocytic property of M1 macrophages was confirmed us-
ing this co-culture model using several different approaches. 
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CONCLUSION 
 
A tumour/ immune cell co-culture model was established that helped to elucidate a 
tumour cell-driven mechanism to influence macrophage polarization and avoid im-
mune reactions within testicular germ cell neoplasia. Tumour cells (TCam-2) can ex-
press cytokines to maintain a special anti-inflammatory cytokine milieu. Furthermore, 
they can express chemokines with the capacity to recruit macrophages which can 
differentiate into immunosuppressive M2 macrophages due to the specific stimulus 
caused by local production of cytokines and chemokines. Collectively, the evidence 
provided in this chapter supports the proposal that TCam-2 cells can influence and 
control macrophage polarization, since all macrophage subtypes expressed M2 spe-
cific markers after co-culture with this seminoma cell line. Future work should ad-
dress the role of specific immune modulators, such as TGF-β and activin A, and the 
impact and regulation of macrophage phagocytic activity on tumour cell survival and 
proliferation.   
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5 FINAL CONCLUSION 
 
This study has shown for the first time that infiltrating DCs and macrophages are 
highly associated with testicular germ cell cancer, being present in GCNIS and semi-
noma. The identification that DC and macrophage subtypes with contrasting proper-
ties, such as tumoricidal and tumour progressive phenotypes, demonstrates that 
completely different immune cell activities are active in these tumours. Importantly, 
this study has provided evidence that seminoma cells have the capacity to control 
immune cell functional polarization. These findings could help to establish new thera-
peutics for testicular cancer that target the polarization of immune cells, especially 
macrophages, by preventing their differentiaton into immunosuppressive phenotypes.  
Experiments in this thesis have revealed that macrophages may migrate into the tes-
ticular tumour environment by chemotaxis under the influence of the chemoattractant 
chemokines, CCL2 and CCL5 (Fig. 5.1). Whether seminoma cells or macrophages 
mediate this recruitment remains to be further explored, and the full range of their 
impact on immune reactions is yet to be determined. It is expected that M1 macro-
phages will act to reinforce immune reactions against seminoma cells by their pro-
duction of pro-inflammatory cytokines that are inevitably associated with neoplasia.  
In contrast, these findings indicate that both seminoma cells and M2 macrophages 
can influence macrophage polarization into an immunosuppressive phenotype by 
secretion of IL-10, TGF-β and IL-6. Outcomes from these experiments showed that, 
as predicted, suppression of TGF-β signaling pathway activity can inhibit macro-
phage polarization into immunosupressive M2 macrophages. Collectively, these fin-
dings indicate that potential macrophage differentiation inhibitors should be consi-
dered, rather than chemotaxis inhibitors, as therapeutics for testicular cancer, since 
infiltrating immune cells are important for synergistic immune reactions against can-
cer cells. Learning more about how their functional polarization can be controlled will 
make this possible. 
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Fig. 5.1: Schematic of key outcomes of macrophage recruitment and polarization as-
sociated with testicular cancer. Testicular cancer is associated with CD68+macrophages 
(probably precursor of M1 and M2), M1 and M2 macrophages. Our findings revealed chemo-
kines (CCL2 and CCL5) which are responsible for macrophage recruitment. Immune modula-
tor such as TGF-β, IL-6 expressed by seminoma cells (SE) as well as IL-10, TGF-β ex-
pressed by M2 macrophages can drive previous recruited macrophages into an immunosup-
pressive M2 phenotype.  
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6 ABSTRACT 
 
In this study, tissue specimens of normal, non-inflamed human testis with intact 
spermatogenesis and testicular germ cell neoplasia (GCNIS, seminoma) containing 
immune cell infiltrations were analysed by immunohistochemistry, immunfluores-
cence and qRT-PCR to reveal phenotypic and functional differences among the im-
mune cells that are contributing to the respective environment, reflected by cytokine 
expression profiles. The focus is set on macrophages and dendritic cells.  
Using specific macrophage and dendritic cell (DC) markers, different subsets of these 
immune cell types were identfied in testicular germ cell neoplasia suggesting a func-
tional polarization. Under physiological conditions in the testis, anti-inflammatory M2 
macrophages as supported by the presence of TGF-β and IL-10 have been detec-
table, whereas DCs that express CD11c were rare. In contrast, GCNIS (known as 
precursor of seminoma) and seminoma was associated with infiltration of different 
DC subsets, i.e. mDC and pDC. A detailed analysis of macrophages revealed that, 
pro-inflammatory M1 and anti-inflammatory M2 macrophages are involved in immune 
cell infiltrates associated with testicular germ cell neoplasia. In line with the detection 
of M1 macrophages, increased levels of trancripts encoding IL-12 and TNF-α were 
found in neoplasia. To delinate why both, anti- and pro-inflammatory macrophages 
could be associated with testicular cancer, chemokines as well as potential macro-
phage polarization factors were analysed. A detailed chemokine expression profile 
revealed CCL2, CCL5, CCL18 and CCL22 as well as TGF-β1, TNF-α and IL-6 as 
potential macrophage polarization factor to be associated with GCNIS and semino-
ma.  
To understand how these factors influence macrophages regarding their migration 
and differentiation/ polarization, an in vitro cell culture model using human monocyte 
derived THP-1 cells was estabilished. The results obtained indicate that CCL2 and 
CCL5 recruit macrophages and also influence macrophage polarization. To test whe-
ther tumour cells could drive macrophage differentiation, a co-culture model was es-
tabilished using a human seminoma cell line (TCam-2) and THP-1 cells that were 
differentiated into M0, M1 and M2 macrophages. The co-culture of M0 and M1 ma-
crophages with TCam-2 revealed a functional polarization of the THP-1-derived cells 
into an immunosuppressive M2 phenotype that may be driven by TGF-β1, IL-6 and 
CCL2. TGF-β1 signalling pathway inhibitor blocked the polarization towards an im-
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munosuppressive M2 phenotype. Furthermore, a functional assessment of THP-1-
derived M0 and M1 macrophages was conducted to reveal potential tumoricidial acti-
vities. In a phagocytosis assay, M1 macrophages showed high phagocytic activity 
enabling these cells to reduce TCam-2 cell numbers in the co-culture model. Howe-
ver, TCam-2 cells are likely to escape the tumoricidal activity by driving these macro-
phages into an immunosuppressive phenotype.  
In conclusion, M2 macrophages are the dominating immune cell population that sup-
port tumour grow. Therefore, as clinical outcome an inhibition of typical M2 polariza-
tion factors should be considered rather than an inhibition of recruitment factors 
(chemokines) since this would also influence the recruitment of phagocytic, tumour 
suppressive M1 macrophages. Future work should address the role of specific im-
mune modulators, such as TGF-β and activin A, and the impact and regulation of 
macrophage phagocytic activity on tumour cell survival and proliferation. Thus, poten-
tial macrophage differentiation inhibitors should be considered, as therapeutics to 
reinforce strong immune reactions against tumour cells. 
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7 ZUSAMMENFASSUNG 
 
In dieser Studie wurden humane Hodenbiopsien mit normaler Spermatogenese oder 
Hodenneoplasien (GCNIS, Seminom) mit lymphatischen Infiltraten mittels Immunhis-
tochemie oder Immunfluoreszenz und qRT-PCR analysiert. Funktional unterschiedli-
che Immunzellen (Makrophagen und dendritische Zellen) wurden durch jeweilige Zy-
tokinexpressionsprofile in den unterschiedlichen Milieus identifiziert. 
Unter Verwendung von spezifischen Makrophagen- und dendritischen Zellmarkern 
wurden verschiedene Immunzellsubtypen mit völlig anderen Funktionen in Neopla-
sie-Proben identifiziert. In den Hoden unter physiologischen Bedingungen waren ent-
zündungshemmende M2-Makrophagen nachweisbar, die durch das Vorhandensein 
von spezifischen Marker wie CD163 und CD206 sowie anti-inflammatorischen Zyto-
kinen, TGF-β und IL-10 nachgewiesen wurden. DCs, die CD11c exprimieren, waren 
kaum detektierbar. Im Gegensatz dazu waren in GCNIS Proben (als Vorstufe von 
Seminomen bekannt) verschiedene DC Subtypen detektierbar, mDC und pDC. In 
Seminomen wurden diese Immunzellen mit einer höheren Frequenz nachgewiesen. 
Eine detaillierte, funktionelle Analyse der DC-Subtypen war jedoch aufgrund ihrer 
anspruchsvollen Vielfalt in dieser Arbeit nicht möglich und muss weiter analysiert 
werden. Eine detaillierte Makrophagen-Analyse im Zusammenhang mit Neoplasien 
ergab, dass proinflammatorische M1 Makrophagen, IL-12 und TNF-α exprimieren 
und das aber auch antiinflammatorische M2 Makrophagen präsent waren. Eine halb-
quantitative Bewertung der einzelnen Makrophagen spezifischen Marker ergab, dass 
eine Balance von beiden, M1 und M2 Makrophagen in Neoplasien vorherrscht. Um 
zu verstehen, warum entzündungshemmende sowohl als auch proinflammatorische 
Makrophagen mit Hodenkrebs in Verbindung gebracht werden, analysierten wir 
Chemokine, die für ihre Funktionen zur Rekrutierung von Immunzellen sowie als po-
tentielle Makrophagen Polarisationsfaktoren bekannt sind. Ein detailliertes Chemo-
kinprofil zeigte, dass die Chemokine CCL2, CCL5, CCL18 und CCL22 nachweisbar 
waren sowie andere potentielle Makrophagen-Polarisationsfaktoren, TGF-β1, TNF-α 
und IL-6 mit testikulären Neoplasien (GCNIS und Seminom) assoziiert sind. Um zu 
verstehen, wie diese Faktoren Makrophagen in Bezug auf ihre Migration und Diffe-
renzierung beeinflussen, entwickelten wir ein In vitro-Zellkulturmodell mit humanen 
Monozyten (THP-1-Zellen). Unsere Ergebnisse zeigen, dass CCL2 und CCL5 Mak-
rophagen rekrutieren und auch die Makrophagen polarisation beeinflussen. Um zu 
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verstehen, warum Tumorzellen eine immunsupressive Makrophagen-Differenzierung 
begünstigen, wurde ein Co-Kulturmodell unter Verwendung von humanen Seminoma 
Zellen (TCAM-2) und humanen Monozyten (THP-1-Zellen), die zuvor in M0, M1 und 
M2 Makrophagen differenziert wurden, entwickelt. Die Co-Kultivierung von M0- und 
M1-Makrophagen mit TCam-2 offenbarte eine funktionelle Polarisierung dieser Mak-
rophagen zu einem immunsuppressiven M2-Phänotyp, der durch TGF-β1, IL-6 und 
CCL2 gesteuert werden kann. Jedoch blockierte der TGF-β1-Signalweg-Inhibitor die 
Polarisation in Richtung eines immunsuppressiven M2 Phänotyp. Zusätzlich wurde 
eine funktionelle Bewertung von M0 und M1 Makrophagen durchgeführt, um potenti-
elle tumorizide Aktivitäten aufzudecken. Dazu wurde ein Phagozytose-Assay etabliert 
und zeigte M1-Makrophagen als hoch phagozytische Zellen, die die Anzahl der 
TCam-2-Zellen in unserem Co-Kultur-Modell reduzieren könnte. Ungünstigerweise 
treiben TCam-2 diese Makrophagen in einen immunsuppressiven Phänotyp, der das 
Wachstum von Tumorzellen durch Phagozytose nicht kontrollieren kann. 
Zusammenfassend kann gesagt werden, dass M2-Makrophagen die dominierende 
Immunzellenpopulation, die das Tumorwachstum begünstigen sind. Als klinisches 
Outcome sollte daher eher eine Inhibition typischer M2-Polarisationsfaktoren als eine 
Hemmung von Rekrutierungsfaktoren (Chemokinen) in Betracht gezogen werden, da 
andernfalls auch die Rekrutierung von phagozytischen, tumorsuppressiven M1-
Makrophagen beeinflusst werden würde. Zukünftige Arbeiten sollten die Rolle von 
spezifischen Immunmodulatoren wie TGF-β und activin A sowie den Einfluss und die 
Regulierung der Phagozytoseaktivität von Makrophagen untersuchen um somit die 
Proliferation von Tumorzellen zu inhibieren. Daher sollten potentielle Makrophagen-
Differenzierungshemmer als Therapeutika zur Verstärkung von Tumor suppressiven 
Immunreaktionen in Betracht gezogen werden. 
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8 APPENDICES  
 
Chemicals and reagents 
2-Propanolol, ≥99.5% Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Acetic acid, 99 – 100% Merck, Darmstadt, Germany 
Agarose, peqGOLD Universal agarose Peqlab Biotechnology GmbH, Erlangen, 
Germany 
3-aminopropyltriethoxysilane (APES) Merck, Darmstadt, Germany 
BSA, Albumin fraction V, ≥98% Merck, Darmstadt, Germany 
Chloroform Merck, Darmstadt, Germany 
3'-Diaminobenzidine (DAB)  Thermo Scientific, Waltham, USA 
Diethylpyrocarbonate (DEPC) Sigma-Aldrich, St. Louis, MO, USA 
Disodium phosphate Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
DNA ladder (100bp), peqGOLD Peqlab Biotechnology GmbH, Erlangen, 
Germany 
EDTA disodium dehydrate SERVA Electrophoresis GmbH, Heidel-
berg, Germany 
EDTA tetrasodium (EDTA 4Na) Sigma-Aldrich, St. Louis, MO, USA 
Eosin G-solution, 0.5% Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Ethanol ROTIPURAN®, ≥99.8% Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Fetal calf serum Quantum Scientific, Australia 
Formalin, 36.5 – 38% Sigma-Aldrich, St. Louis, MO, USA 
GelGreen Nucleid Acid Stain  Biotium, Hayward, CA, USA 
GVA  Genemed Biotechnologies, South San 
Francisco, U.S.A.) 
Hydrochloric acid ROTIPURAN®, ≥25% Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Hydrogen peroxide, 30% Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
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Kaiser´s glycerine gelatine Merck, Darmstadt, Germany 
Luminata, Immobilon Forte Western HRP 
substrate  
Merck, Darmstadt, Germany 
Magnesium chloride Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Mayer´s hematoxylin Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Methanol ≥99 % 
 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
NuPAGE antioxidant Invitrogen, Carlsbad, CA 
NuPAGE® MOPS Running Buffer Invitrogen, Carlsbad, CA 
NuPAGE® Reducing agent Invitrogen, Carlsbad, CA 
NuPAGE® sample buffer Invitrogen, Carlsbad, CA 
NuPAGE® transfer buffer Invitrogen, Carlsbad, CA 
Page Ruler™Plus Thermo Scientific, Waltham, USA 
1x PBS (Dulbecco´s PBS) Gibco, Auckland, New Zealand 
Picric acid, 98% Sigma-Aldrich, St. Louis, MO, USA 
Potassium chloride Merck Millipore, Bayswater, VIC, Austral-
ia 
Potassium dihydrogen phosphate Merck Millipore, Bayswater, VIC, Austral-
ia 
RNA-free water Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Sodium bicarbonate Sigma-Aldrich, St. Louis, MO, USA 
Sodium carbonate Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Sodium chloride, ≥99.5% Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Sodium hydroxide pellets Merck, Darmstadt, Germany 
Tetramethylbenzidine  BD Biosciences, San Diego, CA, USA 
TrisBASE Sigma-Aldrich, St. Louis, MO, USA 
Tris-Pufferan®, ≥99.9% Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Triton X-100 Sigma-Aldrich, St. Louis, MO, USA 
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TRIzol® Reagent Ambion LifeTechnologies, Carlsbad, CA, USA 
Trypsin, 2.5% Gibco, Auckland, New Zealand 
Tween-20 Sigma-Aldrich, St. Louis, MO, USA 
Xylene ROTIPURAN®, ≥99.8% Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
 
Kits 
AllPrep® RNA/ Protein Kit Qiagen, Hilden, Germany 
AmpliTaq GOLD DNA polymerase Applied Biosystems, Foster City, CA, 
USA 
Pierce BCA (Bicinchoninic Acid) Protein 
Assay Kit  
Thermo Scientific, Waltham, USA 
BIOPRIME Peroxidase-Substratkit AEC BIOLOGO Dr. Hartmut Schultheiß e.K., 
Kronshagen, Germany 
Pierce DAB (3'-Diaminobenzidine) Sub-
strate Kit 
Thermo Scientific, Waltham, USA 
DNase I, recombinant Roche Diagnostics, Mannheim, Germany 
DNA-freeTM DNA Removal Kit Ambion LifeTechnologies, Grand Island, NY, USA 
Muliplex 
Human Cytokine/Chemokine Panel I: De-
tects 
IL-6, IL-10, TNFα, IL-1a, IL-12 p40, 
MCP-1 and RANTES 
EMD Millipore, Billerica, MA, USA 
Multiplex 
Millipore Multi-species TGFβ1 magnetic 
panel, 1- 
plex: Detects TGFβ1 
EMD Millipore, Billerica, MA, USA 
SuperScript® III Reverse Transcriptase LifeTechnologies, Grand Island, NY, USA 
Qproteome FFPE Tissue Kit Qiagen, Hilden, Germany 
VECTASTAIN Elite ABC Kit Vectorlabs, Burlingame, CA, USA 
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Equipment and consumables 
7900HT RealTime Cycler Applied Biosystems, Foster City, USA 
BD Polystyrene Filter top (5ml) 
 
Becton Dickinson Labware, Franklin 
Lakes, NJ, USA 
Centrifuge MICRO 120 Hettich Zentrifugen, Tuttlingen, Germany 
Centrifuge MIRCO 22R Hettich Zentrifugen, Tuttlingen, Germany 
CFX96TM RealTime Cycler Bio-Rad, Munich, Germany 
CFX Manager Software 2.0 Bio-Rad, Munich, Germany 
CO2 incubator Memmert GmbH & CO. KG, Schwabach, 
Germany 
Corning™ 96-Well Filter Plate Fluid 
Guard 
Thermo Scientific, Waltham, USA 
Electronic balance EXPLORER OHAUS, Nänikon, Switzerland 
ELISA microplates (96-well) Greiner Bio-one, Monroe, NC, USA 
Falcon® Tissue culture flasks (T75) 
 
Becton Dickinson Labware, Franklin 
Lakes, NJ, USA 
Falcon® Tissue culture flasks (T25) 
 
Becton Dickinson Labware, Franklin 
Lakes, NJ, USA 
Falcon® Tissue culture plates (6-well) 
 
Becton Dickinson Labware, Franklin 
Lakes, NJ, USA 
Filter tips Nerbe plus, Winsen/Luhe, Germany 
IKA® T-10 basic Ultra Turrax Homoge-
nizer 
IKA® Werke GmbH & CO. KG, Staufen 
Germany 
LSRFortessaTM X-20 flow cytometer  BD Biosciences, San Jose, CA, USA 
Luminex x-100 http://www.luminexcorp.com 
Microplate ELISA reader Labsystems Multiscan RC, Vantaa, Fin-
land 
Microscope Leica DM750 Leica, Solms, Germany 
Microwave oven, CB 1273 Bomann, Kempen, Germany 
MILLICELL –CM well inserts Merck Millipore, Bayswater, VIC, Austral-
ia 
Neubauer counting chamber 
 
Paul Marienfeld GmbH & Co. KG, Lauda, 
Germany 
Olympus Fluorescence Microscope Olympus America, Center 
Valley, PA 
PCR tubes Nerbe plus, Winsen/Luhe, Germany 
PerfectBlueTM Horizontal Midi Gel Sys-
tems 
Peqlab Biotechnology GmbH, Erlangen, 
Germany 
PVDF 0.2µm Thermo Scientific, Waltham, USA 
Stericup® Filter units 
 
Merck Millipore, Bayswater, VIC, Austral-
ia 
SuperFrost glass slides 
 
R. Langenbrink, Emmendingen, Germa-
ny 
Sliding microtome, Leica SM2000 R Leica, Solms, Germany 
T3 Thermocycler Biometra GmbH, Göttingen, Germany 
TB1 Thermoblock Biometra GmbH, Göttingen, Germany 
Tissue embedder, Leica EG 1150C Leica, Solms, Germany 
Tissue processor Leica TP 1050 Leica, Solms, Germany 
Transilluminator UVsolo Biometra GmbH, Göttingen, Germany 
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Transilluminator UVIdoc Biometra GmbH, Göttingen, Germany 
Whatman paper  BioRad, Hercules, California 
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8.1 APPENDIX CHAPTER 2 
 
Buffer 
10x TAE buffer, pH 8.0, stock solution 
48.4g TrisBASE (Sigma-Aldrich) 
3.72g EDTA disodium dihydrate (SERVA) 
1l Bidistilled water 
Adjust pH with 4M NaOH. 
 
1x TAE buffer, pH 8.0, working solution 
100ml TAE stock solution 
900ml Bidistilled water 
 
100 ml 1x TAE buffer 
Heat buffer contains agarose at 500 Watt in a microwave ofen (Bomann, Kempen, 
Germany). After agarose is disolved, add: 
15 μl GelGreen Nucleid Acid Stain (Biotium, Hayward, CA, USA) 
 
DNA agarose gel electrophoresis 
1.5 g peqGOLD Universal Agarose (Peqlab Biotechnology GmbH, Erlangen, Germa-
ny) 
 
DEPC H2O 
2 ml DEPC 
2l Bidistilled water 
Mix, let rest for 24h at 37°C, autoclave. 
 
Bouin´s solution 
210 ml Picric acid (Sigma-Aldrich) 
70 ml 36.5 – 38% Formalin (Sigma-Aldrich) 
10 ml Acetic acid (Merck) 
Fix testis biopsy samples in Bouin´s solution for 24 h, wash with 70% ethanol and 
proceed with embedding. 
 
HE staining 
Incubate sections for 2x 5 min in xylene, then rehydrate for 5 min in 100%, 96%, 
80%, 70%, 60%, 50% ethanol, rinse with distilled water. Incubate 1 min in Mayer´s 
hematoxylin, wash under tab water for 10min. Incubate in 0.5% eosin for 5 min, wash 
under tab water. Allow slides to dry and mount slides with Kaisers Glycerine. 
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PCR program: 
 
Reverse transcriptase (RT) program for DNase treatment 
37°C 75°C 4°C 
 
25min 5min hold 
 
RT program for cDNA synthesis 
21°C 42°C 99°C 5°C 4°C 
 
8 min 15 min 5 min 5 min hold 
 
RT-qPCR program 
95°C 95°C 60°C 4°C 
 
10min 15s  1min hold 
 44 cycles   
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8.2 APPENDIX CHAPTER 3 
 
Cell lines 
TCam-2 cells (human seminoma derived cell line) originally obtained from Prof 
Kitizawa, Japan. 
THP-1 cells (human monocytic leukemia cell line; provided by Dr. Ashley Mansell, 
Hudson Institute of Medical Research, Clayton, Australia. 
 
Culture media, complete 
RPMI1640 Gibco, Auckland, New Zealand 
1% penicillin/streptomycin Gibco, Auckland, New Zealand 
10% fetal calf serum Quantum Scientific, Australia  
 
10x Versene (EDTA) solution, sterile filtered 
8 g NaCl (Roth) 
2 g KCl (Merck Millipore) 
0.77 g NaOH (Merck) 
11.5 g KH2PO4 (Merck Millipore) 
2 g EDTA 4Na (Sigma-Aldrich) 
1 l Bidistilled water 
 
0.1% trypsin-versene, sterile filtered 
10 ml Trypsin, 2.5% (Gibco) 
25 ml 10x Versene (EDTA) 
215 ml PBS 
 
Tris-buffered saline (TBS), stock solution 
60.5 g Tris-Pufferan, ≥99.8% p.a. (Roth) 
900 ml Bi-distilled water 
Mix until dissolved. Adjust pH to 7.6 using HCl (Roth). Top up with bidstilled water up 
to 100 ml total volume. 
90 g NaCl (Merck 
 
BSA blocking solution 
1 g BSA (Roth) 
70 ml TBS 
 
10 X Running Buffer (1 litre) 
30.3 g Tris base 
144 g Glycin 
10 g SDS 
pH 8.3 
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1 X Transfer Buffer (1.5 litre) 
4.6 g Tris base 
21.6 g Glycine 
150 ml ethanol 
 
4 X Sample Buffer (25 ml) 
6.0 ml 1M Tris HCL pH 6.8 
2.5 ml Glycerol (100%) 
2 g SDS  
12.5 mg Bromophenol blue 
5 ml β-mercaptoethanol (14.5M) 
Up to 25 ml milliQ water 
 
MasterMix for RT-qPCR, volume/1 reaction 
5 μl TaqMan® Gene Expression Master Mix (LifeTechnologies, Carlsbad, CA, USA) 
0.5 μl TaqMan® Gene Expression Assay (LifeTechnologies, Carlsbad, CA, USA) 
2.5 μl RNA-free water 
2 μl cDNA, diluted 1:20 
10 μl total volume/1 reaction 
 
 
Gel for SDS-PAGE 
                    10%                     12% 
Resolving 
dH20 
30% Acrylamide 
1.5M Tris (pH 8.8) 
10% SDS 
10% Ammonium Persul-
fate 
TEMED 
 
4 ml 
3.3 ml 
2.5 ml 
100 µl 
100 µl 
12 µl 
 
5.1 ml 
6.0 ml 
3.75 ml 
100 µl 
100 µl 
12 µl 
Stacking 5% 
dH20 
30% Acrylamide 
0.5M Tris (pH 6.8) 
10% SDS 
10% Ammonium Persul-
fate 
TEMED 
 
3 ml 
670 µl 
1.25 ml 
50 µl 
50 µl 
12 µl 
 
3 ml 
670 µl 
1.25 ml 
50 µl 
50 µl 
12 µl 
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DNase treatment, volume/1 reaction 
 
1 vol. 10 μg TRIzol® Reagent extracted RNA 
0.1 vol. 10x DNase I buffer 
1μl rDNase I 
Mix gently, incubate at 37°C for 20 min. 
Add 1 μl resuspended Inactivation Reagent 
Incubate at room temperature for 2 min., flick in between. Centrifuge at 10621 rcf for 
1.5 min. Transfer DNase treated RNA into new tube. 
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8.3 APPENDIX CHAPTER 4 
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Figure 4: CD14 expression profile of M0, M1 and M2 macrophages (n=3). All three subsets show similar 
transcripts encoding of CD14.  
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Reagents 
Protein name Manufacturer Cat. 
No. 
Phorbol 12-myristate 13-acetate (PMA) Biolegend 423301 
Lipopolysaccharide (LPS) Sigma 8630 
Recombinant Human IFN-γ (carrier-free) Biolegend 570202 
Recombinant Human IL-13 (carrier-free) Biolegend 571102 
Recombinant Human IL-4 (Animal-Free) Biolegend 714904 
Recombinant Human CCL15 (MIP-1δ) (car-
rier-free) 
Biolegend 587402 
Recombinant Human CCL5 (RANTES) (An-
imal-Free) 
Biolegend 717004 
Recombinant Human CCL2 (MCP-1) (Ani-
mal-Free) 
Biolegend 716504 
IL-10 Biolegend 715602 
Transforming growth factor beta 1 (TGF-β1) Cell Signaling 
8915LC 
 
Activin A Abcam ab50051 
SB431542 Cell Signaling 14775 
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